{
  "index": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    50,
    51,
    52,
    53,
    54,
    55,
    56,
    57,
    58,
    59,
    60,
    61,
    62,
    63,
    64,
    65,
    66,
    67,
    68,
    69,
    70,
    71,
    72,
    73,
    74,
    75,
    76,
    77,
    78,
    79,
    80,
    81,
    82,
    83,
    84,
    85,
    86,
    87,
    88,
    89,
    90,
    91,
    92,
    93,
    94,
    95,
    96,
    97,
    98,
    99,
    100,
    101,
    102,
    103,
    104,
    105,
    106,
    107,
    108,
    109,
    110,
    111,
    112,
    113,
    114,
    115,
    116,
    117,
    118,
    119,
    120,
    121,
    122,
    123,
    124,
    125,
    126,
    127,
    128,
    129,
    130,
    131,
    132,
    133,
    134,
    135,
    136,
    137,
    138,
    139,
    140,
    141,
    142,
    143,
    144,
    145,
    146,
    147,
    148,
    149,
    150,
    151,
    152,
    153,
    154,
    155,
    156,
    157,
    158,
    159,
    160,
    161,
    162,
    163,
    164,
    165,
    166,
    167,
    168,
    169,
    170,
    171,
    172,
    173,
    174,
    175,
    176,
    177,
    178,
    179,
    180,
    181,
    182,
    183,
    184,
    185,
    186,
    187,
    188,
    189,
    190,
    191,
    192,
    193,
    194,
    195,
    196,
    197,
    198,
    199,
    200,
    201,
    202,
    203,
    204,
    205,
    206,
    207,
    208,
    209,
    210,
    211,
    212,
    213,
    214,
    215,
    216,
    217,
    218,
    219,
    220,
    221,
    222,
    223,
    224,
    225,
    226,
    227,
    228,
    229,
    230,
    231,
    232,
    233,
    234,
    235,
    236,
    237,
    238,
    239,
    240,
    241,
    242,
    243,
    244,
    245,
    246,
    247,
    248,
    249,
    250,
    251,
    252,
    253,
    254,
    255,
    256,
    257,
    258,
    259,
    260,
    261,
    262,
    263,
    264,
    265,
    266,
    267,
    268,
    269,
    270,
    271,
    272,
    273,
    274,
    275,
    276,
    277,
    278,
    279,
    280,
    281,
    282,
    283,
    284,
    285,
    286,
    287,
    288,
    289,
    290,
    291,
    292,
    293,
    294,
    295,
    296,
    297,
    298,
    299,
    300,
    301,
    302,
    303,
    304,
    305,
    306,
    307,
    308,
    309,
    310,
    311,
    312,
    313,
    314,
    315,
    316,
    317,
    318,
    319,
    320,
    321,
    322,
    323,
    324,
    325,
    326,
    327,
    328,
    329,
    330,
    331,
    332,
    333,
    334,
    335,
    336,
    337,
    338,
    339,
    340,
    341,
    342,
    343,
    344,
    345,
    346,
    347,
    348,
    349,
    350,
    351,
    352,
    353,
    354,
    355,
    356,
    357,
    358,
    359,
    360,
    361,
    362,
    363,
    364,
    365,
    366,
    367,
    368,
    369,
    370,
    371,
    372,
    373,
    374,
    375,
    376,
    377,
    378,
    379,
    380,
    381,
    382,
    383,
    384,
    385,
    386,
    387,
    388,
    389,
    390,
    391,
    392,
    393,
    394,
    395,
    396,
    397,
    398,
    399,
    400,
    401,
    402,
    403,
    404,
    405,
    406,
    407,
    408,
    409,
    410,
    411,
    412,
    413,
    414,
    415,
    416,
    417,
    418,
    419,
    420,
    421,
    422,
    423,
    424,
    425,
    426,
    427,
    428,
    429,
    430,
    431,
    432,
    433,
    434,
    435,
    436,
    437,
    438,
    439,
    440,
    441,
    442,
    443,
    444,
    445,
    446,
    447,
    448,
    449,
    450,
    451,
    452,
    453,
    454,
    455,
    456,
    457,
    458,
    459,
    460,
    461,
    462,
    463,
    464,
    465,
    466,
    467,
    468,
    469,
    470,
    471,
    472,
    473,
    474,
    475,
    476,
    477,
    478,
    479,
    480,
    481,
    482,
    483,
    484,
    485,
    486,
    487,
    488,
    489,
    490,
    491,
    492,
    493,
    494,
    495,
    496,
    497,
    498,
    499,
    500,
    501,
    502,
    503,
    504,
    505,
    506,
    507,
    508,
    509,
    510,
    511,
    512,
    513,
    514,
    515,
    516,
    517,
    518,
    519,
    520,
    521,
    522,
    523,
    524,
    525,
    526,
    527,
    528,
    529,
    530,
    531,
    532,
    533,
    534,
    535,
    536,
    537,
    538,
    539,
    540,
    541,
    542,
    543,
    544,
    545,
    546,
    547,
    548,
    549,
    550,
    551,
    552,
    553,
    554,
    555,
    556,
    557,
    558,
    559,
    560,
    561,
    562,
    563,
    564,
    565,
    566,
    567,
    568,
    569,
    570,
    571,
    572,
    573,
    574,
    575,
    576,
    577,
    578,
    579,
    580,
    581,
    582,
    583,
    584,
    585,
    586,
    587,
    588,
    589,
    590,
    591,
    592,
    593,
    594,
    595,
    596,
    597,
    598,
    599,
    600,
    601,
    602,
    603,
    604,
    605,
    606,
    607,
    608,
    609,
    610,
    611,
    612,
    613,
    614,
    615,
    616,
    617,
    618,
    619,
    620,
    621,
    622,
    623,
    624,
    625,
    626,
    627,
    628,
    629,
    630,
    631,
    632,
    633,
    634,
    635,
    636,
    637,
    638,
    639,
    640,
    641,
    642,
    643,
    644,
    645,
    646,
    647,
    648,
    649,
    650,
    651,
    652,
    653,
    654,
    655,
    656,
    657,
    658,
    659,
    660,
    661,
    662,
    663,
    664,
    665,
    666,
    667,
    668,
    669,
    670,
    671,
    672,
    673,
    674,
    675,
    676,
    677,
    678,
    679,
    680,
    681,
    682,
    683,
    684,
    685,
    686,
    687,
    688,
    689,
    690,
    691,
    692,
    693,
    694,
    695,
    696,
    697,
    698,
    699,
    700,
    701,
    702,
    703,
    704,
    705,
    706,
    707,
    708,
    709,
    710,
    711,
    712,
    713,
    714,
    715,
    716,
    717,
    718,
    719,
    720,
    721,
    722,
    723,
    724,
    725,
    726,
    727,
    728,
    729,
    730,
    731,
    732,
    733,
    734,
    735,
    736,
    737,
    738,
    739,
    740,
    741,
    742,
    743,
    744,
    745,
    746,
    747,
    748,
    749,
    750,
    751,
    752,
    753,
    754,
    755,
    756,
    757,
    758,
    759,
    760,
    761,
    762,
    763,
    764,
    765,
    766,
    767,
    768,
    769,
    770,
    771,
    772,
    773,
    774,
    775,
    776,
    777,
    778,
    779,
    780,
    781,
    782,
    783,
    784,
    785,
    786,
    787,
    788,
    789,
    790,
    791,
    792,
    793,
    794,
    795,
    796,
    797,
    798,
    799,
    800,
    801,
    802,
    803,
    804,
    805,
    806,
    807,
    808,
    809,
    810,
    811,
    812,
    813,
    814,
    815,
    816,
    817,
    818,
    819,
    820,
    821,
    822,
    823,
    824,
    825,
    826,
    827,
    828,
    829,
    830,
    831,
    832,
    833,
    834,
    835,
    836,
    837,
    838,
    839,
    840,
    841,
    842,
    843,
    844,
    845,
    846,
    847,
    848,
    849,
    850,
    851,
    852,
    853,
    854,
    855,
    856,
    857,
    858,
    859,
    860,
    861,
    862,
    863,
    864,
    865,
    866,
    867,
    868,
    869,
    870,
    871,
    872,
    873,
    874,
    875,
    876,
    877,
    878,
    879,
    880,
    881,
    882,
    883,
    884,
    885,
    886,
    887,
    888,
    889,
    890,
    891,
    892,
    893,
    894,
    895,
    896,
    897,
    898,
    899,
    900,
    901,
    902,
    903,
    904,
    905,
    906,
    907,
    908,
    909,
    910,
    911,
    912,
    913,
    914,
    915,
    916,
    917,
    918,
    919,
    920,
    921,
    922,
    923,
    924,
    925,
    926,
    927,
    928,
    929,
    930,
    931,
    932,
    933,
    934,
    935,
    936,
    937,
    938,
    939,
    940,
    941,
    942,
    943,
    944,
    945,
    946,
    947,
    948,
    949,
    950,
    951,
    952,
    953,
    954,
    955,
    956,
    957,
    958,
    959,
    960,
    961,
    962,
    963,
    964,
    965,
    966,
    967,
    968,
    969,
    970,
    971,
    972,
    973,
    974,
    975,
    976,
    977,
    978,
    979,
    980,
    981,
    982,
    983,
    984,
    985,
    986,
    987,
    988,
    989,
    990,
    991,
    992,
    993,
    994,
    995,
    996,
    997,
    998,
    999,
    1000,
    1001,
    1002,
    1003,
    1004,
    1005,
    1006,
    1007,
    1008,
    1009,
    1010,
    1011,
    1012,
    1013,
    1014,
    1015,
    1016,
    1017,
    1018,
    1019,
    1020,
    1021,
    1022,
    1023,
    1024,
    1025,
    1026,
    1027,
    1028,
    1029,
    1030,
    1031,
    1032,
    1033,
    1034,
    1035,
    1036,
    1037,
    1038,
    1039,
    1040,
    1041,
    1042,
    1043,
    1044,
    1045,
    1046,
    1047,
    1048,
    1049,
    1050,
    1051,
    1052,
    1053,
    1054,
    1055,
    1056,
    1057,
    1058,
    1059,
    1060,
    1061,
    1062,
    1063,
    1064,
    1065,
    1066,
    1067,
    1068,
    1069,
    1070,
    1071,
    1072,
    1073,
    1074,
    1075,
    1076,
    1077,
    1078,
    1079,
    1080,
    1081,
    1082,
    1083,
    1084,
    1085,
    1086,
    1087,
    1088,
    1089,
    1090,
    1091,
    1092,
    1093,
    1094,
    1095,
    1096,
    1097,
    1098,
    1099,
    1100,
    1101,
    1102,
    1103,
    1104,
    1105,
    1106,
    1107,
    1108,
    1109,
    1110,
    1111,
    1112,
    1113,
    1114,
    1115,
    1116,
    1117,
    1118,
    1119,
    1120,
    1121,
    1122,
    1123,
    1124,
    1125,
    1126,
    1127,
    1128,
    1129,
    1130,
    1131,
    1132,
    1133,
    1134,
    1135,
    1136,
    1137,
    1138,
    1139,
    1140,
    1141,
    1142,
    1143,
    1144,
    1145,
    1146,
    1147,
    1148,
    1149,
    1150,
    1151,
    1152,
    1153,
    1154,
    1155,
    1156,
    1157,
    1158,
    1159,
    1160,
    1161,
    1162,
    1163,
    1164,
    1165,
    1166,
    1167,
    1168,
    1169,
    1170,
    1171,
    1172,
    1173,
    1174,
    1175,
    1176,
    1177,
    1178,
    1179,
    1180,
    1181,
    1182,
    1183,
    1184,
    1185,
    1186,
    1187,
    1188,
    1189,
    1190,
    1191,
    1192,
    1193,
    1194,
    1195,
    1196,
    1197,
    1198,
    1199,
    1200,
    1201,
    1202,
    1203,
    1204,
    1205,
    1206,
    1207,
    1208,
    1209,
    1210,
    1211,
    1212,
    1213,
    1214,
    1215,
    1216,
    1217,
    1218,
    1219,
    1220,
    1221,
    1222,
    1223,
    1224,
    1225,
    1226,
    1227,
    1228,
    1229,
    1230,
    1231,
    1232,
    1233,
    1234,
    1235,
    1236,
    1237,
    1238,
    1239,
    1240,
    1241,
    1242,
    1243,
    1244,
    1245,
    1246,
    1247,
    1248,
    1249,
    1250,
    1251,
    1252,
    1253,
    1254,
    1255,
    1256,
    1257,
    1258,
    1259,
    1260,
    1261,
    1262,
    1263,
    1264,
    1265,
    1266,
    1267,
    1268,
    1269,
    1270,
    1271,
    1272,
    1273,
    1274,
    1275,
    1276,
    1277,
    1278,
    1279,
    1280,
    1281,
    1282,
    1283,
    1284,
    1285,
    1286,
    1287,
    1288,
    1289,
    1290,
    1291,
    1292,
    1293,
    1294,
    1295,
    1296,
    1297,
    1298,
    1299,
    1300,
    1301,
    1302,
    1303,
    1304,
    1305,
    1306,
    1307,
    1308,
    1309,
    1310,
    1311,
    1312,
    1313,
    1314,
    1315,
    1316,
    1317,
    1318,
    1319,
    1320,
    1321,
    1322,
    1323,
    1324,
    1325,
    1326,
    1327,
    1328,
    1329,
    1330,
    1331,
    1332,
    1333,
    1334,
    1335,
    1336,
    1337,
    1338,
    1339,
    1340,
    1341,
    1342,
    1343,
    1344,
    1345,
    1346,
    1347,
    1348,
    1349,
    1350,
    1351,
    1352,
    1353,
    1354,
    1355,
    1356,
    1357,
    1358,
    1359,
    1360,
    1361,
    1362,
    1363,
    1364,
    1365,
    1366,
    1367,
    1368,
    1369,
    1370,
    1371,
    1372,
    1373,
    1374,
    1375,
    1376,
    1377,
    1378,
    1379,
    1380,
    1381,
    1382,
    1383,
    1384,
    1385,
    1386,
    1387,
    1388,
    1389,
    1390,
    1391,
    1392,
    1393,
    1394,
    1395,
    1396,
    1397,
    1398,
    1399,
    1400,
    1401,
    1402,
    1403,
    1404,
    1405,
    1406,
    1407,
    1408,
    1409,
    1410,
    1411,
    1412,
    1413,
    1414,
    1415,
    1416,
    1417,
    1418,
    1419,
    1420,
    1421,
    1422,
    1423,
    1424,
    1425,
    1426,
    1427,
    1428,
    1429,
    1430,
    1431,
    1432,
    1433,
    1434,
    1435,
    1436,
    1437,
    1438,
    1439,
    1440,
    1441,
    1442,
    1443,
    1444,
    1445,
    1446,
    1447,
    1448,
    1449,
    1450,
    1451,
    1452,
    1453,
    1454,
    1455,
    1456,
    1457,
    1458,
    1459,
    1460,
    1461,
    1462,
    1463,
    1464,
    1465,
    1466,
    1467,
    1468,
    1469,
    1470,
    1471,
    1472,
    1473,
    1474,
    1475,
    1476,
    1477,
    1478,
    1479,
    1480,
    1481,
    1482,
    1483,
    1484,
    1485,
    1486,
    1487,
    1488,
    1489,
    1490,
    1491,
    1492,
    1493,
    1494,
    1495,
    1496,
    1497,
    1498,
    1499,
    1500,
    1501,
    1502,
    1503,
    1504,
    1505,
    1506,
    1507,
    1508,
    1509,
    1510,
    1511,
    1512,
    1513,
    1514,
    1515,
    1516,
    1517,
    1518,
    1519,
    1520,
    1521,
    1522,
    1523,
    1524,
    1525,
    1526,
    1527,
    1528,
    1529,
    1530,
    1531,
    1532,
    1533,
    1534,
    1535,
    1536,
    1537,
    1538,
    1539,
    1540,
    1541,
    1542,
    1543,
    1544,
    1545,
    1546,
    1547,
    1548,
    1549,
    1550,
    1551,
    1552,
    1553,
    1554,
    1555,
    1556,
    1557,
    1558,
    1559,
    1560,
    1561,
    1562,
    1563,
    1564,
    1565,
    1566,
    1567,
    1568,
    1569,
    1570,
    1571,
    1572,
    1573,
    1574,
    1575,
    1576,
    1577,
    1578,
    1579,
    1580,
    1581,
    1582,
    1583,
    1584,
    1585,
    1586,
    1587,
    1588,
    1589,
    1590,
    1591,
    1592,
    1593,
    1594,
    1595,
    1596,
    1597,
    1598,
    1599,
    1600,
    1601,
    1602,
    1603,
    1604,
    1605,
    1606,
    1607,
    1608,
    1609,
    1610,
    1611,
    1612,
    1613,
    1614,
    1615,
    1616,
    1617,
    1618,
    1619,
    1620,
    1621,
    1622,
    1623,
    1624,
    1625,
    1626,
    1627,
    1628,
    1629,
    1630,
    1631,
    1632,
    1633,
    1634,
    1635,
    1636,
    1637,
    1638,
    1639,
    1640,
    1641,
    1642,
    1643,
    1644,
    1645,
    1646,
    1647,
    1648,
    1649,
    1650,
    1651,
    1652,
    1653,
    1654,
    1655,
    1656,
    1657,
    1658,
    1659,
    1660,
    1661,
    1662,
    1663,
    1664,
    1665,
    1666,
    1667,
    1668,
    1669,
    1670,
    1671,
    1672,
    1673,
    1674,
    1675,
    1676,
    1677,
    1678,
    1679,
    1680,
    1681,
    1682,
    1683,
    1684,
    1685,
    1686,
    1687,
    1688,
    1689,
    1690,
    1691,
    1692,
    1693,
    1694,
    1695,
    1696,
    1697,
    1698,
    1699,
    1700,
    1701,
    1702,
    1703,
    1704,
    1705,
    1706,
    1707,
    1708,
    1709,
    1710,
    1711,
    1712,
    1713,
    1714,
    1715,
    1716,
    1717,
    1718,
    1719,
    1720,
    1721,
    1722,
    1723,
    1724,
    1725,
    1726,
    1727,
    1728,
    1729,
    1730,
    1731,
    1732,
    1733,
    1734,
    1735,
    1736,
    1737,
    1738,
    1739,
    1740,
    1741,
    1742,
    1743,
    1744,
    1745,
    1746,
    1747,
    1748,
    1749,
    1750,
    1751,
    1752,
    1753,
    1754,
    1755,
    1756,
    1757,
    1758,
    1759,
    1760,
    1761,
    1762,
    1763,
    1764,
    1765,
    1766,
    1767,
    1768,
    1769,
    1770,
    1771,
    1772,
    1773,
    1774,
    1775,
    1776,
    1777,
    1778,
    1779,
    1780,
    1781,
    1782,
    1783,
    1784,
    1785,
    1786,
    1787,
    1788,
    1789,
    1790,
    1791,
    1792,
    1793,
    1794,
    1795,
    1796,
    1797,
    1798,
    1799,
    1800,
    1801,
    1802,
    1803,
    1804,
    1805,
    1806,
    1807,
    1808,
    1809,
    1810,
    1811,
    1812,
    1813,
    1814,
    1815,
    1816,
    1817,
    1818,
    1819,
    1820,
    1821,
    1822,
    1823,
    1824,
    1825,
    1826,
    1827,
    1828,
    1829,
    1830,
    1831,
    1832,
    1833,
    1834,
    1835,
    1836,
    1837,
    1838,
    1839,
    1840,
    1841,
    1842,
    1843,
    1844,
    1845,
    1846,
    1847,
    1848,
    1849,
    1850,
    1851,
    1852,
    1853,
    1854,
    1855,
    1856,
    1857,
    1858,
    1859,
    1860,
    1861,
    1862,
    1863,
    1864,
    1865,
    1866,
    1867,
    1868,
    1869,
    1870,
    1871,
    1872,
    1873,
    1874,
    1875,
    1876,
    1877,
    1878,
    1879,
    1880,
    1881,
    1882,
    1883,
    1884,
    1885,
    1886,
    1887,
    1888,
    1889,
    1890,
    1891,
    1892,
    1893,
    1894,
    1895,
    1896,
    1897,
    1898,
    1899,
    1900,
    1901,
    1902,
    1903,
    1904,
    1905,
    1906,
    1907,
    1908,
    1909,
    1910,
    1911,
    1912,
    1913,
    1914,
    1915,
    1916,
    1917,
    1918,
    1919,
    1920,
    1921,
    1922,
    1923,
    1924,
    1925,
    1926,
    1927,
    1928,
    1929,
    1930,
    1931,
    1932,
    1933,
    1934,
    1935,
    1936,
    1937,
    1938,
    1939,
    1940,
    1941,
    1942,
    1943,
    1944,
    1945,
    1946,
    1947,
    1948,
    1949,
    1950,
    1951,
    1952,
    1953,
    1954,
    1955,
    1956,
    1957,
    1958,
    1959,
    1960,
    1961,
    1962,
    1963,
    1964,
    1965,
    1966,
    1967,
    1968,
    1969,
    1970,
    1971,
    1972,
    1973,
    1974,
    1975,
    1976,
    1977,
    1978,
    1979,
    1980,
    1981,
    1982,
    1983,
    1984,
    1985,
    1986,
    1987,
    1988,
    1989,
    1990,
    1991,
    1992,
    1993,
    1994,
    1995,
    1996,
    1997,
    1998,
    1999,
    2000,
    2001,
    2002,
    2003,
    2004,
    2005,
    2006,
    2007,
    2008,
    2009,
    2010,
    2011,
    2012,
    2013,
    2014,
    2015,
    2016,
    2017,
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025,
    2026,
    2027,
    2028,
    2029,
    2030,
    2031,
    2032,
    2033,
    2034,
    2035,
    2036,
    2037,
    2038,
    2039,
    2040,
    2041,
    2042,
    2043,
    2044,
    2045,
    2046,
    2047,
    2048,
    2049,
    2050,
    2051,
    2052,
    2053,
    2054,
    2055,
    2056,
    2057,
    2058,
    2059,
    2060,
    2061,
    2062,
    2063,
    2064,
    2065,
    2066,
    2067,
    2068,
    2069,
    2070,
    2071,
    2072,
    2073,
    2074,
    2075,
    2076,
    2077,
    2078,
    2079,
    2080,
    2081,
    2082,
    2083,
    2084,
    2085,
    2086,
    2087,
    2088,
    2089,
    2090,
    2091,
    2092,
    2093,
    2094,
    2095,
    2096,
    2097,
    2098,
    2099,
    2100,
    2101,
    2102,
    2103,
    2104,
    2105,
    2106,
    2107,
    2108,
    2109,
    2110,
    2111,
    2112,
    2113,
    2114,
    2115,
    2116,
    2117,
    2118,
    2119,
    2120,
    2121,
    2122,
    2123,
    2124,
    2125,
    2126,
    2127,
    2128,
    2129,
    2130,
    2131,
    2132,
    2133,
    2134,
    2135,
    2136,
    2137,
    2138,
    2139,
    2140,
    2141,
    2142,
    2143,
    2144,
    2145,
    2146,
    2147,
    2148,
    2149,
    2150,
    2151,
    2152,
    2153,
    2154,
    2155,
    2156,
    2157,
    2158,
    2159,
    2160,
    2161,
    2162,
    2163,
    2164,
    2165,
    2166,
    2167,
    2168,
    2169,
    2170,
    2171,
    2172,
    2173,
    2174,
    2175,
    2176,
    2177,
    2178,
    2179,
    2180,
    2181,
    2182,
    2183,
    2184,
    2185,
    2186,
    2187,
    2188,
    2189,
    2190,
    2191,
    2192,
    2193,
    2194,
    2195,
    2196,
    2197,
    2198,
    2199,
    2200,
    2201,
    2202,
    2203,
    2204,
    2205,
    2206,
    2207,
    2208,
    2209,
    2210,
    2211,
    2212,
    2213,
    2214,
    2215,
    2216,
    2217,
    2218,
    2219,
    2220,
    2221,
    2222,
    2223,
    2224,
    2225,
    2226,
    2227,
    2228,
    2229,
    2230,
    2231,
    2232,
    2233,
    2234,
    2235,
    2236,
    2237,
    2238,
    2239,
    2240,
    2241,
    2242,
    2243,
    2244,
    2245,
    2246,
    2247,
    2248,
    2249,
    2250,
    2251,
    2252,
    2253,
    2254,
    2255,
    2256,
    2257,
    2258,
    2259,
    2260,
    2261,
    2262,
    2263,
    2264,
    2265,
    2266,
    2267,
    2268,
    2269,
    2270,
    2271,
    2272,
    2273,
    2274,
    2275,
    2276,
    2277,
    2278,
    2279,
    2280,
    2281,
    2282,
    2283,
    2284,
    2285,
    2286,
    2287,
    2288,
    2289,
    2290,
    2291,
    2292,
    2293,
    2294,
    2295,
    2296,
    2297,
    2298,
    2299,
    2300,
    2301,
    2302,
    2303,
    2304,
    2305,
    2306,
    2307,
    2308,
    2309,
    2310,
    2311,
    2312,
    2313,
    2314,
    2315,
    2316,
    2317,
    2318,
    2319,
    2320,
    2321,
    2322,
    2323,
    2324,
    2325,
    2326,
    2327,
    2328,
    2329,
    2330,
    2331,
    2332,
    2333,
    2334,
    2335,
    2336,
    2337,
    2338,
    2339,
    2340,
    2341,
    2342,
    2343,
    2344,
    2345,
    2346,
    2347,
    2348,
    2349,
    2350,
    2351,
    2352,
    2353,
    2354,
    2355,
    2356,
    2357,
    2358,
    2359,
    2360,
    2361,
    2362,
    2363,
    2364,
    2365,
    2366,
    2367,
    2368,
    2369,
    2370,
    2371,
    2372,
    2373,
    2374,
    2375,
    2376,
    2377,
    2378,
    2379,
    2380,
    2381,
    2382,
    2383,
    2384,
    2385,
    2386,
    2387,
    2388,
    2389,
    2390,
    2391,
    2392,
    2393,
    2394,
    2395,
    2396,
    2397,
    2398,
    2399,
    2400,
    2401,
    2402,
    2403,
    2404,
    2405,
    2406,
    2407,
    2408,
    2409,
    2410,
    2411,
    2412,
    2413,
    2414,
    2415,
    2416,
    2417,
    2418,
    2419,
    2420,
    2421,
    2422,
    2423,
    2424,
    2425,
    2426,
    2427,
    2428,
    2429,
    2430,
    2431,
    2432,
    2433,
    2434,
    2435,
    2436,
    2437,
    2438,
    2439,
    2440,
    2441,
    2442,
    2443,
    2444,
    2445,
    2446,
    2447,
    2448,
    2449,
    2450,
    2451,
    2452,
    2453,
    2454,
    2455,
    2456,
    2457,
    2458,
    2459,
    2460,
    2461,
    2462,
    2463,
    2464,
    2465,
    2466,
    2467,
    2468,
    2469
  ],
  "columns": [
    "section_level",
    "CPT_section",
    "type",
    "content",
    "font_info",
    "level_1_CPT_section",
    "file_section",
    "file_section_num",
    "file_section_level",
    "seq_num"
  ],
  "data": [
    [
      "",
      "Unmapped",
      "text",
      "Clinical Study Protocol",
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      1
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      2
    ],
    [
      "",
      "Unmapped",
      "text",
      "Drug Substance",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      3
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      4
    ],
    [
      "",
      "Unmapped",
      "text",
      "Adavosertib (AZD1775)",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      5
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      6
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study Code",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      7
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      8
    ],
    [
      "",
      "Unmapped",
      "text",
      "D601HC00008",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      9
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      10
    ],
    [
      "",
      "Unmapped",
      "text",
      "Version",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      11
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      12
    ],
    [
      "",
      "Unmapped",
      "text",
      "1.0",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      13
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      14
    ],
    [
      "",
      "Unmapped",
      "text",
      "Date",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      15
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      16
    ],
    [
      "",
      "Unmapped",
      "text",
      "9 March 2020",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      17
    ],
    [
      "",
      "Unmapped",
      "text",
      "A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumour Activity of Adavosertib (AZD1775) in Japanese Patients with Advanced Solid Tumours",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      18
    ],
    [
      "",
      "Unmapped",
      "text",
      "Sponsor:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      19
    ],
    [
      "",
      "Unmapped",
      "text",
      "AstraZeneca K.K.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      20
    ],
    [
      "",
      "Unmapped",
      "text",
      "3-1, Ofuka-cho, Kita-ku, Osaka, 530-0011, Japan",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      21
    ],
    [
      "",
      "Unmapped",
      "text",
      "Regulatory Agency Identifying Number(s):",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      22
    ],
    [
      "",
      "Unmapped",
      "text",
      "Not applicable",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TITLE",
      "",
      1,
      23
    ],
    [
      "",
      "Unmapped",
      "header",
      " VERSION HISTORY",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Unmapped",
      "VERSION HISTORY",
      "",
      "1",
      24
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Version 1.0, 9 March 2020</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Initial creation</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "1",
        "TableName": "",
        "Header": [0]
      },
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Unmapped",
      "VERSION HISTORY",
      "",
      "1",
      25
    ],
    [
      "",
      "Unmapped",
      "text",
      "This Clinical Study Protocol has been subject to a peer review according to AstraZeneca Standard procedures.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "VERSION HISTORY",
      "",
      "1",
      26
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Clinical Study Protocol is publicly registered and the results are disclosed and/or published according to the AstraZeneca Global Policy on Bioethics and in compliance with prevailing laws and regulations.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "VERSION HISTORY",
      "",
      "1",
      27
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "VERSION HISTORY",
      "",
      "1",
      28
    ],
    [
      "",
      "Unmapped",
      "header",
      " TABLE OF CONTENTS",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      29
    ],
    [
      "",
      "Unmapped",
      "text",
      "TITLE PAGE........................................................................................................................1",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      30
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      31
    ],
    [
      "",
      "Unmapped",
      "text",
      "LIST OF TABLES",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      32
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Table 1</td>\n      <td>Study of Assessments ................................................................................8</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Table 2</td>\n      <td>Study objectives.......................................................................................17</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Table 3</td>\n      <td>Treatment regimen...................................................................................18</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Table 4</td>\n      <td>Investigational Products...........................................................................24</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Table 5</td>\n      <td>Permitted medications..............................................................................27</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Table 6</td>\n      <td>Screening tests and the number of days prior to the first dose of investigational products...........................................................................34</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>Table 7</td>\n      <td>Laboratory safety variables......................................................................37</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>Table 8</td>\n      <td>Adavosertib QD Monotherapy Dose Level Reductions ............................45</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>Table 9</td>\n      <td>Neutrophil Blood Counts and Study Drug Action ....................................46</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>Table 10</td>\n      <td>Platelet Blood Counts and Study Drug Action..........................................47</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>Table 11</td>\n      <td>Management of anaemia..........................................................................47</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>Table 12</td>\n      <td>Adavosertib dose modifications for QTc prolongation .............................49</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>Table 13</td>\n      <td>PK sampling schedule for adavosertib......................................................51</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>Table 14</td>\n      <td>Populations for analyses ..........................................................................54</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>Table 15</td>\n      <td>Summary of Methods of Assessment .......................................................83</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>Table 16</td>\n      <td>Overall Visit Response for Target Lesions...............................................86</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>Table 17</td>\n      <td>Overall Visit Response for Non-Target Lesions.......................................87</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>Table 18</td>\n      <td>Overall Visit Response ............................................................................88</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "2",
        "TableName": "",
        "Header": []
      },
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      33
    ],
    [
      "",
      "Unmapped",
      "text",
      "LIST OF FIGURES",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      34
    ],
    [
      "",
      "Unmapped",
      "text",
      "Figure 1",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      35
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      36
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study design............................................................................................15",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      37
    ],
    [
      "",
      "Unmapped",
      "text",
      "LIST OF APPENDICES",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      38
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Appendix A</td>\n      <td>Regulatory, ethical and study oversight considerations.............................60</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Appendix B</td>\n      <td>Adverse event (AE) definitions and additional safety information............65</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Appendix C</td>\n      <td>Handling of Human Biological Samples ..................................................70</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Appendix D</td>\n      <td>Genetics...................................................................................................72</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Appendix E</td>\n      <td>Actions required in cases of increases in liver biochemistry and evaluation of Hy’s Law............................................................................76</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Appendix F</td>\n      <td>Heart Failure Stages – New York Heart Association (NYHA) Classification...........................................................................................81</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>Appendix G</td>\n      <td>Guidelines for Evaluation of Objective Tumour Response Using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1...............82</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>Appendix H</td>\n      <td>Acceptable Birth Control Methods...........................................................92</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>Appendix I</td>\n      <td>Eastern Cooperative Oncology Group (ECOG) Performance Status (PS).93</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>Appendix J</td>\n      <td>Disallowed Medications and Medications to be Administered with Caution....................................................................................................94</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>Appendix K</td>\n      <td>Abbreviations ..........................................................................................98</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "3",
        "TableName": "",
        "Header": [0, 1, 2, 3]
      },
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Unmapped",
      "TABLE OF CONTENTS",
      "",
      "1",
      39
    ],
    [
      "1",
      "Protocol Summary",
      "header",
      " 1  PROTOCOL SUMMARY",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Protocol Summary",
      "PROTOCOL SUMMARY",
      "1",
      "1",
      40
    ],
    [
      "2",
      "Schedule of Activities (SoA)",
      "header",
      " 1.1  Schedule of Activities (SoA)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Protocol Summary",
      "Schedule of Activities (SoA)",
      "1.1",
      "2",
      41
    ],
    [
      "2",
      "Schedule of Activities (SoA)",
      "text",
      "Table 1 shows the procedure and assessment schedule during study entry, as well as subsequent assessments in the clinical protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Schedule of Activities (SoA)",
      "1.1",
      "2",
      42
    ],
    [
      "2",
      "Schedule of Activities (SoA)",
      "text",
      "Details of the various procedures and assessments are provided in the subsequent protocol sections.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Schedule of Activities (SoA)",
      "1.1",
      "2",
      43
    ],
    [
      "2",
      "Schedule of Activities (SoA)",
      "text",
      "The assessment schedules for cohorts for different regimens may be added to this protocol as data emerges.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Schedule of Activities (SoA)",
      "1.1",
      "2",
      44
    ],
    [
      "2",
      "Schedule of Activities (SoA)",
      "header",
      " Table 1  Study of Assessments",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Protocol Summary",
      "Schedule of Activities (SoA)",
      "1.1",
      "2",
      45
    ],
    [
      "2",
      "Schedule of Activities (SoA)",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n      <th>5.0</th>\n      <th>6.0</th>\n      <th>7.0</th>\n      <th>8.0</th>\n      <th>9.0</th>\n      <th>10.0</th>\n      <th>11.0</th>\n      <th>12.0</th>\n      <th>13.0</th>\n      <th>14.0</th>\n      <th>15.0</th>\n      <th>16.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Assessments</td>\n      <td>Scree ning</td>\n      <td>Cycle 1</td>\n      <td>Cycle 1</td>\n      <td>Cycle 1</td>\n      <td></td>\n      <td>Cycle 2</td>\n      <td>Cycle 2</td>\n      <td></td>\n      <td>Cycle 3 and beyond</td>\n      <td>Cycle 3 and beyond</td>\n      <td>Every 9 weeks (±7 days) <sup>a</sup></td>\n      <td>EOT <sup>b</sup></td>\n      <td>30 days after the last dose Safety FU (+5 days)</td>\n      <td>Response FU a,c (±7 days)</td>\n      <td>Details in CSP section or Append ix</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>(cycle = 21 days)</td>\n      <td>(cycle = 21 days)</td>\n      <td>(cycle = 21 days)</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td></td>\n      <td></td>\n      <td>Day</td>\n      <td>Day</td>\n      <td>Day</td>\n      <td></td>\n      <td>Day</td>\n      <td>Day</td>\n      <td></td>\n      <td>Day</td>\n      <td>Day</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td></td>\n      <td>(-28 days to -1)</td>\n      <td>1</td>\n      <td>5</td>\n      <td>8</td>\n      <td>15 (±1 day)</td>\n      <td>1 d (+1 day)</td>\n      <td>5</td>\n      <td>8</td>\n      <td>1 d (+3 days)</td>\n      <td>5 e</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Informed consent <sup>f</sup></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>8 Appendi x A</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Hospitalisation <sup>g</sup></td>\n      <td></td>\n      <td> ======= </td>\n      <td> ======= </td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>6.6.2</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>Medical history/ demographics</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>8</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>Physical examination</td>\n      <td>X<sup> h</sup></td>\n      <td>X<sup> h</sup></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>8.2.2</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>Vital signs <sup>i</sup> weight, height</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>8.2.3</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>ECOG PS</td>\n      <td>X<sup> h</sup></td>\n      <td>X<sup> h</sup></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>8.2.4</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>Concomitant medications/procedure <sup>j</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>6.5</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>AE evaluation <sup>j, k</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>8.3</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>12-lead ECG <sup>l</sup></td>\n      <td>X<sup> h</sup></td>\n      <td>X<sup> h</sup></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td></td>\n      <td></td>\n      <td>8.2.5</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>Haematology</td>\n      <td>X<sup> h</sup></td>\n      <td>X<sup> h</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>8.2.1</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>Chemistry</td>\n      <td>X<sup> h</sup></td>\n      <td>X<sup> h</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>8.2.1</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>Coagulation <sup>m</sup></td>\n      <td>X<sup> h</sup></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>8.2.1</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>Pregnancy test if WoCBP <sup>n</sup></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>8.2.1</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>Urinalysis</td>\n      <td>X<sup> h</sup></td>\n      <td>X<sup> h</sup></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td>As clinically indicated</td>\n      <td></td>\n      <td></td>\n      <td>8.2.1</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>PK of adavosertib <sup>o</sup></td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>8.5</td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>Tumour marker <sup>p</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>8.1.2</td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>Tumour assessment <sup>q</sup> CT/MRI chest and abdomen/pelvis</td>\n      <td>X<sup> h</sup></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td>8.1.1</td>\n    </tr>\n    <tr>\n      <th>21</th>\n      <td>Dispense adavosertib <sup>r</sup></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>6.1.1, 6.2, 6.4</td>\n    </tr>\n    <tr>\n      <th>22</th>\n      <td>Antiemetics administration <sup>s, t</sup></td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>8.4.5.2.1</td>\n    </tr>\n    <tr>\n      <th>23</th>\n      <td>Adavosertib administration <sup>u, v</sup></td>\n      <td></td>\n      <td>X<sup> v</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>Figure 1, Table 3 6.4 8.4.5</td>\n    </tr>\n    <tr>\n      <th>24</th>\n      <td>Review and/or collection dosing diary <sup>r</sup></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>6.4</td>\n    </tr>\n    <tr>\n      <th>25</th>\n      <td>Exploratory genetic sample (Optional)</td>\n      <td></td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>8.7</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "4",
        "TableName": "Study of Assessments(Schedule of Assessment)",
        "FootnoteText_0": "5-HT =5-hydroxytryptamine, AE =adverse event, APTT =activated partial thromboplastin time, ASCO = American Society of Clinical Oncology, CSP = Clinical Study Protocol, CT = computed tomography, DLT =dose-limiting toxicity, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology Group, eCRF = electronic case report form, EOT = end of treatment, FU = follow-up, INR = international normalized ratio, IV = intravenously, MRI = magnetic resonance imaging, PD = progressive disease, PK = pharmacokinetics, PO = by mouth, PS = Performance Status, PT = prothrombin time, QD = once daily, RECIST = Response Evaluation Criteria in Solid Tumours, WoCBP = women of childbearing potential",
        "FootnoteText_1": "Subjects without evidence of undue toxicity may continue treatment with the study drug until disease progression, intolerable toxicity, or discontinuation criteria have been met.",
        "FootnoteText_2": "Subjects discontinuing adavosertib should be scheduled for an EOT study visit, preferably within 3 days of stopping drug.",
        "FootnoteText_3": "Subjects discontinuing from adavosertib in the absence of PD should undergo a CT/MRI every 12 weeks (± 7 days) from the last dose of study drug until PD has been assessed by the Investigator, or until the subject begins a new course of cancer therapy or withdraws from the study.",
        "FootnoteText_4": "The allowance after Cycle 2 is based on Day 1 of previous cycle.",
        "FootnoteText_5": "Day 5 is scheduled only for Cycles 3 and 5 (except for Cycles 1 and 2).",
        "FootnoteText_6": "Signed informed consent may be obtained prior to the 28-day screening window, if required.",
        "FootnoteText_7": "All subjects must be hospitalized until Cycle 1 Day 6.",
        "FootnoteText_8": "The screening physical examination, ECOG PS, haematology, clinical chemistry, coagulation, urinalysis, and ECGs should be done ≤7 days prior to initiating treatment.",
        "FootnoteText_9": "Vital signs (resting heart rate, systolic and diastolic blood pressure, and axillary temperature), weight, and height (at screening only) will be collected at screening (within 7 days prior to the first dose of study drug), prior to dosing on Day 1 of each cycle visit, at the EOT visit, and at safety FU visit.",
        "FootnoteText_10": "All subjects will be followed during the off-treatment period until all treatment-related toxicity resolves, or for at least 30 days post-study drug discontinuation.",
        "FootnoteText_11": "PK samples can also be collected at the time of AEs possibly related to adavosertib (unless the last dose of study drug was administered > 1 week prior to the event)",
        "FootnoteText_12": "ECGs will be obtained at screening to confirm eligibility (see Section 5.2), then on Cycle 1 Day 1, Cycle 1 Day 5 and Cycle 2 Day 1.",
        "FootnoteText_13": "Coagulation (PT/INR/APTT) will be obtained at screening.",
        "FootnoteText_14": "Pregnancy tests will only be performed in WoCBP within 3 days prior to the first dose of study treatment, prior to starting each new treatment cycle (except for Cycle 1), at the EOT visit, and at the safety FU visit (see Section 8.2.1).",
        "FootnoteText_15": "PK samples for adavosertib will be collected on Cycle 1 Day 1 and Cycle 1 Day 5 pre-dose and at 1 hour, 2, 4, 6, 8, 10 and 24 hours post-dose.",
        "FootnoteText_16": "When applicable, tumour markers that are elevated and are used by the Investigator to monitor for tumour response will be collected at screening (within 14 days prior to the first dose of study drug), Day 1 of each cycle pre-dose, and at the EOT.",
        "FootnoteText_17": "Initial (i.e., baseline) tumour imaging assessments (e.g., CT/MRI of the chest and abdomen/pelvis) will be performed within 28 days prior to the first dose of study drug and repeated every 9 weeks (± 7 days) relative to the date of first dose until PD unless subjects discontinue treatment in the absence of PD for undue toxicity.",
        "FootnoteText_18": "Adavosertib dosing compliance will be reviewed with the subject and documented at each visit.",
        "FootnoteText_19": "All subjects must receive a 5-HT3 antagonist, ondansetron 8 mg PO QD or granisetron 1 mg PO QD prior to each dose of adavosertib.",
        "FootnoteText_20": "Antiemetics will be taken on the same days of adavosertib dosing; therefore subjects will take antiemetics on a 5/2 dosing schedule (Days 1-5, 8-12 every 21 day-cycle; no treatment on Days 6-7 and 13-21).",
        "FootnoteText_21": "Adavosertib PO QD on Days 1-5 and Days 8-12 every 21 days (no treatment on Days 6-7 and 13-21).",
        "FootnoteText_22": "Due to frequent reports of diarrhoea with adavosertib administration, vigorous anti-diarrhoeal treatment loperamide is required at the first onset of diarrhoea according to ASCO guidelines.",
        "Header": [0, 1, 2, 3]
      },
      { "IsBold": true, "font_size": 18, "font_style": "" },
      "Protocol Summary",
      "Schedule of Activities (SoA)",
      "1.1",
      "2",
      46
    ],
    [
      "2",
      "Synopsis",
      "header",
      " 1.2  Synopsis",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      47
    ],
    [
      "2",
      "Synopsis",
      "header",
      " Principal investigator",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      48
    ],
    [
      "2",
      "Synopsis",
      "text",
      "The names and addresses of principal investigators are shown in Clinical Study Protocol Addendum.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      49
    ],
    [
      "2",
      "Synopsis",
      "text",
      "There is no coordinating investigator in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      50
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Refer to the Clinical Study Protocol Addendum for AstraZeneca personnel contact details.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      51
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Protocol Title:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      52
    ],
    [
      "2",
      "Synopsis",
      "text",
      "A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      53
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Tumour Activity of Adavosertib (AZD1775) in Japanese Patients with Advanced Solid Tumours",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      54
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Rationale:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      55
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Adavosertib is an inhibitor of WEE1, a protein tyrosine kinase.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      56
    ],
    [
      "2",
      "Synopsis",
      "text",
      "WEE1 phosphorylates and inhibits cyclin-dependent kinases 1 (CDK1) and 2 (CDK2), and is involved in regulation of the intra-S and G2 cell cycle checkpoints.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      57
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Proper functioning of these checkpoints is essential for deoxyribonucleic acid (DNA) metabolism and the DNA damage response (Coleman and Dunphy 1994, Parker and Piwnica-Worms 1992).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      58
    ],
    [
      "2",
      "Synopsis",
      "text",
      "CDK1 (also called cell division cycle 2, or CDC2) activity drives a cell from G2 phase of the cell cycle into mitosis.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      59
    ],
    [
      "2",
      "Synopsis",
      "text",
      "In response to DNA damage, WEE1 inhibits CDK1 to prevent the cell from dividing until the damaged DNA is repaired (G2 checkpoint arrest).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      60
    ],
    [
      "2",
      "Synopsis",
      "text",
      "CDK2 activity drives a cell into, and through, S-phase of the cell cycle in which the genome is duplicated in preparation for cell division.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      61
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Inhibition of WEE1 is expected to cause aberrantly high CDK2 activity in S-phase cells that, in turn, leads to unstable DNA replication structures and ultimately DNA damage.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      62
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Therefore, it is anticipated that adavosertib will have independent anti-tumour activity in the absence of added chemotherapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      63
    ],
    [
      "2",
      "Synopsis",
      "text",
      "The tumour suppressor protein p53 regulates G1 checkpoint.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      64
    ],
    [
      "2",
      "Synopsis",
      "text",
      "As the majority of human cancers harbour abnormalities in this pathway they become more dependent on S- and G2phase checkpoints (Sherr 1996).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      65
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Thus, S- and G2-checkpoint abrogation caused by inhibition of WEE1 may selectively sensitise p53-deficient cells to anti-cancer agents (Wang et al 2001).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      66
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Adavosertib used as monotherapy and/or in combination with other agents is being developed as a potential treatment for multiple tumor types, therefore it is considered appropriate to assess tolerability of adavosertib for Japanese patients.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      67
    ],
    [
      "2",
      "Synopsis",
      "header",
      " Objectives and Endpoints",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      68
    ],
    [
      "2",
      "Synopsis",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Primary objective:</td>\n      <td>Endpoint/variable:</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for adavosertib</td>\n      <td>Adverse events (AEs), DLTs, vital signs, electrocardiogram (ECG) results, and laboratory parameters</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Secondary objective:</td>\n      <td>Endpoint/variable:</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>To determine the pharmacokinetics (PK) profile of adavosertib</td>\n      <td>Summary PK parameters for adavosertib, such as maximum plasma drug concentration observed (C max ), time of maximum plasma drug concentration observed (t max ), area under the plasma concentration-time curve from zero to 24 hours (AUC 0-24 ) and trough plasma concentration (C trough )</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>To describe adavosertib’s preliminary anti-tumour activity using the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1</td>\n      <td>Objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progressionfree survival (PFS) assessed based on RECIST v1.1 by investigator assessment</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "5",
        "TableName": "Objectives and Endpoints",
        "Header": [0, 2]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      69
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Overall design:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      70
    ],
    [
      "2",
      "Synopsis",
      "text",
      "This is a phase I, open-label study to assess the safety, tolerability, PK and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      71
    ],
    [
      "2",
      "Synopsis",
      "text",
      "The safety, tolerability, PK and anti-tumour activities of adavosertib in combination with other agents may be explored as needed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      72
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Treatment regimen of each cohort is described in ‘Treatments and treatment duration' in this section.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      73
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Study Period:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      74
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Estimated date of first patient enrolled Q2 2020 Estimated date of last patient completed Q2 2021",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      75
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Number of Subjects:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      76
    ],
    [
      "2",
      "Synopsis",
      "text",
      "At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      77
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Any subjects not evaluable for DLT will be replaced.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      78
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Thus, the total number of subjects will depend upon the available data in each cohort and the Safety Review Committee (SRC)'s decision.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      79
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Treatments and treatment duration:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      80
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Subjects in each part will receive the study treatments as described below:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      81
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Cohort 1: Adavosertib 250 mg by mouth (PO) once daily (QD) for 5 days ON and 2 days OFF for week 1 and 2 of a 21 days cycle",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      82
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Cohort 2: Adavosertib 300 mg PO QD for 5 days ON and 2 days OFF for week 1 and 2 of a 21 days cycle",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      83
    ],
    [
      "2",
      "Synopsis",
      "text",
      "The study drug dose in each cohort may be subject to change in light of emerging data.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      84
    ],
    [
      "2",
      "Synopsis",
      "text",
      "The dose will be determined when each cohort starts.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      85
    ],
    [
      "2",
      "Synopsis",
      "text",
      "For more details, see Figure 1 and Section 6.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      86
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Subjects will be allowed to continue adavosertib until disease progression, intolerable toxicity, or discontinuation criteria have been met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      87
    ],
    [
      "2",
      "Synopsis",
      "header",
      " Statistical methods",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      88
    ],
    [
      "2",
      "Synopsis",
      "text",
      "Safety and tolerability evaluations will include, but not be limited to, AEs, physical examinations, laboratory data, vital signs, and ECGs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      89
    ],
    [
      "2",
      "Synopsis",
      "text",
      "The evaluations will be descriptive using summary statistics.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      90
    ],
    [
      "2",
      "Synopsis",
      "text",
      "PK plasma concentration data and PK parameters for adavosertib will be listed for each subject and summary statistics will be tabulated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      91
    ],
    [
      "2",
      "Synopsis",
      "text",
      "All analyses related to anti-tumour activities of adavosertib, such as ORR and DCR, will be descriptive; no formal statistical testing will be performed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      92
    ],
    [
      "2",
      "Synopsis",
      "text",
      "All analyses and reporting will be conducted by cohort, and overall where appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Synopsis",
      "1.2",
      "2",
      93
    ],
    [
      "2",
      "Schema",
      "header",
      " 1.3  Schema",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Protocol Summary",
      "Schema",
      "1.3",
      "2",
      94
    ],
    [
      "2",
      "Schema",
      "text",
      "The general study design is summarised in Figure 1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Protocol Summary",
      "Schema",
      "1.3",
      "2",
      95
    ],
    [
      "2",
      "Schema",
      "header",
      " Figure 1  Study design",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Protocol Summary",
      "Schema",
      "1.3",
      "2",
      96
    ],
    [
      "2",
      "Schema",
      "text",
      "Adavosertib 250 mg PO QD on 5/2 schedule (n=3-6)",
      { "IsBold": true, "font_size": 19, "font_style": "" },
      "Protocol Summary",
      "Schema",
      "1.3",
      "2",
      97
    ],
    [
      "2",
      "Schema",
      "text",
      "PO=by mouth, QD= once daily",
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Protocol Summary",
      "Schema",
      "1.3",
      "2",
      98
    ],
    [
      "1",
      "Introduction",
      "header",
      " 2  INTRODUCTION",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Introduction",
      "INTRODUCTION",
      "2",
      "1",
      99
    ],
    [
      "2",
      "Study Rationale",
      "header",
      " 2.1  Study rationale",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      100
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "Adavosertib is an inhibitor of WEE1, a protein tyrosine kinase.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      101
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "WEE1 phosphorylates and inhibits CDK1 and CDK2, and is involved in regulation of the intra-S and G2 cell cycle checkpoints.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      102
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "Proper functioning of these checkpoints is essential for DNA metabolism and the DNA damage response (Coleman and Dunphy 1994,Parker and Piwnica-Worms 1992).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      103
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "CDK1 (also called CDC2) activity drives a cell from G2 phase of the cell cycle into mitosis.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      104
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "In response to DNA damage, WEE1 inhibits CDK1 to prevent the cell from dividing until the damaged DNA is repaired (G2 checkpoint arrest).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      105
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "CDK2 activity drives a cell into, and through, S-phase of the cell cycle in which the genome is duplicated in preparation for cell division.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      106
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "Inhibition of WEE1 is expected to cause aberrantly high CDK2 activity in S-phase cells that, in turn, leads to unstable DNA replication structures and ultimately DNA damage.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      107
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "Therefore, it is anticipated that adavosertib will have independent anti-tumour activity in the absence of added chemotherapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      108
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "The tumour suppressor protein p53 regulates G1 checkpoint.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      109
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "As the majority of human cancers harbour abnormalities in this pathway they become more dependent on S- and G2phase checkpoints (Sherr 1996).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      110
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      111
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      112
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "Thus, S- and G2-checkpoint abrogation caused by inhibition of WEE1 may selectively sensitise p53-deficient cells to anti-cancer agents (Wang et al 2001).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      113
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "Adavosertib used as monotherapy and/or in combination with other agents is being developed as a potential treatment for multiple tumor types, therefore it is considered appropriate to assess tolerability of adavosertib for Japanese patients.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      114
    ],
    [
      "2",
      "Study Rationale",
      "text",
      "See Section 4.3 Justification for dose.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Study rationale",
      "2.1",
      "2",
      115
    ],
    [
      "2",
      "Background",
      "header",
      " 2.2  Background",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Introduction",
      "Background",
      "2.2",
      "2",
      116
    ],
    [
      "2",
      "Background",
      "text",
      "A detailed description of the chemistry, pharmacology, efficacy, and safety of adavosertib is provided in the Investigator's Brochure (IB).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Background",
      "2.2",
      "2",
      117
    ],
    [
      "",
      "Unmapped",
      "header",
      " 2.2.1  Experience in humans",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Introduction",
      "Experience in humans",
      "2.2.1",
      "3",
      118
    ],
    [
      "",
      "Unmapped",
      "text",
      "As of 11 November 2019, a total of approximately 883 patients have been exposed to adavosertib in AstraZeneca-sponsored or Merck-sponsored clinical studies studies, with the longest duration of exposure to be about 28 months.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Experience in humans",
      "2.2.1",
      "3",
      119
    ],
    [
      "",
      "Unmapped",
      "text",
      "In addition, approximately 897 patients have also received adavosertib as part of externally-sponsored scientific research.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Experience in humans",
      "2.2.1",
      "3",
      120
    ],
    [
      "",
      "Unmapped",
      "text",
      "These patients include those who have received single doses as high as 1300 mg of adavosertib as monotherapy, 325 mg of adavosertib in a single-dose in combination with chemotherapy, and 325 mg twice daily (BID) in a multiple-dose regimen in combination with chemotherapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Experience in humans",
      "2.2.1",
      "3",
      121
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "header",
      " 2.3  Benefit/risk assessment",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      122
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "The primary objectives of adavosertib studies, to date, have been to determine adavosertib's safety, tolerability, and efficacy as a monotherapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      123
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Adavosertib's preclinical safety profile and emerging clinical data revealed no risks that would have precluded investigation in this setting.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      124
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Monitoring has been, and still is, in place for those risks deemed to be most likely or serious, and for those that require further investigation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      125
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Please see the adavosertib IB for the identified risks (expected events) and standard safety practices to be followed when handling and administering adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      126
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Based on the safety data from the completed adavosertib clinical studies and preliminary data from ongoing studies, adverse drug reactions to adavosertib monotherapy include: anaemia, neutropenia and febrile neutropenia, thrombocytopenia, gastrointestinal events such as dyspepsia, diarrhoea, nausea and vomiting (with or without dehydration or serum electrolyte decreases), as well as decreased appetite.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      127
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Based on information emerging during the adavosertib clinical development programme, potential risks where a causal relationship with adavosertib monotherapy has not been established include asthenia/fatigue, gastrointestinal haemorrhage, lymphopenia/lymphocyte count decreased, leukopenia/white blood cell (WBC) count decreased, myalgia, stomatitis, sepsis, transaminases elevation and corrected QT interval (QTc) prolongation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      128
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Refer to the IB for adavosertib for more information on the potential benefits, assessment of potential, and known risks of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      129
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "The investigation of adavosertib in the patient population of this study appears acceptable based upon the safety profile and the lack of effective alternative treatments available to patients.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      130
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Thus, the benefit/risk ratio for this Phase I study supports the administration of adavosertib to patients with advanced solid tumours.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      131
    ],
    [
      "2",
      "Benefit/Risk Assessment",
      "text",
      "Refer to the IB for more detailed information.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Introduction",
      "Benefit/risk assessment",
      "2.3",
      "2",
      132
    ],
    [
      "",
      "Unmapped",
      "header",
      " 3  OBJECTIVES AND ENDPOINTS",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Introduction",
      "OBJECTIVES AND ENDPOINTS",
      "3",
      "1",
      133
    ],
    [
      "",
      "Unmapped",
      "text",
      "Table 2",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Introduction",
      "OBJECTIVES AND ENDPOINTS",
      "3",
      "1",
      134
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Introduction",
      "OBJECTIVES AND ENDPOINTS",
      "3",
      "1",
      135
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study objectives",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Introduction",
      "OBJECTIVES AND ENDPOINTS",
      "3",
      "1",
      136
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Primary Objective:</td>\n      <td>Endpoint/Variable:</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>To assess the safety and tolerability, describe any DLT for adavosertib</td>\n      <td>AEs, DLTs, vital signs, ECG results, and laboratory parameters</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Secondary Objective:</td>\n      <td>Endpoint/Variable:</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>To determine the PK profile of adavosertib</td>\n      <td>Summary PK parameters for adavosertib, such as C max t max AUC 0-24 and C trough</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>To describe adavosertib’s preliminary anti-tumour activity using the RECIST v1.1</td>\n      <td>ORR, DCR, DoR, and PFS assessed based on RECIST v1.1 by investigator assessment</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "6",
        "TableName": "",
        "Header": [0, 2]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Introduction",
      "OBJECTIVES AND ENDPOINTS",
      "3",
      "1",
      137
    ],
    [
      "1",
      "Study Design",
      "header",
      " 4  STUDY DESIGN",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Study Design",
      "STUDY DESIGN",
      "4",
      "1",
      138
    ],
    [
      "2",
      "Overall Design",
      "header",
      " 4.1  Overall design",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Design",
      "Overall design",
      "4.1",
      "2",
      139
    ],
    [
      "2",
      "Overall Design",
      "text",
      "For an overview of the study design see Figure 1, Section 1.3.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Overall design",
      "4.1",
      "2",
      140
    ],
    [
      "2",
      "Overall Design",
      "text",
      "For details on treatments given during the study, see Table 3 and Section 6.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Overall design",
      "4.1",
      "2",
      141
    ],
    [
      "2",
      "Overall Design",
      "text",
      "For details on what is included in the efficacy and safety endpoints, see Section 3 Objectives and Endpoints.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Overall design",
      "4.1",
      "2",
      142
    ],
    [
      "2",
      "Overall Design",
      "header",
      " Table 3  Treatment regimen",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Study Design",
      "Overall design",
      "4.1",
      "2",
      143
    ],
    [
      "2",
      "Overall Design",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n      <th>5.0</th>\n      <th>6.0</th>\n      <th>7.0</th>\n      <th>8.0</th>\n      <th>9.0</th>\n      <th>10.0</th>\n      <th>11.0</th>\n      <th>12.0</th>\n      <th>13.0</th>\n      <th>14.0</th>\n      <th>15.0</th>\n      <th>16.0</th>\n      <th>17.0</th>\n      <th>18.0</th>\n      <th>19.0</th>\n      <th>20.0</th>\n      <th>21.0</th>\n      <th>22.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>Cycle = 21 days</td>\n      <td>Cycle = 21 days</td>\n      <td>Cycle = 21 days</td>\n      <td>Cycle = 21 days</td>\n      <td>Cycle = 21 days</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Week</td>\n      <td></td>\n      <td></td>\n      <td>Week 1</td>\n      <td>Week 1</td>\n      <td>Week 1</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>Week 2</td>\n      <td>Week 2</td>\n      <td>Week 2</td>\n      <td>Week 2</td>\n      <td>Week 2</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>Week 3</td>\n      <td>Week 3</td>\n      <td>Week 3</td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Day</td>\n      <td>1</td>\n      <td>2</td>\n      <td>3</td>\n      <td>4</td>\n      <td>5</td>\n      <td>6</td>\n      <td>7</td>\n      <td>8</td>\n      <td>9</td>\n      <td>10</td>\n      <td>11</td>\n      <td>12</td>\n      <td>13</td>\n      <td>14</td>\n      <td>15</td>\n      <td>16</td>\n      <td>17</td>\n      <td>18</td>\n      <td>19</td>\n      <td>20</td>\n      <td>21</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Adavosertib 250 mg QD (Cohort 1)/ 300 mg QD (Cohort 2)</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "7",
        "TableName": "(Schedule of Assessment)",
        "Header": [0, 1, 2]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Design",
      "Overall design",
      "4.1",
      "2",
      144
    ],
    [
      "2",
      "Overall Design",
      "text",
      "Subjects will continue to receive treatment with the assigned dose until disease progression, intolerable toxicity, or discontinuation criteria have been met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Overall design",
      "4.1",
      "2",
      145
    ],
    [
      "2",
      "Scientific Rationale for Study Design",
      "header",
      " 4.2  Scientific rationale for study design",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Design",
      "Scientific rationale for study design",
      "4.2",
      "2",
      146
    ],
    [
      "2",
      "Scientific Rationale for Study Design",
      "text",
      "This is a phase 1, open-label study primarily designed to demonstrate adavosertib's safety in Japanese patients with advanced solid malignancies for whom no standard of care regimen currently exists.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Scientific rationale for study design",
      "4.2",
      "2",
      147
    ],
    [
      "2",
      "Scientific Rationale for Study Design",
      "text",
      "Adavosertib used as monotherapy and/or in combination with other agents may have broad applicability in multiple tumours, particularly in endometrial cancer, pancreatic cancer, ovarian tumours (Cuneo et al, 2019; Falchook et al, 2019; Moore et al, 2019; Bauer et al, 2019).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Scientific rationale for study design",
      "4.2",
      "2",
      148
    ],
    [
      "2",
      "Scientific Rationale for Study Design",
      "text",
      "Other data to be evaluated include the PK and anti-tumour activity of the regimens.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Scientific rationale for study design",
      "4.2",
      "2",
      149
    ],
    [
      "2",
      "Scientific Rationale for Study Design",
      "text",
      "The results from this study will form the basis for decisions for future studies.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Scientific rationale for study design",
      "4.2",
      "2",
      150
    ],
    [
      "2",
      "Justification for Dose",
      "header",
      " 4.3  Justification for dose",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Design",
      "Justification for dose",
      "4.3",
      "2",
      151
    ],
    [
      "2",
      "Justification for Dose",
      "text",
      "The doses of adavosertib to be evaluated in this study are 250 mg and 300 mg QD on 5 days on and 2 days off. These are based on the Phase Ib study (study code:D6015C00003) of adavosertib monotherapy in patients with locally advanced or metastatic solid tumours.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Justification for dose",
      "4.3",
      "2",
      152
    ],
    [
      "2",
      "Justification for Dose",
      "text",
      "In study D6015C00003, the overall safety profile of adavosertib 300 mg QD dose on 5 days on and 2 days off, dosing schedule given 2 weeks out of 3 weekly cycles, was considered acceptable and was, therefore, chosen as the recommended Phase II dose.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Justification for dose",
      "4.3",
      "2",
      153
    ],
    [
      "2",
      "Justification for Dose",
      "text",
      "This dose is currently being evaluated further, showing a promising efficacy signal, which also warrants further development in Japan.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Justification for dose",
      "4.3",
      "2",
      154
    ],
    [
      "2",
      "Justification for Dose",
      "text",
      "There was a trend towards an increased exposure to adavosertib as monotherapy in Asian patients (Study code: D6011C00003) compared to that in Western patients (Study code: PN011 [NCT01748825]; refer to IB Section 5.1.1.2 for more details); therefore, the dose one level below the recommended Phase 2 dose (RP2D) defined in Western patients are selected as the starting dose in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "Justification for dose",
      "4.3",
      "2",
      155
    ],
    [
      "2",
      "End of Study Definition",
      "header",
      " 4.4  End of study definition",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Design",
      "End of study definition",
      "4.4",
      "2",
      156
    ],
    [
      "2",
      "End of Study Definition",
      "text",
      "The end of study is defined as the last expected visit/contact of the last subject undergoing the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "End of study definition",
      "4.4",
      "2",
      157
    ],
    [
      "2",
      "End of Study Definition",
      "text",
      "A subject is considered to have completed the study when he/she has completed his/her last scheduled procedure shown in the SoA",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "End of study definition",
      "4.4",
      "2",
      158
    ],
    [
      "2",
      "End of Study Definition",
      "text",
      ".",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "End of study definition",
      "4.4",
      "2",
      159
    ],
    [
      "2",
      "End of Study Definition",
      "text",
      "See Appendix A 5 for guidelines for the dissemination of study results.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Design",
      "End of study definition",
      "4.4",
      "2",
      160
    ],
    [
      "1",
      "Study Population",
      "header",
      " 5  STUDY POPULATION",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Study Population",
      "STUDY POPULATION",
      "5",
      "1",
      161
    ],
    [
      "1",
      "Study Population",
      "text",
      "Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as protocol waivers or exemptions, is not permitted.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "STUDY POPULATION",
      "5",
      "1",
      162
    ],
    [
      "1",
      "Study Population",
      "text",
      "Each subject should meet all of the inclusion criteria and none of the exclusion criteria for this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "STUDY POPULATION",
      "5",
      "1",
      163
    ],
    [
      "1",
      "Study Population",
      "text",
      "Under no circumstances can there be exceptions to this rule.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "STUDY POPULATION",
      "5",
      "1",
      164
    ],
    [
      "1",
      "Study Population",
      "text",
      "Subjects who do not meet the entry requirements are screen failures, refer to Section 5.4.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "STUDY POPULATION",
      "5",
      "1",
      165
    ],
    [
      "1",
      "Study Population",
      "text",
      "For procedures for withdrawal of incorrectly enrolled subjects see Section 7.3.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "STUDY POPULATION",
      "5",
      "1",
      166
    ],
    [
      "2",
      "Inclusion Criteria",
      "header",
      " 5.1  Inclusion criteria",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      167
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "For inclusion in the study, patients should fulfil the following criteria:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      168
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Has read and understands the informed consent form (ICF) and has given written ICF prior to any study-specific procedures.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      169
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Japanese patients ≥20 years of age at the time of study entry.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      170
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0, 1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      171
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Baseline laboratory values within 7 days of starting study drug:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      172
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Absolute neutrophil count (ANC) ≥1,500/μL",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      173
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Haemoglobin ≥9 g/dL, with no blood transfusion in the past 28 days",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      174
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Platelets ≥100,000/μL",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      175
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) or ≤5 x ULN if known hepatic metastases.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      176
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Serum bilirubin within normal limits (WNL) or ≤1.5 x ULN in patients with liver metastases; or total bilirubin (TBL) ≤3.0 x ULN with direct bilirubin WNL in patients with well documented Gilbert's Syndrome.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      177
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Serum creatinine ≤1.5 x ULN, or measured creatinine clearance (CrCl) ≥45 mL/min using either the Cockcroft-Gault method, a 24 hour urine test or another validated test as per local practice (confirmation of CrCl is only required when creatinine is > 1.5 x institutional ULN)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      178
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "(140-age [years]) x (weight[kg]) xF",
      { "IsBold": false, "font_size": 17, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      179
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "a",
      { "IsBold": false, "font_size": 21, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      180
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Estimated CrCl =",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      181
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "(72 x serum creatinine mg/dL)",
      { "IsBold": false, "font_size": 17, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      182
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      183
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "a",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      184
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      185
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "where F = 0.85 for females and F = 1 for males",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      186
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Female patients who are not of child-bearing potential*, and fertile females of childbearing potential who agree to use adequate contraceptive measures from 2 weeks prior to the study drug exposure and until 1 month after study treatment discontinuation, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 3 days prior to start of study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      187
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "*Postmenopausal or premenopausal with evidence of non-childbearing potential is defined as:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      188
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Age ≥60 years, or",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      189
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Age <60 with any one or more of the conditions below:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      190
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Amenorrheic for ≥1 year in the absence of chemotherapy and/or hormonal treatments",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      191
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Luteinizing hormone and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      192
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Radiation-induced oophorectomy with last menses >1 year ago",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      193
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "o",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      194
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Chemotherapy-induced menopause with >1 year interval since last menses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      195
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "o",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      196
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Surgical sterilization (bilateral oophorectomy or hysterectomy)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      197
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Male patients should be willing to use barrier contraception (i.e., condoms) for the duration of the study drug exposure and for 3 months after study treatment discontinuation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      198
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Predicted life expectancy ≥12 weeks.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      199
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Willingness and ability to comply with all study and follow-up procedures.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      200
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Histologically or cytologically documented locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      201
    ],
    [
      "2",
      "Inclusion Criteria",
      "text",
      "Measurable or non-measurable disease according to RECIST v1.1 or Appendix G.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Inclusion criteria",
      "5.1",
      "2",
      202
    ],
    [
      "2",
      "Exclusion Criteria",
      "header",
      " 5.2  Exclusion criteria",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      203
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Patients should not enter the study if any of the following exclusion criteria are fulfilled:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      204
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      205
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Has had prior exposure to adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      206
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Use of anti-cancer treatment drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      207
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "For drugs for which 5 half-lives is ≤21 days, a minimum of",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      208
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "10 days between termination of the prior treatment and administration of adavosertib treatment is required.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      209
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Patients on luteinizing hormone-releasing hormone (LHRH) analogue treatment for more than 6 months may enter the study and continue at the discretion of the Investigator.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      210
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "No other anticancer-therapy (chemotherapy, immunotherapy, hormonal anti-cancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent is permitted while the patient is receiving study medication.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      211
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Use of an investigational drug during the past 30 days or 5 half-lives (whichever is longer) prior to the first dose of the study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      212
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Major surgical procedures ≤28 days, or minor surgical procedures ≤7 days, prior to beginning study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      213
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "No waiting period required following port-a-cath or other central venous access placement.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      214
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Common Terminology Criteria for Adverse Events (CTCAE) Grade >1 toxicity from prior therapy (except for alopecia, anorexia or CTCAE grade 2 peripheral neuropathy).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      215
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Inability to swallow oral medication or any other condition that may impact adavosertib intake/absorption.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      216
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Note: Patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      217
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Any prior palliative radiation must have been completed at least 7 days prior to the start of the study drug, and patients must have recovered from any acute adverse effects prior to the start of study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      218
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases - defined as metastasis having no evidence of progression or haemorrhage for at least 2 weeks after treatment (including brain radiotherapy).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      219
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Must be off any systemic corticosteroids for the treatment of brain metastases for at least 14 days prior to enrolment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      220
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Has had prescription or non-prescription drugs or other products known to be moderate to strong cytochrome P450 (CYP) 3A4 inhibitors/inducers which cannot be discontinued 14 days prior to the first dose of the study drug and withheld throughout the study until 14 days after the last dose of study drug (for more information about CYP3A4 inhibitors/inducers, see Section 6.5.1 and Appendix J).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      221
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Has had breast cancer resistance protein (BCRP) substrates, such as atorvastatin and rosuvastatin, Multidrug and Toxin Extruder 1 (MATE1) and Multidrug and Toxin Extruder 2K (MATE2K) substrates, such as metformin, which cannot be discontinued 7 days prior to the first dose of study drug and withheld throughout the study until 7 days after the last dose of study drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      222
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Please see Section 6.5.1 and Appendix J for further details.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      223
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Has had herbal medications which cannot be discontinued 7 days prior to the first dose of the study drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      224
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Please see Section 6.5.1 and Appendix J for further details.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      225
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Any known hypersensitivity or contraindication to the components of the study drug adavosertib (see Section 6.5).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      226
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Any of the following cardiac diseases currently or within the last 6 months:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      227
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Unstable angina pectoris",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      228
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Congestive heart failure ≥ Class 2 (as defined by New York Heart Association [NYHA]) (see Appendix F)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      229
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Acute myocardial infarction",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      230
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Conduction abnormality not controlled with pacemaker or medication",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      231
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Significant ventricular or supraventricular arrhythmias (patients with chronic ratecontrolled atrial fibrillation in the absence of other cardiac abnormalities are eligible)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      232
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Adavosertib should not be given to patients who have a history of Torsades de pointes (TdP) unless all risk factors that contributed to Torsades have been corrected.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      233
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "a) Resting corrected QT interval using the Fridericia formula (QTcF) >480 msec (as calculated per institutional standards) obtained from an ECG (NOTE: if one ECG demonstrates a QTcF > 480 msec, then a mean QTcF of ≤480 msec obtained from 3 ECGs 2-5 minutes apart, is required at study entry), or b) congenital long QT syndrome",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      234
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Pregnant or breast-feeding women.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      235
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Active hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) at the time of study entry.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      236
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] immunoglobulin G [IgG] and absence of HBsAg and HBV deoxyribonucleic acid [DNA]) are eligible.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      237
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      238
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Any underlying medical condition that would impair the patient's ability to receive study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      239
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Other invasive malignancy within 5 years prior to the first dose of study drug except for non-invasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, nonmelanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured, and gastrointestinal malignancies that have been cured with endoscopic resection.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      240
    ],
    [
      "2",
      "Exclusion Criteria",
      "text",
      "Physical, psychological, familial, sociological, or geographical, or any other conditions that do not permit compliance with protocol/study assessments.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Exclusion criteria",
      "5.2",
      "2",
      241
    ],
    [
      "",
      "Unmapped",
      "header",
      " 5.3  Lifestyle restrictions",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Lifestyle restrictions",
      "5.3",
      "2",
      242
    ],
    [
      "3",
      "Meals and Dietary Restrictions",
      "header",
      " 5.3.1  Meals and Dietary Restrictions",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Meals and Dietary Restrictions",
      "5.3.1",
      "3",
      243
    ],
    [
      "3",
      "Meals and Dietary Restrictions",
      "text",
      "Grapefruit and Seville oranges are moderate inhibitors of CYP3A4; these fruits or their products (including marmalade, juice, etc.) should be avoided while taking adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Meals and Dietary Restrictions",
      "5.3.1",
      "3",
      244
    ],
    [
      "3",
      "Meals and Dietary Restrictions",
      "text",
      "Please refer to Appendix J for further guidance.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Meals and Dietary Restrictions",
      "5.3.1",
      "3",
      245
    ],
    [
      "",
      "Unmapped",
      "header",
      " 5.3.2  Contraception",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      246
    ],
    [
      "",
      "Unmapped",
      "text",
      "WoCBP may be included only if acceptable contraception is in place from 2 weeks prior to the study drug exposure, for the duration of the treatment with the study drug, and for 1 month after the last dose of the study drug (see Section 5.1 for definitions of non-childbearing potential and Appendix H for acceptable contraceptive methods)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      247
    ],
    [
      "",
      "Unmapped",
      "text",
      "WoCBP defined as: Women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      248
    ],
    [
      "",
      "Unmapped",
      "text",
      "The following considerations apply while the subject is receiving study medication and for the specific times before and after:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      249
    ],
    [
      "",
      "Unmapped",
      "text",
      "All methods of female contraception must be used in combination with the use of a condom by a male sexual partner for intercourse.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      250
    ],
    [
      "",
      "Unmapped",
      "text",
      "All WoCBP must have a negative pregnancy test within 3 days prior to the first dose of study treatment and prior to starting each treatment cycle.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      251
    ],
    [
      "",
      "Unmapped",
      "text",
      "Male subjects who are involved in the study must agree to avoid procreative and unprotected sex (i.e., using acceptable forms of contraception as described in",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      252
    ],
    [
      "",
      "Unmapped",
      "text",
      "Appendix H) and must not donate sperm for the duration of study drug exposure and for 3 months after the last dose of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      253
    ],
    [
      "",
      "Unmapped",
      "text",
      "Female partners, who are of child-bearing potential, of men participating in clinical studies of the study treatment will also be required to use effective contraceptive measures (detailed in Appendix H) while their partner is on study drug and for 3 months after the last dose of the study drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      254
    ],
    [
      "",
      "Unmapped",
      "text",
      "Male subjects will be advised to arrange for the freezing of sperm samples prior to the start of the study should they wish to father children while on adavosertib or during the 3 months after stopping adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Contraception",
      "5.3.2",
      "3",
      255
    ],
    [
      "2",
      "Screen Failures",
      "header",
      " 5.4  Screen failures",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Screen failures",
      "5.4",
      "2",
      256
    ],
    [
      "2",
      "Screen Failures",
      "text",
      "Screen failures are defined as subjects who signed the ICF to participate in the clinical study but did not subsequently start the study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Screen failures",
      "5.4",
      "2",
      257
    ],
    [
      "2",
      "Screen Failures",
      "text",
      "A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Screen failures",
      "5.4",
      "2",
      258
    ],
    [
      "2",
      "Screen Failures",
      "text",
      "Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Screen failures",
      "5.4",
      "2",
      259
    ],
    [
      "2",
      "Screen Failures",
      "text",
      "Individuals who do not meet the criteria for participation in this study (screen failure) may not be rescreened.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Screen failures",
      "5.4",
      "2",
      260
    ],
    [
      "2",
      "Screen Failures",
      "text",
      "However, retesting of eligibility for re-obtained blood samples will be permitted within the 28-day screening window, if the patient who has a blood abnormality once subsequently improves such that the eligibility criteria are met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Screen failures",
      "5.4",
      "2",
      261
    ],
    [
      "2",
      "Screen Failures",
      "text",
      "These subjects should have the reason for study withdrawal recorded in the electronic case report form (eCRF).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Screen failures",
      "5.4",
      "2",
      262
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6  STUDY TREATMENTS",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Study Population",
      "STUDY TREATMENTS",
      "6",
      "1",
      263
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study treatment is defined as any investigational product(s) (including marketed product comparator and placebo) or medical device(s) intended to be administered to a study participant according to the study protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "STUDY TREATMENTS",
      "6",
      "1",
      264
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study treatment in this study refers to Table 4.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "STUDY TREATMENTS",
      "6",
      "1",
      265
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.1 Treatments administered",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Treatments administered",
      "6.1",
      "2",
      266
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.1.1 Investigational products",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Investigational products",
      "6.1.1",
      "3",
      267
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 4  Investigational Products",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Study Population",
      "Investigational products",
      "6.1.1",
      "3",
      268
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Investigational products name:</td>\n      <td>AZD1775 capsules</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Dosage formulation:</td>\n      <td>50 mg, 75 mg, or 100 mg capsules</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Route of administration:</td>\n      <td>Oral administration</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Provider:</td>\n      <td>AsterZeneca K.K.</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "8",
        "TableName": "Investigational Products",
        "Header": [0, 1, 2, 3]
      },
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Study Population",
      "Investigational products",
      "6.1.1",
      "3",
      269
    ],
    [
      "",
      "Unmapped",
      "text",
      "Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local regulatory guidelines.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Investigational products",
      "6.1.1",
      "3",
      270
    ],
    [
      "",
      "Unmapped",
      "text",
      "The labels will fulfil GMP Annex 13 requirements for labelling.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Investigational products",
      "6.1.1",
      "3",
      271
    ],
    [
      "",
      "Unmapped",
      "text",
      "Label text will be translated into local languages.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Investigational products",
      "6.1.1",
      "3",
      272
    ],
    [
      "",
      "Unmapped",
      "text",
      "Specific dosing instructions will not be included on the label.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Investigational products",
      "6.1.1",
      "3",
      273
    ],
    [
      "2",
      "Preparation/Handling/Storage/Accountability",
      "header",
      " 6.2  Preparation/handling/storage/accountability",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Preparation/handling/storage/accountability",
      "6.2",
      "2",
      274
    ],
    [
      "2",
      "Preparation/Handling/Storage/Accountability",
      "text",
      "The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study treatment received and any discrepancies are reported and resolved before use of the study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Preparation/handling/storage/accountability",
      "6.2",
      "2",
      275
    ],
    [
      "2",
      "Preparation/Handling/Storage/Accountability",
      "text",
      "Only subjects enrolled in the study may receive study treatment and only authorised site staff may supply or administer study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Preparation/handling/storage/accountability",
      "6.2",
      "2",
      276
    ],
    [
      "2",
      "Preparation/Handling/Storage/Accountability",
      "text",
      "All study treatments must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labelled storage conditions with access limited to the investigator and authorised site staff.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Preparation/handling/storage/accountability",
      "6.2",
      "2",
      277
    ],
    [
      "2",
      "Preparation/Handling/Storage/Accountability",
      "text",
      "The investigator, institution, or the head of the medical institution (where applicable) is responsible for study treatment accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Preparation/handling/storage/accountability",
      "6.2",
      "2",
      278
    ],
    [
      "2",
      "Preparation/Handling/Storage/Accountability",
      "text",
      "The study drug provided for this study will be used only as directed in the Clinical Study Protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Preparation/handling/storage/accountability",
      "6.2",
      "2",
      279
    ],
    [
      "2",
      "Measures to Minimize Bias: Randomization and Blinding",
      "header",
      " 6.3  Measures to minimise bias: randomisation and blinding",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Measures to minimise bias: randomisation and blinding",
      "6.3",
      "2",
      280
    ],
    [
      "2",
      "Measures to Minimize Bias: Randomization and Blinding",
      "text",
      "Not applicable as this is an open-label study and randomization is not planned for enrolled subjects.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Measures to minimise bias: randomisation and blinding",
      "6.3",
      "2",
      281
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.4  Treatment compliance",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      282
    ],
    [
      "",
      "Unmapped",
      "text",
      "For treatment regimens, see Table 3.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      283
    ],
    [
      "",
      "Unmapped",
      "text",
      "Adavosertib should be taken with a cup of water (about 150-200 mL), regardless of the timing of food intake.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      284
    ],
    [
      "",
      "Unmapped",
      "text",
      "Whenever possible, all doses of adavosertib should be taken at approximately the same times.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      285
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a subject misses a dose according to the schedule, the dose should be taken as soon as possible, but no more than 12 hours after the missed dose was scheduled.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      286
    ],
    [
      "",
      "Unmapped",
      "text",
      "If greater than 12 hours, the missed dose should be skipped and the subject should take the next dose when scheduled.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      287
    ],
    [
      "",
      "Unmapped",
      "text",
      "If vomiting occurs after a subject takes the adavosertib dose, the subject should be instructed not to retake the dose, but to wait until the next scheduled dose of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      288
    ],
    [
      "",
      "Unmapped",
      "text",
      "If no dose is scheduled for the following day, the dose will not be ‘made up'.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      289
    ],
    [
      "",
      "Unmapped",
      "text",
      "If vomiting persists, the subject should contact the Investigator.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      290
    ],
    [
      "",
      "Unmapped",
      "text",
      "The time of vomiting will be recorded in source documents if the vomiting occurred on a PK collection day or during the DLT evaluation period.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      291
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any change from the dosing schedule, dose interruptions, dose reductions, dose discontinuations should be recorded in eCRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      292
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Investigational Product Storage Manager is responsible for managing the study drug from receipt by the study site until the destruction or return of all unused study drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      293
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Investigator(s) is responsible for ensuring that the subject has returned all unused study drug, in addition to returning any empty bottles.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      294
    ],
    [
      "",
      "Unmapped",
      "text",
      "The subject will be provided with study drug at each treatment cycle visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      295
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dosing diaries will be collected at the beginning of each new cycle and at the end of treatment (EOT).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      296
    ],
    [
      "",
      "Unmapped",
      "text",
      "Adavosertib dosing compliance will be reviewed with the subject and documented at each visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      297
    ],
    [
      "",
      "Unmapped",
      "text",
      "The subject should come to the study site without taking the study drug; instead, the subject should bring the study drug to the study site and take it as instructed by the investigator during the scheduled visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment compliance",
      "6.4",
      "2",
      298
    ],
    [
      "2",
      "Concomitant Therapy",
      "header",
      " 6.5  Concomitant therapy",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Concomitant therapy",
      "6.5",
      "2",
      299
    ],
    [
      "2",
      "Concomitant Therapy",
      "text",
      "All concomitant medications/procedure taken within 14 days before the first dose of adavosertib and up to 30 days after the last dose of adavosertib should be recorded in the appropriate sections of eCRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Concomitant therapy",
      "6.5",
      "2",
      300
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.5.1  Prohibited concomitant medications",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      301
    ],
    [
      "",
      "Unmapped",
      "text",
      "The following treatments and medications are prohibited while in this study (For details, see Appendix J).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      302
    ],
    [
      "",
      "Unmapped",
      "text",
      "If such medications are required for a subject, then the subject must be withdrawn from the study before taking them.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      303
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any further questions regarding concomitant treatments should be referred to the Study Physician.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      304
    ],
    [
      "",
      "Unmapped",
      "text",
      "In vitro",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      305
    ],
    [
      "",
      "Unmapped",
      "text",
      "data has shown that adavosertib is metabolised by CYP3A4.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      306
    ],
    [
      "",
      "Unmapped",
      "text",
      "In clinic, coadministration of adavosertib with aprepitant, a moderate CYP3A4 inhibitor, resulted in a 40% increase in the plasma levels of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      307
    ],
    [
      "",
      "Unmapped",
      "text",
      "Drugs known to be moderate to strong inhibitors or inducers of CYP3A4 are, therefore, prohibited for use in this study, including aprepitant and fosaprepitant.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      308
    ],
    [
      "",
      "Unmapped",
      "text",
      "In vitro",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      309
    ],
    [
      "",
      "Unmapped",
      "text",
      "transporter studies have shown adavosertib is a BCRP inhibitor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      310
    ],
    [
      "",
      "Unmapped",
      "text",
      "This finding is particularly relevant for drugs administered orally where exposure is normally limited by BCRP-mediated efflux, such as atorvastatin and rosuvastatin.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      311
    ],
    [
      "",
      "Unmapped",
      "text",
      "Use of metformin is prohibited in this study since adavosertib is an inhibitor of MATE1 and MATE2K transporters.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      312
    ],
    [
      "",
      "Unmapped",
      "text",
      "A drug interaction with substrates of either transporter cannot be ruled out; metformin is the most important substrate known to date.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      313
    ],
    [
      "",
      "Unmapped",
      "text",
      "Herbal preparations/medications are not allowed throughout the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      314
    ],
    [
      "",
      "Unmapped",
      "text",
      "These herbal medications include, but are not limited to, those containing: St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      315
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects should stop using these herbal medications 7 days prior to the first dose of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      316
    ],
    [
      "",
      "Unmapped",
      "text",
      "No other anticancer-therapy (chemotherapy, immunotherapy, hormonal anti-cancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent is to be permitted while the subject is receiving the study medication.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      317
    ],
    [
      "",
      "Unmapped",
      "text",
      "Receipt of live virus and live bacterial vaccines whilst the subject is receiving study medication and during the 30-day follow up period is prohibited.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      318
    ],
    [
      "",
      "Unmapped",
      "text",
      "Inactivated flu vaccines are permitted.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Prohibited concomitant medications",
      "6.5.1",
      "3",
      319
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.5.2  Restricted concomitant medications",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      320
    ],
    [
      "",
      "Unmapped",
      "text",
      "The following treatments and medications should be used with caution while in this study (For details, see Appendix J).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      321
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any further questions regarding concomitant treatments should be referred to the Study Physician.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      322
    ],
    [
      "",
      "Unmapped",
      "text",
      "In vitro",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      323
    ],
    [
      "",
      "Unmapped",
      "text",
      "studies have shown that adavosertib may be a substrate and inhibitor for human P-glycoprotein (P-gp).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      324
    ],
    [
      "",
      "Unmapped",
      "text",
      "Caution should be exercised when agents that are inhibitors or substrates of P-gp are administered concomitantly with adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      325
    ],
    [
      "",
      "Unmapped",
      "text",
      "Adavosertib is a BCRP inhibitor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      326
    ],
    [
      "",
      "Unmapped",
      "text",
      "The drugs where the disposition is mediated via BCRP, except for atorvastatin and rosuvastatin which are prohibited in this study, should be administered with caution; Dose modification or an alternative drug should be considered.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      327
    ],
    [
      "",
      "Unmapped",
      "text",
      "Adavosertib is an inhibitor of MATE1 and MATE2K transporters.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      328
    ],
    [
      "",
      "Unmapped",
      "text",
      "The substrates of either transporter (e.g., cimetidine, acyclovir and fexofenadine) should be used with caution, except for metformin, which is prohibited in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Restricted concomitant medications",
      "6.5.2",
      "3",
      329
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.5.3  Permitted concomitant medications",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Permitted concomitant medications",
      "6.5.3",
      "3",
      330
    ],
    [
      "",
      "Unmapped",
      "text",
      "The following treatments are permitted to use while in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Permitted concomitant medications",
      "6.5.3",
      "3",
      331
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 5  Permitted medications",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Population",
      "Permitted concomitant medications",
      "6.5.3",
      "3",
      332
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Permitted medication/class of drug:</td>\n      <td>Usage (including limits for duration permitted and special situations in which it’s allowed):</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Antiemetics (excluding aprepitant and fosaprepitant)</td>\n      <td>Premedication with antiemetics is mandatory (excluding aprepitant and fosaprepitant) as presented in Section 8.4.5.2.1.</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Loperamide</td>\n      <td>Loperamide is required at the first onset of diarrhoea according to ASCO guidelines (see Section 8.4.5.2.2).</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Medications including but not limited to the following: Bisphosphonates and RANKL inhibitors (e.g., denosumab). Subjects requiring therapeutic warfarin or coumadin-derivative anticoagulants will be monitored with INR, PT and APTT at screening and at the beginning of each cycle. Low molecular weight heparin, rivaroxaban, or equivalent anticoagulant therapy is permitted where clinically indicated. Subjects may receive treatment with megestrol acetate when prescribed for appetite stimulation.</td>\n      <td>Medications may be administered for maintenance of existing conditions prior to study enrolment or for a new condition that develops while on study.</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Hematopoietic growth factors</td>\n      <td>Consider using G-CSF in the event of severe neutropenia or febrile neutropenia according to institutional guidelines.</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Palliative radiotherapy</td>\n      <td>Subjects may receive palliative radiotherapy during the trial only for local pain control, and only if in the opinion of the treating Investigator the subject does not have disease progression.</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "9",
        "TableName": "Permitted medications",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Population",
      "Permitted concomitant medications",
      "6.5.3",
      "3",
      333
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.5.4  Other concomitant treatment",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Other concomitant treatment",
      "6.5.4",
      "3",
      334
    ],
    [
      "",
      "Unmapped",
      "text",
      "Medication other than that described above, which is considered necessary for the subject's safety and wellbeing, may be given at the discretion of the Investigator and recorded in the appropriate sections of the case report form (CRF).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Other concomitant treatment",
      "6.5.4",
      "3",
      335
    ],
    [
      "2",
      "Dose Modification",
      "header",
      " 6.6  Dose modification",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Dose modification",
      "6.6",
      "2",
      336
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.6.1  Dose escalation guideline",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      337
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dose escalation will occur in accordance with the following rules:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      338
    ],
    [
      "",
      "Unmapped",
      "text",
      "Initially, 3 subjects will be enrolled in each cohort.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      339
    ],
    [
      "",
      "Unmapped",
      "text",
      "If one of the first 3 subjects treated in a given cohort experiences a DLT, additional subjects, up to 6 total, will be treated in that cohort.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      340
    ],
    [
      "",
      "Unmapped",
      "text",
      "If less than one-third of evaluable subjects in a given cohort experiences a DLT (i.e., 0 of 3 or 1 of 6), escalation may proceed to the next higher dose level.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      341
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a DLT is observed in one-third or more of subjects (e.g., 2 or more of up to 6 evaluable subjects), the enrolment in that cohort will be stopped.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      342
    ],
    [
      "",
      "Unmapped",
      "text",
      "If less than one-third of subjects experience a DLT in Cohort 2, the assessment will be completed and that dose level will be declared tolerable.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      343
    ],
    [
      "",
      "Unmapped",
      "text",
      "Alternative dose levels/cohorts and dosing schedules may include reductions of dose interval and may be guided by PK evaluations as well as tolerability and may be evaluated before or after the maximum-tolerated dose (MTD)/recommended dose is defined.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      344
    ],
    [
      "",
      "Unmapped",
      "text",
      "Modified PK assessments will be obtained to harmonise and accommodate the investigation of alternative dose levels and/or schedules.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      345
    ],
    [
      "",
      "Unmapped",
      "text",
      "The SRC will evaluate emerging safety, tolerability, and PK profiles (if possible) to support dose escalation decisions (see Section 6.6.3).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      346
    ],
    [
      "",
      "Unmapped",
      "text",
      "Intra-subject dose escalation is not permitted.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      347
    ],
    [
      "",
      "Unmapped",
      "text",
      "Intermittent or alternative doses and schedules of adavosertib may be explored.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose escalation guideline",
      "6.6.1",
      "3",
      348
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.6.2  Dose-limiting Toxicity (DLT)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      349
    ],
    [
      "",
      "Unmapped",
      "text",
      "DLTs will be evaluated from the first dose of study drug until assessment prior to the planned first dose of Cycle 2.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      350
    ],
    [
      "",
      "Unmapped",
      "text",
      "Toxicity will be graded according to the CTCAE V 5.0.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      351
    ],
    [
      "",
      "Unmapped",
      "text",
      "Toxicities that are potential DLTs should be followed closely enough to determine the recovery and judge whether they are DLTs (e.g., complete blood counts [CBC] should be repeated within 7 days, rather than on Day 23 (Day 22+1 day allowance) following grade 4 haematologic toxicities on Cycle 1 Day 15, in consideration of DLT: Haematologic toxicity ≥ Grade 4 for more than 7 days including infection with febrile neutropenia).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      352
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects must complete safety evaluations and must receive at least 70% of the planned dose to be considered evaluable for DLT as judged by the SRC.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      353
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects must complete safety evaluations to be evaluable for DLT.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      354
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any subjects who are not evaluable for DLT will be replaced unless they experienced a DLT confirmed by the SRC.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      355
    ],
    [
      "",
      "Unmapped",
      "text",
      "DLTs are defined as any of the following toxicities not attributable to the disease or diseaserelated process under investigation, which occur from the first dose of study treatment up to the assessment prior to the planned first dose of Cycle 2, and that meet at least one of the criteria below:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      356
    ],
    [
      "",
      "Unmapped",
      "text",
      "Haematologic toxicity ≥ Grade 4 for more than 7 days",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      357
    ],
    [
      "",
      "Unmapped",
      "text",
      "Grade ≥3 thrombocytopenia associated with bleeding",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      358
    ],
    [
      "",
      "Unmapped",
      "text",
      "Febrile neutropenia",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      359
    ],
    [
      "",
      "Unmapped",
      "text",
      "Non-haematologic toxicity ≥ Grade 3",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      360
    ],
    [
      "",
      "Unmapped",
      "text",
      "Liver function tests (LFTs), Grade ≥3 TBL, hepatic transaminase ALT or AST or alkaline phosphatase (ALP) lasting >48 hours, or any change in liver functions tests consistent with Hy's Law (see Appendix E.)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      361
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any other toxicity that is clinically significant and/or unacceptable that does not respond to supportive care, results in a disruption of dosing schedule of more than 7 days, or is judged to be a DLT by the Investigator in collaboration with the Study Physician.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      362
    ],
    [
      "",
      "Unmapped",
      "text",
      "A DLT excludes:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      363
    ],
    [
      "",
      "Unmapped",
      "text",
      "Nausea, vomiting, or diarrhoea that responds to supportive care",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      364
    ],
    [
      "",
      "Unmapped",
      "text",
      "Isolated laboratory change of any grade without clinical sequelae or clinical significance",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      365
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      366
    ],
    [
      "",
      "Unmapped",
      "text",
      "Alopecia of any grade",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      367
    ],
    [
      "",
      "Unmapped",
      "text",
      "Cycle 1 data for each cohort will be reviewed by an SRC after completion of each dose level cohort.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      368
    ],
    [
      "",
      "Unmapped",
      "text",
      "Participating sites will be informed of the findings and of the next cohort to be evaluated as soon as possible.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose-limiting Toxicity (DLT)",
      "6.6.2",
      "3",
      369
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.6.3  Safety Review Committee (SRC)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      370
    ],
    [
      "",
      "Unmapped",
      "text",
      "Regarding each dose level, the SRC will evaluate the safety and tolerability and PK (where applicable) of adavosertib to decide the next step.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      371
    ],
    [
      "",
      "Unmapped",
      "text",
      "The SRC will consist of:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      372
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      373
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study Team Physician, who will chair the committee, or delegate",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      374
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      375
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      376
    ],
    [
      "",
      "Unmapped",
      "text",
      "Principal Investigator or delegate from each investigational site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      377
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Clinical Pharmacology Scientist, Study Statistician, Patient Safety Scientist, Study Leader, etc.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      378
    ],
    [
      "",
      "Unmapped",
      "text",
      "may also be invited as appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      379
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Safety Review Committee Remit document for this study will define the exact membership and who should be present for decisions to be made.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      380
    ],
    [
      "",
      "Unmapped",
      "text",
      "Further internal or external experts may be consulted by the SRC as necessary.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      381
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Global Safety Physician or delegate should tell opinions to the SRC if there are safety issues for discussion.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      382
    ],
    [
      "",
      "Unmapped",
      "text",
      "Once there are at least 3 evaluable subjects at a dose level, the SRC will review and assess all available safety data from the cohort, along with available PK data, to decide on the dose for the next cohort of subjects.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      383
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any dose interruptions or reductions will be considered.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      384
    ],
    [
      "",
      "Unmapped",
      "text",
      "The decision may be to:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      385
    ],
    [
      "",
      "Unmapped",
      "text",
      "Proceed with next dose level",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      386
    ],
    [
      "",
      "Unmapped",
      "text",
      "Expand the cohort to a maximum of 6 evaluable subjects",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      387
    ],
    [
      "",
      "Unmapped",
      "text",
      "De-escalate the dose either to a lower dose level (up to a maximum of 6 evaluable subjects) or to an intermediate lower dose level",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      388
    ],
    [
      "",
      "Unmapped",
      "text",
      "Stop the dose escalation",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      389
    ],
    [
      "",
      "Unmapped",
      "text",
      "Evaluate alternative dosing schedules",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      390
    ],
    [
      "",
      "Unmapped",
      "text",
      "When there are other subjects that are ongoing at the time of this review, the SRC may decide to defer their decision until these further subjects become evaluable.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      391
    ],
    [
      "",
      "Unmapped",
      "text",
      "The SRC will review any subject started on treatment in error, as he or she failed to comply with all of the selection criteria but meets the criteria of an evaluable subject, on a case by case basis to determine whether the subject should be included or excluded in the dose escalation decision.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      392
    ],
    [
      "",
      "Unmapped",
      "text",
      "The SRC's decisions on the next dose level will be documented and provided to the investigators.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Safety Review Committee (SRC)",
      "6.6.3",
      "3",
      393
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.6.4  Dose modifications due to toxicities",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Dose modifications due to toxicities",
      "6.6.4",
      "3",
      394
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any toxicities observed during the course of the study can be managed by interrupting or reducing the dose of study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose modifications due to toxicities",
      "6.6.4",
      "3",
      395
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dose reductions of adavosertib should be considered if the toxicity is considered to be related to adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose modifications due to toxicities",
      "6.6.4",
      "3",
      396
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dose re-escalation is not permitted.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose modifications due to toxicities",
      "6.6.4",
      "3",
      397
    ],
    [
      "",
      "Unmapped",
      "text",
      "For details, see Section 8.4.5.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Dose modifications due to toxicities",
      "6.6.4",
      "3",
      398
    ],
    [
      "",
      "Unmapped",
      "header",
      " 6.7  Treatment after the end of the study",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Treatment after the end of the study",
      "6.7",
      "2",
      399
    ],
    [
      "",
      "Unmapped",
      "text",
      "Not applicable.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Treatment after the end of the study",
      "6.7",
      "2",
      400
    ],
    [
      "",
      "Unmapped",
      "header",
      " 7  DISCONTINUATION OF TREATMENT AND SUBJECT WITHDRAWAL",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Study Population",
      "DISCONTINUATION OF TREATMENT AND SUBJECT WITHDRAWAL",
      "7",
      "1",
      401
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "header",
      " 7.1  Discontinuation of study treatment",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      402
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Subjects may be discontinued from investigational product in the following situations.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      403
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Note that discontinuation from study treatment is NOT the same thing as a complete withdrawal from the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      404
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Subject decision.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      405
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "The subject is at any time free to discontinue treatment, without prejudice to further treatment",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      406
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "AE which the investigator judges that the study treatment discontinuation is clinically reasonable.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      407
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Severe non-compliance with the Clinical Study Protocol",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      408
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Clinical deterioration and/or no further benefit from treatment, regardless of whether there has been progressive disease (PD), according to RECIST v1.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      409
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Objective disease progression",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      410
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Subjects incorrectly initiated on investigational product",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      411
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "A female subject becomes pregnant during the course of the study",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      412
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Investigator discretion",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      413
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      414
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Sponsor decision",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      415
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "After subjects complete the study treatment, or are discontinued from the study they will have an EOT study visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      416
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Upon DLT, treatment may continue after recovery from the AE and discussion including the sponsor and with consideration of dose reduction when the investigator judges the benefit of the treatment outweighs the risk.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      417
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "All subjects will be followed during the off-treatment period until all study treatment related toxicity resolves, or for at least 30 days post-study drug discontinuation is started.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      418
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "This can be done via telephone contact at the Investigator's discretion (Safety follow-up.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      419
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "See Section",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      420
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "8.3.4).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      421
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "Subjects discontinuing the study treatment in the absence of PD should have tumour assessments performed every 12 weeks (± 7 days) from the last dose of study drug until PD has been assessed by the Investigator, or until the subject begins a new course of cancer therapy or withdraws from the study (Response follow-up.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      422
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "See Section 8.1.1).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      423
    ],
    [
      "2",
      "Discontinuation of Study Intervention",
      "text",
      "See the SoA for data to be collected at the time of treatment discontinuation and follow-up and for any further evaluations that need to be completed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Discontinuation of study treatment",
      "7.1",
      "2",
      424
    ],
    [
      "3",
      "Temporary Discontinuation",
      "header",
      " 7.1.1  Temporary discontinuation",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Temporary discontinuation",
      "7.1.1",
      "3",
      425
    ],
    [
      "3",
      "Temporary Discontinuation",
      "text",
      "A subject can temporarily discontinue for up to 21 days.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Temporary discontinuation",
      "7.1.1",
      "3",
      426
    ],
    [
      "",
      "Unmapped",
      "header",
      " 7.1.1.1  Interruptions for intercurrent, non-toxicity related events",
      { "IsBold": false, "font_size": -1, "font_style": "Heading4" },
      "Study Population",
      "Interruptions for intercurrent, non-toxicity related events",
      "7.1.1.1",
      "4",
      427
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study treatment dose interruption for conditions other than toxicity resolution should be kept as short as possible.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Interruptions for intercurrent, non-toxicity related events",
      "7.1.1.1",
      "4",
      428
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any subject who cannot restart study treatment within 21 days for resolution of intercurrent conditions not related to disease progression or toxicity will have to discontinue the study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Interruptions for intercurrent, non-toxicity related events",
      "7.1.1.1",
      "4",
      429
    ],
    [
      "",
      "Unmapped",
      "text",
      "All dose reductions and interruptions (including any missed doses), and the reasons for the reductions/interruptions are to be recorded in the eCRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Interruptions for intercurrent, non-toxicity related events",
      "7.1.1.1",
      "4",
      430
    ],
    [
      "",
      "Unmapped",
      "header",
      " 7.1.2  Procedures for discontinuation of study treatment",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      431
    ],
    [
      "",
      "Unmapped",
      "text",
      "The investigator should instruct the subject to contact the site before or at the time if Study treatment is stopped.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      432
    ],
    [
      "",
      "Unmapped",
      "text",
      "A subject that decides to discontinue Study treatment will always be asked about the reason(s) and the presence of any AEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      433
    ],
    [
      "",
      "Unmapped",
      "text",
      "The date of last intake of Study treatment should be documented in the CRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      434
    ],
    [
      "",
      "Unmapped",
      "text",
      "All Study treatment should be returned by the subject at their next on-site study visit or unscheduled visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      435
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects permanently discontinuing Study treatment should be given locally available standard of care therapy, at the discretion of the Investigator.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      436
    ],
    [
      "",
      "Unmapped",
      "text",
      "Discontinuation of Study treatment, for any reason, does not impact on the subject´s participation in the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      437
    ],
    [
      "",
      "Unmapped",
      "text",
      "The subject should continue attending subsequent study visits and data collection should continue according to the study protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      438
    ],
    [
      "",
      "Unmapped",
      "text",
      "If the subject does not agree to continue in-person study visits, a modified follow-up must be arranged to ensure the collection of endpoints and safety information.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      439
    ],
    [
      "",
      "Unmapped",
      "text",
      "This could be a telephone contact with the subject, a contact with a relative or treating physician, or information from medical records.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      440
    ],
    [
      "",
      "Unmapped",
      "text",
      "The approach taken should be recorded in the medical records.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      441
    ],
    [
      "",
      "Unmapped",
      "text",
      "A subject that agrees to modified follow-up is not considered to have withdrawn consent or to have withdrawn from the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Procedures for discontinuation of study treatment",
      "7.1.2",
      "3",
      442
    ],
    [
      "2",
      "Lost to Follow up",
      "header",
      " 7.2  Lost to follow-up",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      443
    ],
    [
      "2",
      "Lost to Follow up",
      "text",
      "A subject will be considered potentially lost to follow-up if he or she fails to return for scheduled visits and is unable to be contacted by the study site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      444
    ],
    [
      "2",
      "Lost to Follow up",
      "text",
      "The following actions must be taken if a subject fails to return to the clinic for a required study visit:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      445
    ],
    [
      "2",
      "Lost to Follow up",
      "text",
      "The site must attempt to contact the subject and reschedule the missed visit as soon as possible and counsel the subject on the importance of maintaining the assigned visit schedule.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      446
    ],
    [
      "2",
      "Lost to Follow up",
      "text",
      "Before a subject is deemed lost to follow up, the investigator or designee must make every effort to regain contact with the subject or next of kin by e.g., repeat telephone calls, certified letter to the subject´s last known mailing address or local equivalent methods.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      447
    ],
    [
      "2",
      "Lost to Follow up",
      "text",
      "These contact attempts should be documented in the subject's medical record.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      448
    ],
    [
      "2",
      "Lost to Follow up",
      "text",
      "Efforts to reach the subject should continue until the end of the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      449
    ],
    [
      "2",
      "Lost to Follow up",
      "text",
      "Should the subject be unreachable at the end of the study the subject should be considered to be lost to follow up with unknown vital status at end of study and censored at latest follow up contact.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Lost to follow-up",
      "7.2",
      "2",
      450
    ],
    [
      "",
      "Unmapped",
      "header",
      " 7.3  Withdrawal from the study",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      451
    ],
    [
      "",
      "Unmapped",
      "text",
      "A subject may withdraw from the study (eg, withdraw consent), at any time (investigational product",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      452
    ],
    [
      "",
      "Unmapped",
      "text",
      "and",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      453
    ],
    [
      "",
      "Unmapped",
      "text",
      "assessments) at his/her own request, without prejudice to further treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      454
    ],
    [
      "",
      "Unmapped",
      "text",
      "A subject who considers withdrawing from the study must be informed by the Investigator about modified follow-up options (eg, telephone contact, a contact with a relative or treating physician, or information from medical records).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      455
    ],
    [
      "",
      "Unmapped",
      "text",
      "If the subject withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      456
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a subject withdraws from the study, he/she may request destruction of any samples taken, and the investigator must document this in the site study records.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      457
    ],
    [
      "",
      "Unmapped",
      "text",
      "A subject who withdraws consent will always be asked about the reason(s) and the presence of any AEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      458
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Investigator will follow up subjects as medically indicated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      459
    ],
    [
      "",
      "Unmapped",
      "text",
      "See SoA, for data to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      460
    ],
    [
      "",
      "Unmapped",
      "text",
      "All Study treatment should be returned by the subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Population",
      "Withdrawal from the study",
      "7.3",
      "2",
      461
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "header",
      " 8  STUDY ASSESSMENTS AND PROCEDURES",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      462
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Study procedures and their timing are summarised in the SoA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      463
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "At enrolment, obtain the signed ICF from the potential subject before any study specific procedures are performed (Please see Appendix A for ethical and regulatory requirements).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      464
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Signed ICF must also be obtained before the start of first dose of Cycle 2 Day 1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      465
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The study site staff will assign a unique enrolment number (E code) to subjects in sequence and inform the AZ study team by email (AZD1775registration@astrazeneca.com).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      466
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "If a subject withdraws from participation, then his/her enrolment number cannot be reused.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      467
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "In order to confirm eligibility (see Section 5.1 and 5.2), screening tests will be conducted on each subject within the defined number of days prior to the first dose of investigational products (see Table 1, and Table 6).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      468
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "However, if any of these initial examinations are required at Cycle 1 Day 1 and obtained within 72 hours prior to the initiation of treatment, they do not have to be repeated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      469
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Procedures conducted as part of the subject's routine clinical management (eg, blood count) and obtained before signing of the ICF may be utilised for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the SoA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      470
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Table 6",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      471
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      472
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Screening tests and the number of days prior to the first dose of investigational products",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      473
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>≤28 days</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Informed consent</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>AEs evaluation</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Tumour assessments (RECIST v1.1) (should be performed as close to the start of treatment as possible)</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>≤14 days</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Concomitant medications/procedure</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>Tumour marker, if applicable</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>≤7 days</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>Physical examination</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>Vital signs, weight</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>Height</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>ECOG PS</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>12-lead ECG</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>Haematology</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>Chemistry</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>Coagulation</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>Urinalysis</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>≤3 days</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>Pregnancy test if WoCBP</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "10",
        "TableName": "Screening tests and the number of days prior to the first dose of investigational products",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      474
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Demographics will be recorded and will include the date of birth, sex, race and/or ethnicity, alcohol consumption, and smoking history.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      475
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "A standard medical history, medication, and surgical history will be obtained with review of the selection criteria with the subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      476
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Prior tumour-related treatments will be recorded.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      477
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "All screening evaluations must be completed and reviewed to confirm that potential subjects meet all eligibility criteria.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      478
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The study site staff will inform the AZ study team if potential subjects meet all eligibility criteria or not by email (AZD1775registration@astrazeneca.com) immediately after screening assessment completion.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      479
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The investigator will maintain a screening log to record details of all subjects screened and to confirm eligibility or record reasons for screening failure, as applicable.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      480
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The sponsor will inform the investigator of suspension and restarting of enrolment by email.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      481
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The investigator will ensure that data are recorded on the CRFs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      482
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The Electronic Data Capture (EDC) system will be used for data collection and query handling.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      483
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The investigator ensures the accuracy, completeness, and timeliness of the data recorded and of the provision of answers to data queries according to the Clinical Study Agreement.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      484
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "The investigator will sign the completed CRFs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      485
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "A copy of the completed CRFs will be archived at the study site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      486
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to determine if the subject should continue or discontinue Study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      487
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      488
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Subjects without evidence of undue toxicity may continue treatment with study medications until disease progression, intolerable toxicity, or discontinuation criteria have been met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      489
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Subjects with PD or unacceptable toxicity should be discontinued from study treatment; subjects with stable disease (SD) or response to therapy will continue treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      490
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "Tumour imaging studies will be repeated every 9 weeks (± 7 days) relative to the date of first dose until disease progression or withdrawal of consent.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      491
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "After subjects complete study treatment, or are discontinued from the study treatment, they will have an EOT study visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      492
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "All subjects will be followed during the off-treatment period until all study treatment related toxicity resolves, or for at least 30 days post-study drug discontinuation is started.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      493
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "This can be done via telephone contact at the Investigator's discretion.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      494
    ],
    [
      "1",
      "Study Assessments and Procedures",
      "text",
      "All concomitant medications received 30 days after the last dose of study medication(s) should be recorded in the medical record and eCRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "STUDY ASSESSMENTS AND PROCEDURES",
      "8",
      "1",
      495
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.1  Efficacy assessments",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Efficacy assessments",
      "8.1",
      "2",
      496
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.1.1  Tumour assessments",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      497
    ],
    [
      "",
      "Unmapped",
      "text",
      "Baseline tumour imaging studies (e.g., computed tomography [CT] scan or magnetic resonance imaging [MRI] of the chest and abdomen/pelvis) will be performed within 28 days prior to the first dose of study drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      498
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects with measurable or non-measurable disease will be evaluated according to RECIST v1.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      499
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects with PD or unacceptable toxicity should be discontinued from study treatment; subjects with SD or response to therapy will continue treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      500
    ],
    [
      "",
      "Unmapped",
      "text",
      "The same assessment method and technique must be used to characterise each identified and reported lesion, both at baseline and during subsequent imaging procedures.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      501
    ],
    [
      "",
      "Unmapped",
      "text",
      "Tumour imaging studies (e.g., CT scan or MRI of the chest and abdomen/pelvis) will be repeated every 9 weeks (± 7 days) relative to the date of first dose until PD or withdrawal of consent.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      502
    ],
    [
      "",
      "Unmapped",
      "text",
      "Tumour imaging studies that show progression must be documented in eCRF as EOT scans.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      503
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects discontinuing adavosertib in the absence of PD should undergo CT scans or MRI",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      504
    ],
    [
      "",
      "Unmapped",
      "text",
      "(chest and abdomen/pelvis) every 12 weeks (± 7 days) from the last dose of study drug until PD has been assessed by the Investigator, or until the subject begins a new course of cancer therapy, or withdraws from the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour assessments",
      "8.1.1",
      "3",
      505
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.1.2  Tumour markers",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Tumour markers",
      "8.1.2",
      "3",
      506
    ],
    [
      "",
      "Unmapped",
      "text",
      "Tumour specific markers will be analysed, as appropriate, for disease specific assessments at the study sites.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour markers",
      "8.1.2",
      "3",
      507
    ],
    [
      "",
      "Unmapped",
      "text",
      "If applicable, disease specific tumour marker (e.g., carbohydrate antigen 125 [CA-125] for ovarian cancer) samples will be collected at screening (within 14 days prior to the first dose of study drug), Day 1 of each cycle pre-dose, and at the end of study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Tumour markers",
      "8.1.2",
      "3",
      508
    ],
    [
      "2",
      "Safety Assessments",
      "header",
      " 8.2  Safety assessments",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Safety assessments",
      "8.2",
      "2",
      509
    ],
    [
      "2",
      "Safety Assessments",
      "text",
      "Planned time points for all safety assessments are provided in the SoA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Safety assessments",
      "8.2",
      "2",
      510
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "header",
      " 8.2.1  Clinical safety laboratory assessments",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      511
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "See Table 7 for the list of clinical safety laboratory tests to be performed and to the SoA (Table 1) for the timing and frequency.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      512
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "All protocol-required laboratory assessments, as defined in the table, must be conducted in accordance with the SoA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      513
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "The Investigator should make an assessment of the available results with regard to clinically relevant abnormalities.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      514
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "The laboratory results should be signed and dated and retained at centre as source data for laboratory variables.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      515
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "For information on how AEs based on laboratory tests should be recorded and reported, see Section 8.3.8.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      516
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Additional safety samples may be collected if clinically indicated at the discretion of the Investigator.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      517
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "The date, time of collection and results (values, units and reference ranges) will be recorded on the appropriate CRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      518
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "The clinical chemistry, haematology, coagulation and urinalysis will be performed at a local laboratory at or near to the Investigator site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      519
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Sample tubes and sample sizes may vary depending on laboratory method used and routine practice at the site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      520
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Coagulation will be examined at the beginning of every cycle if the subject is on Warfarin or coumadin.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      521
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "CBC will be obtained for all subjects at the beginning of each treatment week in Cycle 1 and 2 (i.e.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      522
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Day 1 and Day 8), and the beginning of each treatment cycle from Cycle 3 onwards (i.e.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      523
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Day 1), and CBC must be reviewed prior to dose administration.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      524
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Management of haematologic toxicities should be guided by the specific toxicity management guidelines.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      525
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "In the event of significant haematologic toxicity, treatment should be held and ANC, platelets and haemoglobin should be monitored at least weekly.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      526
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Subjects should be managed as medically indicated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      527
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Treatment should not be resumed until recovery to Grade 1 (ANC ≥1.5 × 10",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      528
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "9",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      529
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "/L; platelets ≥75 × 10",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      530
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "9",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      531
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "/L).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      532
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "header",
      " Table 7  Laboratory safety variables",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      533
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Haematology (2 mL whole blood)</td>\n      <td>Clinical Chemistry (5 mL serum or plasma)</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Haemoglobin</td>\n      <td>Albumin</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Leukocyte</td>\n      <td>ALT</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Haematocrit</td>\n      <td>AST</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Red blood cell count</td>\n      <td>ALP</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Absolute leukocyte differential count</td>\n      <td>Bilirubin, total</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>Neutrophils</td>\n      <td>Calcium, total</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>Lymphocytes</td>\n      <td>Creatinine</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>Monocytes</td>\n      <td>Chloride</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>Basophils</td>\n      <td>Potassium</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>Eosinophils</td>\n      <td>Sodium</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>Platelet count</td>\n      <td>Urea nitrogen or blood urea nitrogen</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>Urinalysis</td>\n      <td>Coagulation (2 mL whole blood)</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>Specific gravity</td>\n      <td>PT</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>pH</td>\n      <td>INR</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>Bilirubin</td>\n      <td>APTT</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>Blood</td>\n      <td>Pregnancy test (Blood or urine)</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>Glucose</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>Ketones</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>Protein</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>If abnormal (urine dipstick), microscopy including white blood cells/HPF, red blood cells/HPF</td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "11",
        "TableName": "Laboratory safety variables",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      534
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "Pre-menopausal WoCBP must have a negative urine or serum pregnancy test within 3 days prior to the first dose of study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      535
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "WoCBP must have a negative pregnancy test prior to starting each new treatment cycle, at the EOT visit, and at the safety follow-up (FU) visit (See SoA).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      536
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "In the event of suspected pregnancy during the study, the test should be repeated and, if positive, the subject should be discontinued from study treatment immediately.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      537
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "NB.",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      538
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "In case a subject shows an AST",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      539
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "or",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      540
    ],
    [
      "3",
      "Clinical Safety Laboratory Assessments",
      "text",
      "ALT ≥3×ULN together with TBL ≥2×ULN please refer to Appendix E ‘Actions required in cases of increases in liver biochemistry and evaluation of Hy's Law', for further instructions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Clinical safety laboratory assessments",
      "8.2.1",
      "3",
      541
    ],
    [
      "3",
      "Physical Examinations",
      "header",
      " 8.2.2  Physical examinations",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Physical examinations",
      "8.2.2",
      "3",
      542
    ],
    [
      "3",
      "Physical Examinations",
      "text",
      "A complete physical examination will be performed and include an assessment of the following: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculo-skeletal (including spine and extremities) and neurological systems.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Physical examinations",
      "8.2.2",
      "3",
      543
    ],
    [
      "3",
      "Physical Examinations",
      "text",
      "Physical examination will be performed at timelines as specified in the SoA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Physical examinations",
      "8.2.2",
      "3",
      544
    ],
    [
      "3",
      "Physical Examinations",
      "text",
      "Investigators should pay special attention to clinical signs related to previous serious illnesses, new or worsening abnormalities may qualify as AEs, see Section 8.3.8 for details.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Physical examinations",
      "8.2.2",
      "3",
      545
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.2.3  Vital signs, weight and height",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Vital signs, weight and height",
      "8.2.3",
      "3",
      546
    ],
    [
      "",
      "Unmapped",
      "text",
      "Vital signs (resting heart rate, systolic and diastolic blood pressure, and axillary temperature [°C]), weight (kg), and height (cm) will be collected at timelines as specified in the SoA and prior to dosing of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Vital signs, weight and height",
      "8.2.3",
      "3",
      547
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.2.4  Performance Status (PS)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Performance Status (PS)",
      "8.2.4",
      "3",
      548
    ],
    [
      "",
      "Unmapped",
      "text",
      "PS will be assessed using the ECOG PS criteria (See Appendix I) at timelines as specified in the SoA (Table 1).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Performance Status (PS)",
      "8.2.4",
      "3",
      549
    ],
    [
      "3",
      "Electrocardiograms",
      "header",
      " 8.2.5  Electrocardiograms (ECGs)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      550
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "A 12-lead ECG (paper ECG printout of 10 seconds for Investigator review) will be taken at screening, Cycle 1 Day 1, Cycle 1 Day 5 and Cycle 2 Day 1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      551
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "If a prolonged QTc is detected, it must be monitored closely, as clinically indicated, to the best of clinical practice (for more information about the management of QTc prolongation, see Section 8.4.5.2).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      552
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "ECG assessments must be performed before the pre-dose PK sample is collected.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      553
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "The subjects will rest for at least 10 minutes before the start of the ECG recording, and they must be in the same supine body position (maximum 30 degrees flexion in the hip and feet not in contact with the footboard) at the recording time point.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      554
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "If one ECG demonstrates a QTcF > 480 msec, then a mean QTcF of ≤480 msec obtained from 3 ECGs 2-5 minutes apart, is required.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      555
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "The Investigator will judge the overall interpretation as normal or abnormal.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      556
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "If abnormal, the Investigator will decide whether or not the abnormality is clinically significant.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      557
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "The paper copy of each ECG reading will be retained with the subject's completed source documents.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      558
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "Only overall evaluation (normal/abnormal) will be recorded in the eCRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      559
    ],
    [
      "3",
      "Electrocardiograms",
      "text",
      "If there is a clinically significant abnormal unscheduled ECG finding during the treatment period, this should be recorded on the AE eCRF, according to standard AE collection and reporting processes (see Section 8.3).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Electrocardiograms (ECGs)",
      "8.2.5",
      "3",
      560
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3  Collection of adverse events (AEs)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Collection of adverse events (AEs)",
      "8.3",
      "2",
      561
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Principal Investigator is responsible for ensuring that all staff involved in the study are familiar with the content of this section.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of adverse events (AEs)",
      "8.3",
      "2",
      562
    ],
    [
      "",
      "Unmapped",
      "text",
      "The definitions of an AE or SAE can be found in Appendix B.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of adverse events (AEs)",
      "8.3",
      "2",
      563
    ],
    [
      "",
      "Unmapped",
      "text",
      "AE will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or the subject's legally authorized representative).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of adverse events (AEs)",
      "8.3",
      "2",
      564
    ],
    [
      "",
      "Unmapped",
      "text",
      "The investigator and any designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of adverse events (AEs)",
      "8.3",
      "2",
      565
    ],
    [
      "",
      "Unmapped",
      "text",
      "For information on how to follow/up AEs see Section 8.3.4.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of adverse events (AEs)",
      "8.3",
      "2",
      566
    ],
    [
      "3",
      "Adverse Events of Special Interest",
      "header",
      " 8.3.1  Adverse events of special interest (AESIs)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Adverse events of special interest (AESIs)",
      "8.3.1",
      "3",
      567
    ],
    [
      "3",
      "Adverse Events of Special Interest",
      "text",
      "There are no adverse events of special interest (AESI) for adavosertib which require additional data collection.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events of special interest (AESIs)",
      "8.3.1",
      "3",
      568
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.2  Method of detecting adverse events (AEs) and serious adverse events (SAEs)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Method of detecting adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.2",
      "3",
      569
    ],
    [
      "",
      "Unmapped",
      "text",
      "Care will be taken not to introduce bias when detecting AEs and/or SAEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Method of detecting adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.2",
      "3",
      570
    ],
    [
      "",
      "Unmapped",
      "text",
      "Open-ended and non-leading verbal questioning of the subject is the preferred method to inquire about AE occurrences.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Method of detecting adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.2",
      "3",
      571
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.3  Time period and frequency for collecting adverse event (AE) and",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      572
    ],
    [
      "",
      "Unmapped",
      "header",
      " serious adverse event (SAE) information",
      { "IsBold": false, "font_size": -1, "font_style": "Heading5" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      573
    ],
    [
      "",
      "Unmapped",
      "text",
      "AEs will be collected from time of signature of ICF throughout the treatment period and including the follow-up period.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      574
    ],
    [
      "",
      "Unmapped",
      "text",
      "SAEs will be recorded from the time of signing of ICF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      575
    ],
    [
      "",
      "Unmapped",
      "text",
      "All SAEs will be recorded and reported to the sponsor or designee within 24 hours, as indicated in Appendix B.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      576
    ],
    [
      "",
      "Unmapped",
      "text",
      "The investigator will submit any updated SAE data to the sponsor within 24 hours of it being available.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      577
    ],
    [
      "",
      "Unmapped",
      "text",
      "Investigators are not obligated to actively seek AE or SAE in former study subjects.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      578
    ],
    [
      "",
      "Unmapped",
      "text",
      "However, if the investigator learns of any SAE, including a death, at any time after a subject's last visit and he/she considers the event to be reasonably related to the Study treatment or study participation, the investigator may notify the sponsor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      579
    ],
    [
      "",
      "Unmapped",
      "text",
      "The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting SAE reports are provided in Section 8.4.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Time period and frequency for collecting adverse event (AE) and serious adverse event (SAE) information",
      "8.3.3",
      "3",
      580
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.4  Follow-up of adverse events (AEs) and serious adverse events (SAEs)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Follow-up of adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.4",
      "3",
      581
    ],
    [
      "",
      "Unmapped",
      "text",
      "After the initial AE/SAE report, the investigator is required to proactively follow each subject at subsequent visits/contacts.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Follow-up of adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.4",
      "3",
      582
    ],
    [
      "",
      "Unmapped",
      "text",
      "All SAE/non-serious AEs will be followed until resolution, stabilization, the event is otherwise explained, or the subject is lost to follow-up",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Follow-up of adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.4",
      "3",
      583
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any AEs that are unresolved at the end of follow-up period in the study are followed up by the Investigator for as long as medically indicated, but without further recording in the CRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Follow-up of adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.4",
      "3",
      584
    ],
    [
      "",
      "Unmapped",
      "text",
      "AstraZeneca retains the right to request additional information for any subject with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Follow-up of adverse events (AEs) and serious adverse events (SAEs)",
      "8.3.4",
      "3",
      585
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.5  Adverse event (AE) data collection",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      586
    ],
    [
      "",
      "Unmapped",
      "text",
      "'The following variables will be collected for each AE;",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      587
    ],
    [
      "",
      "Unmapped",
      "text",
      "AE (verbatim)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      588
    ],
    [
      "",
      "Unmapped",
      "text",
      "The date when the AE started and stopped",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      589
    ],
    [
      "",
      "Unmapped",
      "text",
      "Changes in CTCAE grade",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      590
    ],
    [
      "",
      "Unmapped",
      "text",
      "Whether the AE is serious or not",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      591
    ],
    [
      "",
      "Unmapped",
      "text",
      "Investigator causality rating against the Investigational Product(s) (yes or no)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      592
    ],
    [
      "",
      "Unmapped",
      "text",
      "Action taken with regard to Investigational Product(s)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      593
    ],
    [
      "",
      "Unmapped",
      "text",
      "AE caused subject's withdrawal from study (yes or no)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      594
    ],
    [
      "",
      "Unmapped",
      "text",
      "Outcome",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      595
    ],
    [
      "",
      "Unmapped",
      "text",
      "In addition, the following variables will be collected for SAEs:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      596
    ],
    [
      "",
      "Unmapped",
      "text",
      "Date AE met criteria for SAE",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      597
    ],
    [
      "",
      "Unmapped",
      "text",
      "Date Investigator became aware of SAE",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      598
    ],
    [
      "",
      "Unmapped",
      "text",
      "AE is serious due to",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      599
    ],
    [
      "",
      "Unmapped",
      "text",
      "Date of hospitalisation",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      600
    ],
    [
      "",
      "Unmapped",
      "text",
      "Date of discharge",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      601
    ],
    [
      "",
      "Unmapped",
      "text",
      "Probable cause of death",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      602
    ],
    [
      "",
      "Unmapped",
      "text",
      "Date of death",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      603
    ],
    [
      "",
      "Unmapped",
      "text",
      "Autopsy performed",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      604
    ],
    [
      "",
      "Unmapped",
      "text",
      "Causality assessment in relation to Study procedure(s)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      605
    ],
    [
      "",
      "Unmapped",
      "text",
      "Causality assessment to other medication",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse event (AE) data collection",
      "8.3.5",
      "3",
      606
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.6  Causality collection",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Causality collection",
      "8.3.6",
      "3",
      607
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Investigator will assess causal relationship between Investigational Product and each AE, and answer ‘yes' or ‘no' to the question ‘Do you consider that there is a reasonable possibility that the event may have been caused by the investigational product?'",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Causality collection",
      "8.3.6",
      "3",
      608
    ],
    [
      "",
      "Unmapped",
      "text",
      "For SAEs, causal relationship will also be assessed for other medication and study procedures.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Causality collection",
      "8.3.6",
      "3",
      609
    ],
    [
      "",
      "Unmapped",
      "text",
      "Note that for SAEs that could be associated with any study procedure the causal relationship is implied as ‘yes'.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Causality collection",
      "8.3.6",
      "3",
      610
    ],
    [
      "",
      "Unmapped",
      "text",
      "A guide to the interpretation of the causality question is found in Appendix B to the Clinical Study Protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Causality collection",
      "8.3.6",
      "3",
      611
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.7  Adverse events (AEs) based on signs and symptoms",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on signs and symptoms",
      "8.3.7",
      "3",
      612
    ],
    [
      "",
      "Unmapped",
      "text",
      "All AEs spontaneously reported by the subject or reported in response to the open question from the study site staff: ‘Have you had any health problems since the previous visit/you were last asked?', or revealed by observation will be collected and recorded in the CRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on signs and symptoms",
      "8.3.7",
      "3",
      613
    ],
    [
      "",
      "Unmapped",
      "text",
      "When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on signs and symptoms",
      "8.3.7",
      "3",
      614
    ],
    [
      "",
      "Unmapped",
      "text",
      "However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on signs and symptoms",
      "8.3.7",
      "3",
      615
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.8  Adverse events (AEs) based on examinations and tests",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      616
    ],
    [
      "",
      "Unmapped",
      "text",
      "The results from the Clinical Study Protocol mandated laboratory tests and vital signs will be summarised in the Clinical Study Report (CSR).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      617
    ],
    [
      "",
      "Unmapped",
      "text",
      "Deterioration as compared to baseline in protocol-mandated laboratory values and vital signs should therefore only be reported as AEs if they fulfil any of the SAE criteria, are the reason for discontinuation of treatment with the investigational product or are considered to be clinically relevant as judged by the investigator (which may include but not limited to consideration as to whether treatment or non-planned visits were required or other action was taken with the study treatment, e,g., dose adjustment or drug interruption).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      618
    ],
    [
      "",
      "Unmapped",
      "text",
      "If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result/vital sign will be considered as additional information.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      619
    ],
    [
      "",
      "Unmapped",
      "text",
      "Wherever possible the reporting Investigator uses the clinical, rather than the laboratory term (e.g., anaemia versus low haemoglobin value).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      620
    ],
    [
      "",
      "Unmapped",
      "text",
      "In the absence of clinical signs or symptoms, clinically relevant deteriorations in nonmandated parameters should be reported as AE(s).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      621
    ],
    [
      "",
      "Unmapped",
      "text",
      "Deterioration of a laboratory value, which is unequivocally due to disease progression, should not be reported as an AE/SAE.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      622
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study, see Section 8.3.10.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Adverse events (AEs) based on examinations and tests",
      "8.3.8",
      "3",
      623
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.9  Hy's Law",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Hy's Law",
      "8.3.9",
      "3",
      624
    ],
    [
      "",
      "Unmapped",
      "text",
      "Cases where a subject shows elevation in liver biochemistry may require further evaluation and occurrences of AST or ALT ≥ 3×ULN together with TBL ≥ 2×ULN will need to be reported as SAEs if criteria is met for a Potential Hy's Law.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Hy's Law",
      "8.3.9",
      "3",
      625
    ],
    [
      "",
      "Unmapped",
      "text",
      "Please refer to Appendix E for further instruction on cases of increases in liver biochemistry and evaluation of Hy's Law.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Hy's Law",
      "8.3.9",
      "3",
      626
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.3.10  Disease progression",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Disease progression",
      "8.3.10",
      "3",
      627
    ],
    [
      "",
      "Unmapped",
      "text",
      "Disease progression can be considered as a worsening of a subject's condition attributable to the disease for which the investigational product is being studied.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Disease progression",
      "8.3.10",
      "3",
      628
    ],
    [
      "",
      "Unmapped",
      "text",
      "It may be an increase in the severity of the disease under study and/or increases in the symptoms of the disease.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Disease progression",
      "8.3.10",
      "3",
      629
    ],
    [
      "",
      "Unmapped",
      "text",
      "The development of new, or progression of existing metastasis to the primary cancer under study should be considered as disease progression and not an AE.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Disease progression",
      "8.3.10",
      "3",
      630
    ],
    [
      "",
      "Unmapped",
      "text",
      "Events, which are unequivocally due to disease progression, should not be reported as an AE during the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Disease progression",
      "8.3.10",
      "3",
      631
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4  Safety reporting and medical management",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Safety reporting and medical management",
      "8.4",
      "2",
      632
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.1  Reporting of serious adverse events (SAEs)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      633
    ],
    [
      "",
      "Unmapped",
      "text",
      "All SAEs have to be reported, whether or not considered causally related to the investigational product, or to the study procedure(s).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      634
    ],
    [
      "",
      "Unmapped",
      "text",
      "All SAEs will be recorded in the CRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      635
    ],
    [
      "",
      "Unmapped",
      "text",
      "If any SAE occurs in the course of the study, then Investigators or other site personnel inform the appropriate AstraZeneca representatives within one day i.e., immediately but",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      636
    ],
    [
      "",
      "Unmapped",
      "text",
      "no later than 24 hours",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      637
    ],
    [
      "",
      "Unmapped",
      "text",
      "of when he or she becomes aware of it.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      638
    ],
    [
      "",
      "Unmapped",
      "text",
      "The designated AstraZeneca representative works with the Investigator to ensure that all the necessary information is provided to the AstraZeneca Patient Safety data entry site",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      639
    ],
    [
      "",
      "Unmapped",
      "text",
      "within 1 calendar day",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      640
    ],
    [
      "",
      "Unmapped",
      "text",
      "of initial receipt for fatal and life threatening events",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      641
    ],
    [
      "",
      "Unmapped",
      "text",
      "and within 5 calendar days",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      642
    ],
    [
      "",
      "Unmapped",
      "text",
      "of initial receipt for all other SAEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      643
    ],
    [
      "",
      "Unmapped",
      "text",
      "For fatal or life-threatening AEs where important or relevant information is missing, active follow-up is undertaken immediately.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      644
    ],
    [
      "",
      "Unmapped",
      "text",
      "Investigators or other site personnel inform AstraZeneca representatives of any follow-up information on a previously reported SAE within one calendar day i.e., immediately but",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      645
    ],
    [
      "",
      "Unmapped",
      "text",
      "no later than 24 hours",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      646
    ],
    [
      "",
      "Unmapped",
      "text",
      "of when he or she becomes aware of it.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      647
    ],
    [
      "",
      "Unmapped",
      "text",
      "Once the Investigators or other site personnel indicate an AE is serious in the EDC system, an automated email alert is sent to the designated AstraZeneca representative.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      648
    ],
    [
      "",
      "Unmapped",
      "text",
      "If the EDC system is not available, then the Investigator or other study site staff reports a SAE to the appropriate AstraZeneca representative by telephone, etc.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      649
    ],
    [
      "",
      "Unmapped",
      "text",
      "The AstraZeneca representative will advise the Investigator/study site staff how to proceed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      650
    ],
    [
      "",
      "Unmapped",
      "text",
      "For further guidance on the definition of a SAE, see Appendix B of the Clinical Study Protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Reporting of serious adverse events (SAEs)",
      "8.4.1",
      "3",
      651
    ],
    [
      "3",
      "Pregnancy",
      "header",
      " 8.4.2  Pregnancy",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Pregnancy",
      "8.4.2",
      "3",
      652
    ],
    [
      "3",
      "Pregnancy",
      "text",
      "All pregnancies and outcomes of pregnancy should be reported to AstraZeneca except for:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Pregnancy",
      "8.4.2",
      "3",
      653
    ],
    [
      "3",
      "Pregnancy",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Pregnancy",
      "8.4.2",
      "3",
      654
    ],
    [
      "3",
      "Pregnancy",
      "text",
      "If the pregnancy is discovered before the study subject has received any study drug",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Pregnancy",
      "8.4.2",
      "3",
      655
    ],
    [
      "3",
      "Pregnancy",
      "text",
      "If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of learning of the pregnancy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Pregnancy",
      "8.4.2",
      "3",
      656
    ],
    [
      "3",
      "Pregnancy",
      "text",
      "Abnormal pregnancy outcomes (eg, spontaneous abortion, foetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Pregnancy",
      "8.4.2",
      "3",
      657
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.2.1  Maternal exposure",
      { "IsBold": false, "font_size": -1, "font_style": "Heading4" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      658
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a subject becomes pregnant during the course of the study, investigational product should be discontinued immediately.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      659
    ],
    [
      "",
      "Unmapped",
      "text",
      "Pregnancy itself is not regarded as an AE unless there is a suspicion that the investigational product under study may have interfered with the effectiveness of a contraceptive medication.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      660
    ],
    [
      "",
      "Unmapped",
      "text",
      "Congenital abnormalities/birth defects and spontaneous miscarriages should be reported and handled as SAEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      661
    ],
    [
      "",
      "Unmapped",
      "text",
      "Elective abortions without complications should not be handled as AEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      662
    ],
    [
      "",
      "Unmapped",
      "text",
      "The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth or congenital abnormality) should be followed up and documented even if the subject was discontinued from the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      663
    ],
    [
      "",
      "Unmapped",
      "text",
      "If any pregnancy occurs in the course of the study, then the Investigator or other site personnel informs the appropriate AstraZeneca representatives within 1 day i.e., immediately but",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      664
    ],
    [
      "",
      "Unmapped",
      "text",
      "no later than 24 hours",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      665
    ],
    [
      "",
      "Unmapped",
      "text",
      "of when he or she becomes aware of it.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      666
    ],
    [
      "",
      "Unmapped",
      "text",
      "The designated AstraZeneca representative works with the Investigator to ensure that all relevant information is provided to the AstraZeneca Patient Safety data entry site within 1 or 5 calendar days for SAEs (see Appendix B) and within 30 days for all other pregnancies.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      667
    ],
    [
      "",
      "Unmapped",
      "text",
      "The same timelines apply when outcome information is available.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      668
    ],
    [
      "",
      "Unmapped",
      "text",
      "The PREGREP module in the CRF is used to report the pregnancy and the PREGOUT is used to report the outcome of the pregnancy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Maternal exposure",
      "8.4.2.1",
      "4",
      669
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.2.2  Paternal exposure",
      { "IsBold": false, "font_size": -1, "font_style": "Heading4" },
      "Study Assessments and Procedures",
      "Paternal exposure",
      "8.4.2.2",
      "4",
      670
    ],
    [
      "",
      "Unmapped",
      "text",
      "Pregnancy of the subject's partner is not considered an AE.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Paternal exposure",
      "8.4.2.2",
      "4",
      671
    ],
    [
      "",
      "Unmapped",
      "text",
      "However, for any conception occurring from the first dose until 90 days after the last dose, the investigator should ask the",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Paternal exposure",
      "8.4.2.2",
      "4",
      672
    ],
    [
      "",
      "Unmapped",
      "text",
      "subject's partner to sign “ADULT STUDY INFORMATION AND CONSENT FORM FOR PREGNANT PARTNERS OF STUDY SUBJECTS”, report to the Sponsor, and follow up for the outcome.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Paternal exposure",
      "8.4.2.2",
      "4",
      673
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.3  Overdose",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      674
    ],
    [
      "",
      "Unmapped",
      "text",
      "For this study, any adavosertib dose in excess of that specified according to the protocol will be considered an overdose.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      675
    ],
    [
      "",
      "Unmapped",
      "text",
      "There is currently no known antidote to adavosertib, and overdose treatment should be supportive for the symptoms.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      676
    ],
    [
      "",
      "Unmapped",
      "text",
      "In addition, adavosertib may be withheld and close monitoring should be implemented as needed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      677
    ],
    [
      "",
      "Unmapped",
      "text",
      "Such overdoses should be recorded as follows:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      678
    ],
    [
      "",
      "Unmapped",
      "text",
      "An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the relevant AE modules in the CRF and on the Overdose CRF module.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      679
    ],
    [
      "",
      "Unmapped",
      "text",
      "An overdose without associated symptoms is only reported on the Overdose CRF module",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      680
    ],
    [
      "",
      "Unmapped",
      "text",
      "If an overdose on an AstraZeneca study drug occurs in the course of the study, then the Investigator or other site personnel inform appropriate AstraZeneca representatives immediately, or",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      681
    ],
    [
      "",
      "Unmapped",
      "text",
      "no later than 24 hours",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      682
    ],
    [
      "",
      "Unmapped",
      "text",
      "of when he or she becomes aware of it.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      683
    ],
    [
      "",
      "Unmapped",
      "text",
      "The designated AstraZeneca representative works with the Investigator to ensure that all relevant information is provided to the AstraZeneca Patient Safety data entry site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      684
    ],
    [
      "",
      "Unmapped",
      "text",
      "For overdoses associated with a SAE, the standard reporting timelines apply, see Section",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      685
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.3.  For other overdoses, reporting must occur within 30 days.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Overdose",
      "8.4.3",
      "3",
      686
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.4  Medication error",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Medication error",
      "8.4.4",
      "3",
      687
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a medication error occurs in the course of the study, then the Investigator or other site personnel informs the appropriate AstraZeneca representatives within 1 day i.e., immediately but no later than 24 hours of when he or she becomes aware of it.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Medication error",
      "8.4.4",
      "3",
      688
    ],
    [
      "",
      "Unmapped",
      "text",
      "The designated AstraZeneca representative works with the Investigator to ensure that all relevant information is completed within 1 (Initial Fatal/Life-Threatening or follow up Fatal/Life-Threatening) or 5 (other serious initial and follow up) calendar days if there is an SAE associated with the medication error (see Section 8.3.3) and within 30 days for all other medication errors.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Medication error",
      "8.4.4",
      "3",
      689
    ],
    [
      "",
      "Unmapped",
      "text",
      "The definition of a Medication Error can be found in Appendix B.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Medication error",
      "8.4.4",
      "3",
      690
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.5  Management of toxicities",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      691
    ],
    [
      "",
      "Unmapped",
      "text",
      "Substantial acute toxicities should be managed as medically indicated and with temporary suspension of study treatment, as appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      692
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dose adjustments will be based on the organ system exhibiting the greatest degree of toxicity.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      693
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dose reductions and holds are allowed as clinically indicated by the investigators and if in line with the guideline provided in the protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      694
    ],
    [
      "",
      "Unmapped",
      "text",
      "A maximum of 2 dose reductions for the adavosertib will be allowed for Cohort 2 and one dose reduction will be allowed for Cohort 1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      695
    ],
    [
      "",
      "Unmapped",
      "text",
      "A dose of 200 mg QD will be given as the minimum dose for adavosertib in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      696
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects requiring further dose reduction due to toxicity must discontinue study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      697
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dose re-escalation is not allowed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      698
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any subject requiring a toxicity-related dose delay of more than 21 days from the intended day of the next scheduled dose must be discontinued from the study unless there is approval from the Study Physician for the subject to continue.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      699
    ],
    [
      "",
      "Unmapped",
      "text",
      "In case a dose reduction is necessary, the Study treatment will be administered as shown in Table 8.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      700
    ],
    [
      "",
      "Unmapped",
      "text",
      "Note that dose reduction is not allowed during DLT evaluation period.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      701
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 8  Adavosertib QD Monotherapy Dose Level Reductions",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      702
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Adavosertib 0 Dose Level</td>\n      <td>Adavosertib -1 Dose Level</td>\n      <td>Adavosertib -2 Dose Level</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>300 mg QD</td>\n      <td>250 mg QD <sup>a</sup></td>\n      <td>200 mg QD <sup>b</sup></td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "12",
        "TableName": "Adavosertib QD Monotherapy Dose Level Reductions",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      703
    ],
    [
      "",
      "Unmapped",
      "text",
      "Full details of the adavosertib regimens are provided in Figure 1 and Table 3",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of toxicities",
      "8.4.5",
      "3",
      704
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.5.1  Management of haematologic toxicity",
      { "IsBold": false, "font_size": -1, "font_style": "Heading4" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      705
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.5.1.1  Dose modifications due to haematologic toxicity",
      { "IsBold": false, "font_size": -1, "font_style": "Heading8" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      706
    ],
    [
      "",
      "Unmapped",
      "text",
      "CBC will be obtained for all subjects at the beginning of each treatment week in Cycle 1 and 2 (i.e.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      707
    ],
    [
      "",
      "Unmapped",
      "text",
      "Day 1 and Day 8), and the beginning of each treatment cycle from Cycle 3 onwards (i.e.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      708
    ],
    [
      "",
      "Unmapped",
      "text",
      "Day 1), and CBC must be reviewed prior to dose administration.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      709
    ],
    [
      "",
      "Unmapped",
      "text",
      "If significant haematologic toxicity occurs, treatment should be held, and ANC, platelets and haemoglobin should be monitored at least weekly and until blood counts recover to enable dosing of the study drugs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      710
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dosing may then resume according to the dosing guidelines in Table 9, Table 10 and Table 11.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      711
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects should be managed as medically indicated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      712
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 9  Neutrophil Blood Counts and Study Drug Action",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      713
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n      <th>5.0</th>\n      <th>6.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Neutrophil count</td>\n      <td>Action Adavosertib</td>\n      <td>2nd event</td>\n      <td>Action Adavosertib</td>\n      <td>3rd event</td>\n      <td>Action Adavosertib</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Grade 2 <1.5-1.0×10 <sup>9</sup> /L</td>\n      <td>Investigator judgement to continue adavosertib or interrupt until Grade 1 (≥1.5-1.0×10 <sup>9</sup> /L)</td>\n      <td>Investigator judgement to continue adavosertib or interrupt until Grade 1 (≥1.5-1.0×10 <sup>9</sup> /L)</td>\n      <td>Investigator judgement to continue adavosertib or interrupt until Grade 1 (≥1.5-1.0×10 <sup>9</sup> /L)</td>\n      <td>Investigator judgement to continue adavosertib or interrupt until Grade 1 (≥1.5-1.0×10 <sup>9</sup> /L)</td>\n      <td>Investigator judgement to continue adavosertib or interrupt until Grade 1 (≥1.5-1.0×10 <sup>9</sup> /L)</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Grade 3 <1.0-0.5×10 <sup>9</sup> /L</td>\n      <td>Hold Resume at same dose</td>\n      <td></td>\n      <td>Hold Resume with 1 dose level reduction</td>\n      <td></td>\n      <td>Hold Resume with 2 dose level reduction</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Grade 3 <1.0-0.5×10 <sup>9</sup> /L with documented infection and/or fever</td>\n      <td>Hold Resume with 1 dose level reduction</td>\n      <td></td>\n      <td>Hold Resume with 2 dose level reduction</td>\n      <td></td>\n      <td>Hold Contact Study Physician</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Grade 4 <0.5×10 <sup>9</sup> /L</td>\n      <td>Hold Resume with 1 dose level reduction</td>\n      <td></td>\n      <td>Hold Resume with 2 dose level reduction</td>\n      <td></td>\n      <td>Discontinue and follow for disease progression</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Grade 4 Febrile neutropenia or Grade 4 Infection with neutropenia</td>\n      <td>Discontinue and follow for disease progression</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "13",
        "TableName": "Neutrophil Blood Counts and Study Drug Action",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      714
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 10  Platelet Blood Counts and Study Drug Action",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      715
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n      <th>5.0</th>\n      <th>6.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Platelet count</td>\n      <td>Action Adavosertib</td>\n      <td>2nd event</td>\n      <td>Action Adavosertib</td>\n      <td>3rd event</td>\n      <td>Action Adavosertib</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Grade 2 75,000-50,000/ μL</td>\n      <td>Hold Resume at same dose</td>\n      <td></td>\n      <td>Hold Resume with 1 dose level reduction</td>\n      <td></td>\n      <td>Hold Resume with 1 dose level reduction</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Grade 3 50,000- 25,000/ μL</td>\n      <td>Hold Resume with 1 dose level reduction</td>\n      <td></td>\n      <td>Hold Resume with 2 dose level reduction</td>\n      <td></td>\n      <td>Hold Resume with 2 dose level reduction</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Grade 4 <25,000/ μL without any evidence of bleeding</td>\n      <td>Hold Resume with 1 dose level reduction</td>\n      <td></td>\n      <td>Hold Resume with 2 dose level reduction</td>\n      <td></td>\n      <td>Discontinue and follow for disease progression</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Thrombocytopenic haemorrhage (gross occult bleeding) associated with platelet count <50,000/ μL</td>\n      <td>Discontinue and follow for disease progression</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "14",
        "TableName": "Platelet Blood Counts and Study Drug Action",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      716
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 11  Management of anaemia",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      717
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Haemoglobin (Hb)</td>\n      <td>Action to be taken</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Hb <9 but ≥8 g/dL (CTCAE Grade 2)</td>\n      <td>Give appropriate supportive treatment and investigate causality. Investigator judgement to continue adavosertib with supportive treatment or interrupt dose for a maximum of 21 days. If repeat Hb<9 but ≥8 g/dL, interrupt dose for a maximum of 21 days until Hb ≥9 g/dL</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Hb <8 g/dL</td>\n      <td>Give appropriate supportive treatment and investigate causality. Interrupt adavosertib for a maximum of 21 days, until improved to Hb ≥9 g/dL. Upon recovery dose reduce adavosertib. In case of a repeat episode of Hb<8g/ dL, interrupt dose for a maximum of 21 days and further dose reduce adavosertib. In case of a third episode of Hb<8g/ dL, discontinue treatment.</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "15",
        "TableName": "Management of anaemia",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      718
    ],
    [
      "",
      "Unmapped",
      "text",
      "If the subject has concurrent neutropenia and thrombocytopenia, please follow the most conservative guidance in Table 9 and Table 10 and discuss with the Study Physician as needed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      719
    ],
    [
      "",
      "Unmapped",
      "text",
      "Granulocyte-colony stimulating factor (G-CSF) may be used in the event of neutropenia according to institutional standards.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      720
    ],
    [
      "",
      "Unmapped",
      "text",
      "Please consider using G-CSF in the event of severe neutropenia or febrile neutropenia.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      721
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.5.1.2  Management of Febrile neutropenia",
      { "IsBold": false, "font_size": -1, "font_style": "Heading8" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      722
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects experiencing febrile neutropenia with significant symptoms should be managed under hospitalisation according to standard procedures, with the urgent initiation of IV antibiotic therapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      723
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects with febrile neutropenia without symptoms should be managed according to standard institutional guideline.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      724
    ],
    [
      "",
      "Unmapped",
      "text",
      "Please consider using G-CSF in the event of febrile neutropenia according to institutional standards.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of haematologic toxicity",
      "8.4.5.1",
      "4",
      725
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.5.2  Management of Non-haematologic toxicity",
      { "IsBold": false, "font_size": -1, "font_style": "Heading4" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      726
    ],
    [
      "",
      "Unmapped",
      "text",
      "Substantial acute toxicities should be managed as medically indicated and with temporary suspension of investigational product, as appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      727
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dose reductions or holds and initiation of supportive care are allowed as clinically indicated by the investigator.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      728
    ],
    [
      "",
      "Unmapped",
      "text",
      "In general, if a subject experiences a Grade 1/2 non-haematological toxicity, no dose modification is required.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      729
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a subject experiences a Grade 3 or Grade 4 toxicity which is not attributable to the disease or disease-related processes under investigation, dosing will be interrupted and/or reduced, and supportive therapy administered as required.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      730
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any subject who develops a Grade 3 or 4 non-haematologic toxicity that does not resolve to ≤ Grade 1 within 21 days should be discontinued from the study treatment unless approved by the study physician.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      731
    ],
    [
      "",
      "Unmapped",
      "text",
      "Attention should be paid to any detected increases in QTc.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      732
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects who develop mean resting value of QTc of 480 msec or a shift from baseline of ≥ 60ms, should pause taking adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      733
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dosing may be resumed at the same or reduced dose after return of the resting QTc to Grade 1 or baseline has been confirmed and correction of possible electrolyte imbalance has been made, if needed, following cardiologist's advice.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      734
    ],
    [
      "",
      "Unmapped",
      "text",
      "For more details, see Table 12.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      735
    ],
    [
      "",
      "Unmapped",
      "text",
      "Monitoring of QTc, checking and correction of abnormal electrolyte levels and renal function are advised, especially in case of severe/prolonged diarrhoea.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      736
    ],
    [
      "",
      "Unmapped",
      "text",
      "If QTc increases markedly from baseline, but stays below the above limit of Grade 1 (per CTCAE V 5.0), a cardiologist's advice is recommended (Refer to Table 12).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      737
    ],
    [
      "",
      "Unmapped",
      "text",
      "The concomitant use of ondansetron (known to prolong the QTc in rare cases, per labelling) as premedication should be taken into account when interpreting QTc changes.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      738
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 12  Adavosertib dose modifications for QTc prolongation",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      739
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>ECG QTc prolonged</td>\n      <td>ECG QTc prolonged</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>QTcF Value (triplicate) <sup>a, b</sup></td>\n      <td>Action to be taken</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>QTcF 481-500 ms (Grade2) <sup>c</sup></td>\n      <td>Hold treatment for up to 21 days. Consider seeking cardiologist’s advice. Once QTc has returned to Grade 1 and correction of possible electrolyte imbalance has been made, treatment may resume the same dose level.</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>QTcF ≥ 501 ms or Shift from baseline of ≥ 60 ms (Grade 3) <sup>c</sup></td>\n      <td>Hold treatment for up to 21 days. Seek cardiologist’s advice and correct any electrolyte imbalance. If QTc recovers to ≤ 480 ms (Grade 1) or baseline if there was a shift from baseline of ≥ 60 ms, then may resume treatment at next lower dose level, if cardiologist agrees. If QTc doesn’t recover to  ≤ 480 ms or baseline if there was a shift from baseline of  ≥ 60 ms, then discontinue treatment permanently.</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Torsades de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia (Grade 4) <sup>c</sup></td>\n      <td>Discontinue treatment permanently. Seek cardiologist’s advice.</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "16",
        "TableName": "Adavosertib dose modifications for QTc prolongation",
        "Header": [0, 1]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      740
    ],
    [
      "",
      "Unmapped",
      "text",
      "ECG should be assessed if electrolyte abnormalities are detected or suspected (e.g.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      741
    ],
    [
      "",
      "Unmapped",
      "text",
      "in relation to gastrointestinal toxicity).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      742
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a prolongation of the QTc is detected this must be closely monitored as clinically indicated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      743
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.5.2.1  Management of nausea and vomiting",
      { "IsBold": false, "font_size": -1, "font_style": "Heading8" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      744
    ],
    [
      "",
      "Unmapped",
      "text",
      "All subjects must receive a 5-hydroxytryptamine (5-HT)3 antagonist, ondansetron 8 mg PO QD or granisetron 1 mg PO QD prior to each dose of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      745
    ],
    [
      "",
      "Unmapped",
      "text",
      "If nausea and vomiting continue, a second dose of antiemetics can be taken 8 hours later if necessary.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      746
    ],
    [
      "",
      "Unmapped",
      "text",
      "In addition, dexamethasone 4 mg PO will be given with each adavosertib dose as a minimum on the first day of dosing adavosertib of every 5 days dosing period, unless contraindicated or not welltolerated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      747
    ],
    [
      "",
      "Unmapped",
      "text",
      "Dexamethasone or the 5-HT3 antagonist may be given by intravenous (IV) route as needed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      748
    ],
    [
      "",
      "Unmapped",
      "text",
      "Promethazine, prochlorperazine, and benzodiazepine may still be used as additional adjunctive treatments during adavosertib therapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      749
    ],
    [
      "",
      "Unmapped",
      "text",
      "Please note: aprepitant and fosaprepitant are not permitted due to known drug-drug interactions.",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      750
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects should be encouraged to maintain liberal oral fluid intake.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      751
    ],
    [
      "",
      "Unmapped",
      "text",
      "Gastrointestinal AEs, including decreased appetite, dyspepsia, nausea, vomiting and diarrhoea (with or without dehydration or serum electrolyte decreases) have been associated with adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      752
    ],
    [
      "",
      "Unmapped",
      "text",
      "The use of prophylactic antiemetics is mandatory, and prompt introduction of vigorous anti-diarrhoeal therapy at the first onset is advised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      753
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Investigator must consult the study protocol for specific guidance to manage gastrointestinal toxicities, including prophylactic medications.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      754
    ],
    [
      "",
      "Unmapped",
      "text",
      "Therefore, subjects should be monitored closely for signs of gastrointestinal AEs, and subjects' hydration status, electrolytes, weight, and other vital signs should be monitored carefully.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      755
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects should be managed clinically with supportive therapy and dose modification and should be strongly encouraged to maintain liberal oral fluid intake.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      756
    ],
    [
      "",
      "Unmapped",
      "text",
      "Aprepitant and fosaprepitant are not permitted as co-medications due to known drug-drug interactions with adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      757
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.4.5.2.2  Management of diarrhoea",
      { "IsBold": false, "font_size": -1, "font_style": "Heading8" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      758
    ],
    [
      "",
      "Unmapped",
      "text",
      "Due to frequent reports of diarrhoea with adavosertib administration, anti-diarrhoeal treatment with loperamide is required at the",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      759
    ],
    [
      "",
      "Unmapped",
      "text",
      "first",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      760
    ],
    [
      "",
      "Unmapped",
      "text",
      "onset of diarrhoea according to American Society of Clinical Oncology (ASCO) guidelines.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      761
    ],
    [
      "",
      "Unmapped",
      "text",
      "Oral loperamide 4mg should be administered at the first onset of diarrhoea and then 2mg every 2 hours until subject is diarrhoea-free for at least 12 hours.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      762
    ],
    [
      "",
      "Unmapped",
      "text",
      "The first dose of loperamide could be lowered to 2 mg if the diarrhoea is recurrent and if, in the opinion of the investigator, the diarrhoea is not severe.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      763
    ],
    [
      "",
      "Unmapped",
      "text",
      "The dose of loperamide should not exceed 16 mg in a 24-hour period.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      764
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects should be instructed to notify the Investigator or research staff of the occurrence of bloody or black stools, symptoms of dehydration, fever, inability to take liquids by mouth, and inability to control diarrhoea within 24 hours of using loperamide or other prescribed antidiarrhoeal medications",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      765
    ],
    [
      "",
      "Unmapped",
      "text",
      "If diarrhoea is severe (i.e., requiring IV rehydration) and/or associated with fever or severe neutropenia (Grade 3 or 4), broad-spectrum antibiotics must be prescribed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      766
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects with severe diarrhoea or any diarrhoea associated with severe nausea or vomiting should be hospitalised for IV hydration and correction of electrolyte imbalances.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Management of Non-haematologic toxicity",
      "8.4.5.2",
      "4",
      767
    ],
    [
      "2",
      "Pharmacokinetics",
      "header",
      " 8.5  Pharmacokinetics (PK)",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Pharmacokinetics (PK)",
      "8.5",
      "2",
      768
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.5.1  Collection of pharmacokinetic samples",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      769
    ],
    [
      "",
      "Unmapped",
      "text",
      "Whole blood samples (2 mL) will be collected to measure plasma concentrations of the study treatment as specified in Table 13.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      770
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects should be instructed to hold their dose of adavosertib on any day PK sampling is scheduled so it may have timed administration in the site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      771
    ],
    [
      "",
      "Unmapped",
      "text",
      "Unscheduled PK samples can be collected for AEs possibly related to investigational drug(s) unless the last dose of study drug was administered >1 week prior to the event.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      772
    ],
    [
      "",
      "Unmapped",
      "text",
      "Samples may be collected at additional time points during the study if warranted and agreed upon between the investigator and the sponsor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      773
    ],
    [
      "",
      "Unmapped",
      "text",
      "Instructions for the collection and handling of biological samples will be provided by the sponsor or analytical test site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      774
    ],
    [
      "",
      "Unmapped",
      "text",
      "The actual date and time (24-hour clock time) of each sample will be recorded in the medical records and eCRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      775
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any changes in the timing or addition of time points for any planned study assessments must be documented and approved by the relevant study team member and then archived in the sponsor and site study files, but will not constitute a protocol amendment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      776
    ],
    [
      "",
      "Unmapped",
      "text",
      "The institutional review board (IRB) will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      777
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 13  PK sampling schedule for adavosertib",
      { "IsBold": false, "font_size": -1, "font_style": "Heading7" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      778
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n      <th>5.0</th>\n      <th>6.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Timing of sample</td>\n      <td>Cycle 1 Day 1</td>\n      <td>Cycle 1 Day 5</td>\n      <td>Cycle 2 Day 5</td>\n      <td>Cycle 3 Day 5</td>\n      <td>Cycle 5 Day 5</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Pre-dose <sup>a</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n      <td>X</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>1 hour post dose <sup>b</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>2 hours post dose <sup>b</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>4 hours post dose <sup>b</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>6 hours post dose <sup>b</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>8 hours post dose <sup>b</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>10 hours post dose <sup>b</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>24 hours post dose <sup>c</sup></td>\n      <td>X</td>\n      <td>X</td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "17",
        "TableName": "PK sampling schedule for adavosertib(Schedule of Assessment)",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      779
    ],
    [
      "",
      "Unmapped",
      "text",
      "The PK sample timing may be adjusted during the study, depending on emerging data and in order to ensure appropriate characterization of the plasma concentration-time profiles.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      780
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a subject misses any doses of adavosertib a day prior to PK sampling, the Study Physician should be contacted regarding any effect of the missed doses and potential changes required on the timing of the PK assessments.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      781
    ],
    [
      "",
      "Unmapped",
      "text",
      "All other assessments, including laboratory safety assessments, vital signs and RECIST, should continue to be performed according to the study plan, relative to baseline assessments.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      782
    ],
    [
      "",
      "Unmapped",
      "text",
      "Samples will be collected, labelled, stored, and shipped as detailed in the Laboratory Manual.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Collection of pharmacokinetic samples",
      "8.5.1",
      "3",
      783
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.5.2  Determination of drug concentration",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Determination of drug concentration",
      "8.5.2",
      "3",
      784
    ],
    [
      "",
      "Unmapped",
      "text",
      "Samples for determination of drug concentration in plasma will be analysed by analytical test sites on behalf of AstraZeneca, using an appropriate bioanalytical method.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Determination of drug concentration",
      "8.5.2",
      "3",
      785
    ],
    [
      "",
      "Unmapped",
      "text",
      "Full details of the analytical method used will be described in a separate bioanalytical report.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Determination of drug concentration",
      "8.5.2",
      "3",
      786
    ],
    [
      "",
      "Unmapped",
      "text",
      "Incurred sample reproducibility analysis, if any, will be performed alongside the bioanalysis of the test samples.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Determination of drug concentration",
      "8.5.2",
      "3",
      787
    ],
    [
      "",
      "Unmapped",
      "text",
      "The results from the evaluation will not be reported in the CSR but separately in a Bioanalytical Report.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Determination of drug concentration",
      "8.5.2",
      "3",
      788
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.5.3  Storage and destruction of pharmacokinetic samples",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Storage and destruction of pharmacokinetic samples",
      "8.5.3",
      "3",
      789
    ],
    [
      "",
      "Unmapped",
      "text",
      "PK samples will be disposed of after the Bioanalytical Report finalization or six months after issuance of the draft Bioanalytical Report (whichever is earlier), unless requested for future analyses.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of pharmacokinetic samples",
      "8.5.3",
      "3",
      790
    ],
    [
      "",
      "Unmapped",
      "text",
      "PK samples may be disposed of or anonymised by pooling.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of pharmacokinetic samples",
      "8.5.3",
      "3",
      791
    ],
    [
      "",
      "Unmapped",
      "text",
      "Additional analyses may be conducted on the anonymised, pooled PK samples to further evaluate and validate the analytical method.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of pharmacokinetic samples",
      "8.5.3",
      "3",
      792
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any results from such analyses may be reported separately from the CSR.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of pharmacokinetic samples",
      "8.5.3",
      "3",
      793
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.5.4  Calculation or derivation of pharmacokinetic variables",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      794
    ],
    [
      "",
      "Unmapped",
      "text",
      "Pharmacokinetic analysis of plasma for adavosertib concentration data will be performed by Covance on behalf of AstraZeneca.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      795
    ],
    [
      "",
      "Unmapped",
      "text",
      "The actual sampling times will be used in the parameter calculations and PK parameters will be derived using standard, non-compartmental methods.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      796
    ],
    [
      "",
      "Unmapped",
      "text",
      "When possible, the following PK parameters will be determined:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      797
    ],
    [
      "",
      "Unmapped",
      "text",
      "C",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      798
    ],
    [
      "",
      "Unmapped",
      "text",
      "max",
      { "IsBold": false, "font_size": 16, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      799
    ],
    [
      "",
      "Unmapped",
      "text",
      "Plasma concentration at 8/10 hours post-dose (C",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      800
    ],
    [
      "",
      "Unmapped",
      "text",
      "8/10h",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      801
    ],
    [
      "",
      "Unmapped",
      "text",
      ")",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      802
    ],
    [
      "",
      "Unmapped",
      "text",
      "t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      803
    ],
    [
      "",
      "Unmapped",
      "text",
      "max",
      { "IsBold": false, "font_size": 16, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      804
    ],
    [
      "",
      "Unmapped",
      "text",
      "Time to last detectable concentration (t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      805
    ],
    [
      "",
      "Unmapped",
      "text",
      "last",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      806
    ],
    [
      "",
      "Unmapped",
      "text",
      ")",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      807
    ],
    [
      "",
      "Unmapped",
      "text",
      "Terminal half life (t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      808
    ],
    [
      "",
      "Unmapped",
      "text",
      "½",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      809
    ],
    [
      "",
      "Unmapped",
      "text",
      ")",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      810
    ],
    [
      "",
      "Unmapped",
      "text",
      "Area under the plasma concentration-time curve from zero to 10 hours (AUC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      811
    ],
    [
      "",
      "Unmapped",
      "text",
      "0-10",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      812
    ],
    [
      "",
      "Unmapped",
      "text",
      "), from zero to the time of the last measurable concentration (AUC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      813
    ],
    [
      "",
      "Unmapped",
      "text",
      "0-t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      814
    ],
    [
      "",
      "Unmapped",
      "text",
      "), and AUC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      815
    ],
    [
      "",
      "Unmapped",
      "text",
      "0-24",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      816
    ],
    [
      "",
      "Unmapped",
      "text",
      "C",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      817
    ],
    [
      "",
      "Unmapped",
      "text",
      "trough",
      { "IsBold": false, "font_size": 16, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      818
    ],
    [
      "",
      "Unmapped",
      "text",
      "The C",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      819
    ],
    [
      "",
      "Unmapped",
      "text",
      "max",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      820
    ],
    [
      "",
      "Unmapped",
      "text",
      "and t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      821
    ],
    [
      "",
      "Unmapped",
      "text",
      "max",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      822
    ],
    [
      "",
      "Unmapped",
      "text",
      "parameters will be determined by inspecting the concentration time profiles.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      823
    ],
    [
      "",
      "Unmapped",
      "text",
      "Where possible, the terminal elimination rate constant (λ",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      824
    ],
    [
      "",
      "Unmapped",
      "text",
      "z",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      825
    ],
    [
      "",
      "Unmapped",
      "text",
      ") will be calculated by log linear regression of the terminal portion of the concentration-time profiles when there are sufficient data and the terminal elimination half-life (t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      826
    ],
    [
      "",
      "Unmapped",
      "text",
      "½",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      827
    ],
    [
      "",
      "Unmapped",
      "text",
      "λz) will be calculated as 1n2/λz.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      828
    ],
    [
      "",
      "Unmapped",
      "text",
      "The AUC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      829
    ],
    [
      "",
      "Unmapped",
      "text",
      "0-t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      830
    ],
    [
      "",
      "Unmapped",
      "text",
      "and the AUC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      831
    ],
    [
      "",
      "Unmapped",
      "text",
      "0-10",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      832
    ],
    [
      "",
      "Unmapped",
      "text",
      "will be calculated using the linear up, log down trapezoidal rule.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      833
    ],
    [
      "",
      "Unmapped",
      "text",
      "Where appropriate, the AUC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      834
    ],
    [
      "",
      "Unmapped",
      "text",
      "0-t",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      835
    ],
    [
      "",
      "Unmapped",
      "text",
      "will be extrapolated to infinity using λz to obtain area under the plasma concentration-time curve (AUC).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      836
    ],
    [
      "",
      "Unmapped",
      "text",
      "The apparent oral steady state clearance (CL",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      837
    ],
    [
      "",
      "Unmapped",
      "text",
      "ss",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      838
    ],
    [
      "",
      "Unmapped",
      "text",
      "/F) following multiple dosing will be determined from the ratio of dose/AUC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      839
    ],
    [
      "",
      "Unmapped",
      "text",
      "0-24",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      840
    ],
    [
      "",
      "Unmapped",
      "text",
      ".",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      841
    ],
    [
      "",
      "Unmapped",
      "text",
      "The apparent volume of distribution (V",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      842
    ],
    [
      "",
      "Unmapped",
      "text",
      "z",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      843
    ],
    [
      "",
      "Unmapped",
      "text",
      "/F) will be determined from the apparent oral clearance (CL/F) divided by λz, as appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Calculation or derivation of pharmacokinetic variables",
      "8.5.4",
      "3",
      844
    ],
    [
      "2",
      "Pharmacokinetics",
      "header",
      " 8.6  Pharmacodynamics",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Pharmacodynamics",
      "8.6",
      "2",
      845
    ],
    [
      "2",
      "Pharmacokinetics",
      "text",
      "Pharmacodynamic parameters are not evaluated in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Pharmacodynamics",
      "8.6",
      "2",
      846
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.7  Genetics",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Genetics",
      "8.7",
      "2",
      847
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.7.1  Optional exploratory genetic sample",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Optional exploratory genetic sample",
      "8.7.1",
      "3",
      848
    ],
    [
      "",
      "Unmapped",
      "text",
      "Approximately 6 mL whole blood sample for DNA isolation will be collected from subjects who have consented to participate in the genetic analysis component of the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Optional exploratory genetic sample",
      "8.7.1",
      "3",
      849
    ],
    [
      "",
      "Unmapped",
      "text",
      "Participation is optional.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Optional exploratory genetic sample",
      "8.7.1",
      "3",
      850
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects who do not wish to participate in the genetic research may still participate in the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Optional exploratory genetic sample",
      "8.7.1",
      "3",
      851
    ],
    [
      "",
      "Unmapped",
      "text",
      "See Appendix D for Information regarding genetic research.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Optional exploratory genetic sample",
      "8.7.1",
      "3",
      852
    ],
    [
      "",
      "Unmapped",
      "text",
      "Details on processes for collection and shipment and destruction of these samples can be found in Appendix D or in the Laboratory Manual.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Optional exploratory genetic sample",
      "8.7.1",
      "3",
      853
    ],
    [
      "",
      "Unmapped",
      "header",
      " 8.7.2  Storage and destruction of genetic samples",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Study Assessments and Procedures",
      "Storage and destruction of genetic samples",
      "8.7.2",
      "3",
      854
    ],
    [
      "",
      "Unmapped",
      "text",
      "The processes adopted for the coding and storage of samples for genetic analysis are important to maintain subject confidentiality.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of genetic samples",
      "8.7.2",
      "3",
      855
    ],
    [
      "",
      "Unmapped",
      "text",
      "Samples may be stored for a maximum of 15 years or as per local regulations from the date of the Last Subject's Last Visit, after which they will be destroyed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of genetic samples",
      "8.7.2",
      "3",
      856
    ],
    [
      "",
      "Unmapped",
      "text",
      "DNA is a finite resource that may be used up during analyses.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of genetic samples",
      "8.7.2",
      "3",
      857
    ],
    [
      "",
      "Unmapped",
      "text",
      "The results of any further analyses will be reported in the CSR or in a separate study summary.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of genetic samples",
      "8.7.2",
      "3",
      858
    ],
    [
      "",
      "Unmapped",
      "text",
      "No personal details identifying the individual will be available to AstraZeneca or designated organizations working with the DNA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Storage and destruction of genetic samples",
      "8.7.2",
      "3",
      859
    ],
    [
      "2",
      "Biomarkers",
      "header",
      " 8.8  Biomarkers",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Biomarkers",
      "8.8",
      "2",
      860
    ],
    [
      "2",
      "Biomarkers",
      "text",
      "Biomarkers are not evaluated in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Biomarkers",
      "8.8",
      "2",
      861
    ],
    [
      "2",
      "[Health Economics OR Medical Resource Utilization and Health Economics]",
      "header",
      " 8.9  Medical Resource Utilization and Health Economics",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Study Assessments and Procedures",
      "Medical Resource Utilization and Health Economics",
      "8.9",
      "2",
      862
    ],
    [
      "2",
      "[Health Economics OR Medical Resource Utilization and Health Economics]",
      "text",
      "Medical Resource Utilization and Health Economics parameters are not evaluated in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Study Assessments and Procedures",
      "Medical Resource Utilization and Health Economics",
      "8.9",
      "2",
      863
    ],
    [
      "1",
      "Statistical Considerations",
      "header",
      " 9  STATISTICAL CONSIDERATIONS",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Statistical Considerations",
      "STATISTICAL CONSIDERATIONS",
      "9",
      "1",
      864
    ],
    [
      "2",
      "Statistical Hypotheses",
      "header",
      " 9.1  Statistical hypotheses",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Statistical Considerations",
      "Statistical hypotheses",
      "9.1",
      "2",
      865
    ],
    [
      "2",
      "Statistical Hypotheses",
      "text",
      "Statistical hypotheses will not be set in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical hypotheses",
      "9.1",
      "2",
      866
    ],
    [
      "2",
      "Sample Size Determination",
      "header",
      " 9.2  Sample size determination",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Statistical Considerations",
      "Sample size determination",
      "9.2",
      "2",
      867
    ],
    [
      "2",
      "Sample Size Determination",
      "text",
      "The study's primary objective is to investigate the safety and tolerability of the study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Sample size determination",
      "9.2",
      "2",
      868
    ],
    [
      "2",
      "Sample Size Determination",
      "text",
      "Hence, the number of subjects has been based on the desire to obtain adequate tolerability, safety and pharmacokinetic data while exposing as few subjects as possible to the study treatments and procedures.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Sample size determination",
      "9.2",
      "2",
      869
    ],
    [
      "2",
      "Sample Size Determination",
      "text",
      "At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Sample size determination",
      "9.2",
      "2",
      870
    ],
    [
      "2",
      "Sample Size Determination",
      "text",
      "Any subjects not evaluable for DLT will be replaced.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Sample size determination",
      "9.2",
      "2",
      871
    ],
    [
      "2",
      "Sample Size Determination",
      "text",
      "Thus, the total number of subjects will depend upon the available data in each cohort and the SRC's decision.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Sample size determination",
      "9.2",
      "2",
      872
    ],
    [
      "",
      "Unmapped",
      "header",
      " 9.3  Populations for analyses",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Statistical Considerations",
      "Populations for analyses",
      "9.3",
      "2",
      873
    ],
    [
      "",
      "Unmapped",
      "text",
      "For purposes of analysis, the following populations are defined:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Populations for analyses",
      "9.3",
      "2",
      874
    ],
    [
      "",
      "Unmapped",
      "header",
      " Table 14  Populations for analyses",
      { "IsBold": false, "font_size": 24, "font_style": "Heading6" },
      "Statistical Considerations",
      "Populations for analyses",
      "9.3",
      "2",
      875
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Population</td>\n      <td>Description</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>All subjects set</td>\n      <td>All subjects who sign the ICF</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Safety Analysis Set</td>\n      <td>Subjects who received at least one dose of study treatment. Subjects will be evaluated according to the treatment received.</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>DLT Analysis Set</td>\n      <td>All subjects who are evaluable for DLT as specified in Section 6.6.2.</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Tumour Response Analysis Set</td>\n      <td>Subjects who had measurable tumour assessment data at baseline (within 28 days prior to the first dose of study treatment, as specified in Table 1) and received at least one dose of study treatment.</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>PK Analysis Set</td>\n      <td>Dosed subjects who have at least 1 quantifiable plasma concentration for adavosertib or metabolites collected post dose without protocol deviations or events that would affect the PK analysis.</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "18",
        "TableName": "Populations for analyses",
        "Header": [0]
      },
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Populations for analyses",
      "9.3",
      "2",
      876
    ],
    [
      "2",
      "Statistical Analyses",
      "header",
      " 9.4  Statistical analyses",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      877
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "Analyses will be performed by AstraZeneca or its representatives.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      878
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "A comprehensive Statistical Analysis Plan will be developed and finalised before database lock and will describe the subject populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      879
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "This section is a summary of the planned statistical analyses of the primary and secondary endpoints.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      880
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "Any deviations from this plan will be reported in the CSR.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      881
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "The baseline value is defined as the last result obtained prior to the first administration of the study treatments.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      882
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "Change from baseline is defined as post-baseline value minus baseline value.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      883
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "Percent change from baseline is defined as ([post-baseline value] - [baseline value]) / (baseline value) * 100.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      884
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "Change from baseline and percent change from baseline will not be calculated for subjects whose baseline or post-baseline values are missing.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      885
    ],
    [
      "2",
      "Statistical Analyses",
      "text",
      "The data will be summarized by cohort and overall, where appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Statistical analyses",
      "9.4",
      "2",
      886
    ],
    [
      "",
      "Unmapped",
      "header",
      " 9.4.1  Demographic data",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Statistical Considerations",
      "Demographic data",
      "9.4.1",
      "3",
      887
    ],
    [
      "",
      "Unmapped",
      "text",
      "Demographic data will be summarised using the safety analysis set.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Demographic data",
      "9.4.1",
      "3",
      888
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subject characteristics, including medical history and disease characteristics at baseline, will be listed and summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Demographic data",
      "9.4.1",
      "3",
      889
    ],
    [
      "",
      "Unmapped",
      "header",
      " 9.4.2  Exposure",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Statistical Considerations",
      "Exposure",
      "9.4.2",
      "3",
      890
    ],
    [
      "",
      "Unmapped",
      "text",
      "Exposure data will be summarised using the safety analysis set.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Exposure",
      "9.4.2",
      "3",
      891
    ],
    [
      "",
      "Unmapped",
      "text",
      "Exposure to adavosertib (i.e., total amount of adavosertib received) will be listed for all subjects and summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Exposure",
      "9.4.2",
      "3",
      892
    ],
    [
      "",
      "Unmapped",
      "text",
      "Total time on study (date of last dose minus date of first dose), the number and percentage of subjects with at least one dose interruption/dose delay and at least one dose reduction will be summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Exposure",
      "9.4.2",
      "3",
      893
    ],
    [
      "",
      "Unmapped",
      "text",
      "Reasons for discontinuing the study treatment will be summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Exposure",
      "9.4.2",
      "3",
      894
    ],
    [
      "",
      "Unmapped",
      "header",
      " 9.4.3  Safety analyses",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      895
    ],
    [
      "",
      "Unmapped",
      "text",
      "DLT will be summarized using the DLT analysis set.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      896
    ],
    [
      "",
      "Unmapped",
      "text",
      "Safety analyses will be presented using the safety analysis set and will be done by means of descriptive statistics.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      897
    ],
    [
      "",
      "Unmapped",
      "text",
      "Safety profiles will be assessed in terms of AEs, vital signs (including blood pressure, pulse rate and body temperature), laboratory data (clinical chemistry and haematology), ECG data, and physical examinations.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      898
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any AE occurring after the first administration of study treatment (or worsening if present before the first administration of study treatment) and within the defined 30 days follow-up period after discontinuing the study treatment will be included in the AE summaries.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      899
    ],
    [
      "",
      "Unmapped",
      "text",
      "The number of subjects experiencing each AE will be summarised by the Medical Dictionary for Regulatory Activities (MedDRA) system organ class, preferred term and CTCAE grade.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      900
    ],
    [
      "",
      "Unmapped",
      "text",
      "Furthermore, SAEs, CTCAE grade ≥ 3, AEs causally related to study treatment, AEs that led to dose interruption or dose delay, AEs that led to dose reduction, AEs that led to withdrawal, and AEs that led to death will be summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      901
    ],
    [
      "",
      "Unmapped",
      "text",
      "All AE data will be listed for all subjects.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      902
    ],
    [
      "",
      "Unmapped",
      "text",
      "In addition, AEs that led to death will be listed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      903
    ],
    [
      "",
      "Unmapped",
      "text",
      "Vital signs, laboratory data and ECG data will be listed and summarised appropriately.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      904
    ],
    [
      "",
      "Unmapped",
      "text",
      "Vital signs and laboratory data (clinical chemistry and haematology) will be summarised using observed values during the scheduled visit and if there are changes from baseline values.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      905
    ],
    [
      "",
      "Unmapped",
      "text",
      "For laboratory variables, which are included in the CTCAE, the CTCAE grade will be summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      906
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any qualitative assessments will be summarised using the number of subjects with results of negative, trace or positive.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Safety analyses",
      "9.4.3",
      "3",
      907
    ],
    [
      "",
      "Unmapped",
      "header",
      " 9.4.4  Pharmacokinetics (PK) analyses",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Statistical Considerations",
      "Pharmacokinetics (PK) analyses",
      "9.4.4",
      "3",
      908
    ],
    [
      "",
      "Unmapped",
      "text",
      "PK will be summarised as per the PK analysis set.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Pharmacokinetics (PK) analyses",
      "9.4.4",
      "3",
      909
    ],
    [
      "",
      "Unmapped",
      "text",
      "All plasma concentration data for adavosertib and derived PK parameters will be summarised and presented according to AstraZeneca standards as described in the Statistical Analysis Plan.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Pharmacokinetics (PK) analyses",
      "9.4.4",
      "3",
      910
    ],
    [
      "",
      "Unmapped",
      "header",
      " 9.4.5  Efficacy analyses",
      { "IsBold": false, "font_size": -1, "font_style": "Heading3" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      911
    ],
    [
      "",
      "Unmapped",
      "text",
      "Tumour response data will be analysed using Tumour Response Analysis Set.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      912
    ],
    [
      "",
      "Unmapped",
      "text",
      "Overall visit response data will be listed using the following response categories based on RECIST v1.1 guidelines (Eisenhauer et al, 2009): complete response (CR), partial response (PR), SD, PD, and not evaluable (NE), per Appendix G.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      913
    ],
    [
      "",
      "Unmapped",
      "text",
      "SD needs to be maintained for ≥ 9 weeks [±7 days] from start of treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      914
    ],
    [
      "",
      "Unmapped",
      "text",
      "The best overall response of confirmed CR, confirmed PR, SD, PD, and NE, based on overall visit response data, will be summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      915
    ],
    [
      "",
      "Unmapped",
      "text",
      "ORR, defined as the proportion of subjects who have a best overall response of confirmed CR or confirmed PR, will be calculated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      916
    ],
    [
      "",
      "Unmapped",
      "text",
      "DCR, defined as the proportion of subjects who have a best overall response of confirmed CR, confirmed PR, or SD, will be calculated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      917
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Clopper-Pearson exact method for binomial proportion will be used to calculate the 95% confidence interval (CI) for ORR and DCR.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      918
    ],
    [
      "",
      "Unmapped",
      "text",
      "DoR is defined as the duration from the date of first documentation of response (CR or PR), which is subsequently confirmed, to the date of documented disease progression or death due to any cause in the absence of disease progression (i.e., date of PFS event or censoring - date for first response + 1).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      919
    ],
    [
      "",
      "Unmapped",
      "text",
      "The DoR will only be evaluated for the subgroup of subjects in Tumour Response Analysis Set with a best overall response of confirmed CR or confirmed PR.  DoR will be listed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      920
    ],
    [
      "",
      "Unmapped",
      "text",
      "The percentage change in tumour size will be determined for subjects with measurable disease at baseline.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      921
    ],
    [
      "",
      "Unmapped",
      "text",
      "It is derived at each RECIST assessment visit by the percentage change from baseline, in sum of the diameters of target lesions (TLs), and will be listed and summarised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      922
    ],
    [
      "",
      "Unmapped",
      "text",
      "Waterfall plots (bar charts), indicating the best percentage change from baseline in sum of the diameters of TLs, will be produced.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      923
    ],
    [
      "",
      "Unmapped",
      "text",
      "Spider plots, presenting percentage changes from baseline in sum of the diameters of TLs versus time from the start of study treatment, will be produced.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      924
    ],
    [
      "",
      "Unmapped",
      "text",
      "PFS will be evaluated using Safety Analysis Set.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      925
    ],
    [
      "",
      "Unmapped",
      "text",
      "PFS is defined as the time from the first dose of study treatment until the date of objective disease progression or death by any cause (in the absence of progression), regardless of whether the subject withdraws from the study or receives another anti-cancer therapy prior to progression (i.e., date of PFS event or censoring date of first dose + 1).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      926
    ],
    [
      "",
      "Unmapped",
      "text",
      "PFS will be listed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Efficacy analyses",
      "9.4.5",
      "3",
      927
    ],
    [
      "2",
      "Interim Analysis",
      "header",
      " 9.5  Interim analyses",
      { "IsBold": false, "font_size": -1, "font_style": "Heading2" },
      "Statistical Considerations",
      "Interim analyses",
      "9.5",
      "2",
      928
    ],
    [
      "2",
      "Interim Analysis",
      "text",
      "Not planned",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Interim analyses",
      "9.5",
      "2",
      929
    ],
    [
      "2",
      "Interim Analysis",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Statistical Considerations",
      "Interim analyses",
      "9.5",
      "2",
      930
    ],
    [
      "1",
      "References",
      "header",
      " 10  REFERENCES",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "References",
      "REFERENCES",
      "10",
      "1",
      931
    ],
    [
      "1",
      "References",
      "text",
      "Bauer et al, 2019",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      932
    ],
    [
      "1",
      "References",
      "text",
      "Bauer TM, Moore K, Rader JS, et al.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      933
    ],
    [
      "1",
      "References",
      "text",
      "Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts [abstract].",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      934
    ],
    [
      "1",
      "References",
      "text",
      "In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      935
    ],
    [
      "1",
      "References",
      "text",
      "Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT012.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      936
    ],
    [
      "1",
      "References",
      "text",
      "Coleman and Dunphy 1994",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      937
    ],
    [
      "1",
      "References",
      "text",
      "Coleman TR, Dunphy WG.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      938
    ],
    [
      "1",
      "References",
      "text",
      "Cdc2 regulatory factors.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      939
    ],
    [
      "1",
      "References",
      "text",
      "Curr Opin Cell Biol 1994;6(6):877-82.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      940
    ],
    [
      "1",
      "References",
      "text",
      "Cuneo et al, 2019",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      941
    ],
    [
      "1",
      "References",
      "text",
      "Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, et al.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      942
    ],
    [
      "1",
      "References",
      "text",
      "Dose Escalation",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      943
    ],
    [
      "1",
      "References",
      "text",
      "Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      944
    ],
    [
      "1",
      "References",
      "text",
      "J Clin Oncol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      945
    ],
    [
      "1",
      "References",
      "text",
      "2019 Oct 10;37(29):2643-2650.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      946
    ],
    [
      "1",
      "References",
      "text",
      "Eisenhauer et al, 2009",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      947
    ],
    [
      "1",
      "References",
      "text",
      "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      948
    ],
    [
      "1",
      "References",
      "text",
      "New response evaluation criteria in solid tumours: Revised RECIST guidelines (version 1.1).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      949
    ],
    [
      "1",
      "References",
      "text",
      "Eur J Cancer.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      950
    ],
    [
      "1",
      "References",
      "text",
      "2009;45:228-47.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      951
    ],
    [
      "1",
      "References",
      "text",
      "Falchook et al, 2019",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      952
    ],
    [
      "1",
      "References",
      "text",
      "Falchook GS, Sachdev J, Imedio ER, et al.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      953
    ],
    [
      "1",
      "References",
      "text",
      "A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors [abstract].",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      954
    ],
    [
      "1",
      "References",
      "text",
      "In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      955
    ],
    [
      "1",
      "References",
      "text",
      "Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT022.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      956
    ],
    [
      "1",
      "References",
      "text",
      "Moore et al, 2019",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      957
    ],
    [
      "1",
      "References",
      "text",
      "Moore KN, Chambers SK, Hamilton EP et al.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      958
    ],
    [
      "1",
      "References",
      "text",
      "Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      959
    ],
    [
      "1",
      "References",
      "text",
      "J Clin Oncol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      960
    ],
    [
      "1",
      "References",
      "text",
      "37, no. 15_suppl (May 20, 2019) 5513-5513.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      961
    ],
    [
      "1",
      "References",
      "text",
      "Parker and Piwnica-Worms 1992",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      962
    ],
    [
      "1",
      "References",
      "text",
      "Parker LL, Piwnica-Worms H.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      963
    ],
    [
      "1",
      "References",
      "text",
      "Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      964
    ],
    [
      "1",
      "References",
      "text",
      "Science 1992;257(5078):1955-7.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      965
    ],
    [
      "1",
      "References",
      "text",
      "Sherr 1996",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      966
    ],
    [
      "1",
      "References",
      "text",
      "Sherr CJ. Cancer cell cycles.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      967
    ],
    [
      "1",
      "References",
      "text",
      "Science 1996;274(5293):1672-7.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      968
    ],
    [
      "1",
      "References",
      "text",
      "Wang et al 2001",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      969
    ],
    [
      "1",
      "References",
      "text",
      "Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      970
    ],
    [
      "1",
      "References",
      "text",
      "Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2 Checkpoint Abrogator.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      971
    ],
    [
      "1",
      "References",
      "text",
      "Cancer Res 2001;61(22):8211-7.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      972
    ],
    [
      "1",
      "References",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "References",
      "REFERENCES",
      "10",
      "1",
      973
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "header",
      " 11  SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      { "IsBold": false, "font_size": -1, "font_style": "Heading1" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      974
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Appendix A",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      975
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      976
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Regulatory, ethical and study oversight considerations",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      977
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 1",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      978
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      979
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Regulatory and ethical considerations",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      980
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This study will be conducted in accordance with the protocol and with the following:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      981
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      982
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      983
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Applicable laws and regulations",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      984
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, advertisements) must be submitted to an IRB/ independent ethics committee (IEC) by the investigator and reviewed and approved by the IRB/IEC before the study is initiated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      985
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study subjects.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      986
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator will be responsible for the following:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      987
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      988
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      989
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Providing oversight of the conduct of the study at the site and adherence to requirements of 21 of the Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      990
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The study will be performed in accordance with the AstraZeneca policy on Bioethics and Human Biological Samples.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      991
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Regulatory Reporting Requirements for SAEs",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      992
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Prompt notification by the investigator to the sponsor of a SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      993
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      994
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRB/IEC, and investigators.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      995
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For all studies except those utilizing medical devices investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR) according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      996
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "An investigator who receives an investigator safety report describing a SAE or other specific safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it along with the IB or other documents in the investigator site file and will notify the IRB/IEC, if appropriate according to local requirements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      997
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 2",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      998
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      999
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Financial disclosure",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1000
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1001
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1002
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 3",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1003
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1004
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Informed consent process",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1005
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator or his/her representative will explain the nature of the study to the subject or his/her legally authorised representative and answer all questions regarding the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1006
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Subjects must be informed that their participation is voluntary.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1007
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Subjects or their legally authorised representative will be required to sign a statement of informed consent that meets the requirements of local regulations, ICH guidelines, and the IRB/IEC or study centre.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1008
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The medical record must include a statement that written informed consent was obtained before the subject was enrolled in the study and the date the written consent was obtained.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1009
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The authorised person obtaining the informed consent must also sign the ICF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1010
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Subjects must be re-consented to the most current version of the ICF(s) during their participation in the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1011
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A copy of the ICF(s) must be provided to the subject or the subject's legally authorised representative.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1012
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If a subject declines to participate in any voluntary exploratory genetic research component of the study, there will be no penalty or loss of benefit to the subject and he/she will not be excluded from other aspects of the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1013
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If a subject's partner becomes pregnant from starting the investigational product administration until 90 days after the last dose of investigational product, the partner is asked to sign the \"Adult Study Informed Consent Form for Pregnant Partners of Study Subjects\" and provide information about the pregnancy accordingly.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1014
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 4",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1015
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1016
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Data protection",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1017
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Each subject will be assigned a unique identifier by the sponsor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1018
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Any subject records or data sets transferred to the sponsor will contain only the identifier; subject names or any information which would make the subject identifiable will not be transferred.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1019
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The subject must be informed that his/her personal study-related data will be used by the sponsor in accordance with local data protection law.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1020
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The level of disclosure must also be explained to the subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1021
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The subject must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorised personnel appointed by the sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1022
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 5",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1023
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1024
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Dissemination of clinical study data",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1025
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A description of this clinical trial will be available on http://astrazenecaclinicaltrials.com and http://www.clinicaltrials.gov as will the summary of the study results when they are available.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1026
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The clinical trial and/or summary of study results may also be available on other websites according to the regulations of the countries in which the study is conducted.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1027
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 6",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1028
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1029
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Data quality assurance",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1030
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "All subject data relating to the study will be recorded on printed or electronic CRF unless transmitted to the sponsor or designee electronically (eg, laboratory data).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1031
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1032
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1033
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1034
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The sponsor or designee is responsible for the data management of this study including quality checking of the data.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1035
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorised site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of subjects are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1036
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1037
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "No records may be destroyed during the retention period without the written approval of the sponsor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1038
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "No records may be transferred to another location or party without written notification to the sponsor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1039
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 7",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1040
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1041
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Source documents",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1042
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1043
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Source documents are filed at the investigator's site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1044
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Data reported on the CRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1045
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator may need to request previous medical records or transfer records, depending on the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1046
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Also, current medical records must be available.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1047
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Definitions of what constitutes source data can be found in Clinical Study Agreement and/or other documents.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1048
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 8",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1049
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1050
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Study and Site Start and Closure",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1051
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The study start date is the date on which the clinical study will be open for recruitment of participants.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1052
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The first act of recruitment is the first site open and will be the study start date.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1053
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The sponsor designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1054
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Study sites will be closed upon study completion.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1055
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1056
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1057
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Reasons for the early closure of a study site by the sponsor or investigator may include but are not limited to:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1058
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1059
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Inadequate recruitment of participants by the investigator",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1060
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Discontinuation of further study intervention development",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1061
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If the study is prematurely terminated or suspended, the sponsor shall promptly inform the investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1062
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1063
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Participants from terminated sites will have the opportunity to be transferred to another site to continue the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1064
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A 9",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1065
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1066
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Publication policy",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1067
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The results of this study may be published or presented at scientific meetings.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1068
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1069
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This allows the sponsor to protect proprietary information and to provide comments.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1070
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The sponsor will comply with the requirements for publication of study results.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1071
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicentre studies only in their entirety and not as individual site data.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1072
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In this case, a coordinating investigator will be designated by mutual agreement.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1073
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1074
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Appendix B",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1075
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1076
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Adverse event (AE) definitions and additional safety information",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1077
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 1",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1078
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1079
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Definition of adverse events (AEs)",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1080
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "An AE is the development of any untoward medical occurrence in a subject or clinical study subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1081
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "An AE can therefore be any unfavourable and unintended sign (e.g.,  an abnormal laboratory finding), symptom (for example nausea, chest pain), or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1082
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The term AE is used to include both serious and non-serious AEs and can include a deterioration of a pre-existing medical occurrence.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1083
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "An AE may occur at any time, including run-in or washout periods, even if no Study treatment has been administered.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1084
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 2",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1085
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1086
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Definitions of serious adverse event (SAE)",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1087
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A SAE is an AE occurring during any study phase (i.e., run-in, treatment, washout, followup), that fulfils one or more of the following criteria:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1088
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Results in death",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1089
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Is immediately life-threatening",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1090
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Requires in-subject hospitalisation or prolongation of existing hospitalisation",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1091
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1092
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Results in persistent or significant disability or incapacity.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1093
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Is a congenital abnormality or birth defect",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1094
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Is an important medical event that may jeopardise the subject or may require medical treatment to prevent one of the outcomes listed above.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1095
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AEs for",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1096
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "malignant tumours",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1097
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "reported during a study should generally be assessed as",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1098
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Serious",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1099
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1100
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If no other seriousness criteria apply, the ‘Important Medical Event' criterion should be used.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1101
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In certain situations, however, medical judgement on an individual event basis should be applied to clarify that the malignant tumour event should be assessed and reported as a",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1102
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "NonSerious",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1103
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AE.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1104
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For example, if the tumour is included as medical history and progression occurs during the study, but the progression does not change treatment and/or prognosis of the malignant tumour, the AE may not fulfil the attributes for being assessed as Serious, although reporting of the progression of the malignant tumour as an AE is valid and should occur.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1105
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Also, some types of malignant tumours, which do not spread remotely after a routine treatment that does not require hospitalization, may be assessed as Non-Serious; examples in adults include Stage 1 basal cell carcinoma and Stage 1A1 cervical cancer removed via cone biopsy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1106
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The above instruction applies only when the malignant tumour event in question is a new malignant tumour (i.e., it is",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1107
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "not",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1108
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "the tumour for which entry into the study is a criterion and that is being treated by the investigational product under study and is not the development of new or progression of existing metastasis to the tumour under study).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1109
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Malignant tumours that - as part of normal, if rare, progression - undergo transformation (e.g., Richter's transformation of B cell chronic lymphocytic leukaemia into diffuse large B cell lymphoma) should not be considered a new malignant tumour.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1110
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 3",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1111
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1112
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Life threatening",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1113
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "‘Life-threatening' means that the subject was at immediate risk of death from the AE as it occurred or it is suspected that use or continued use of the product would result in the subject's death.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1114
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "‘Life-threatening' does not mean that had an AE occurred in a more severe form it might have caused death (e.g., hepatitis that resolved without hepatic failure).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1115
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 4",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1116
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1117
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Hospitalisation",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1118
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons for it may be (e.g., bronchospasm, laryngeal oedema).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1119
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Hospital admissions and/or surgical operations planned before or during a study are not considered AEs if the illness or disease existed before the subject was enrolled in the study, provided that it did not deteriorate in an unexpected way during the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1120
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 5",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1121
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1122
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Important medical event or medical treatment",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1123
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Medical and scientific judgement should be exercised in deciding whether a case is serious in situations where important medical events may not be immediately life threatening or result in death, hospitalisation, disability or incapacity but may jeopardize the subject or may require medical treatment to prevent one or more outcomes listed in the definition of serious.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1124
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "These should usually be considered as serious.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1125
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Simply stopping the suspect drug does not mean that it is an important medical event; medical judgement must be used.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1126
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Angioedema not severe enough to require intubation but requiring iv hydrocortisone treatment",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1127
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment with N-acetylcysteine",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1128
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Intensive treatment in an emergency room or at home for allergic bronchospasm",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1129
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Blood dyscrasias (e.g., neutropenia or anaemia requiring blood transfusion, etc.) or convulsions that do not result in hospitalisation",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1130
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Development of drug dependency or drug abuse",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1131
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 6",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1132
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1133
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Intensity rating scale:",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1134
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The grading scales found in the revised CTCAE latest version will be utilised for all events with an assigned CTCAE grading.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1135
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For those events without assigned CTCAE grades, the recommendation in the CTCAE criteria that converts mild, moderate and severe events into CTCAE grades should be used.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1136
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A copy of the CTCAE can be downloaded from the Cancer Therapy Evaluation Program website (http://ctep.cancer.gov).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1137
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The applicable version of CTCAE should be described clearly.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1138
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "It is important to distinguish between serious and severe AEs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1139
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Severity is a measure of intensity whereas seriousness is defined by the criteria in Appendix B 2.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1140
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "An AE of severe intensity need not necessarily be considered serious.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1141
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For example, nausea that persists for several hours may be considered severe nausea, but not a SAE unless it meets the criteria shown in Appendix B 2.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1142
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "On the other hand, a stroke that results in only a limited degree of disability may be considered a mild stroke but would be a SAE when it satisfies the criteria shown in Appendix B 2.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1143
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 7",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1144
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1145
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A Guide to Interpreting the Causality Question",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1146
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "When making an assessment of causality consider the following factors when deciding if there is a ‘reasonable possibility' that an AE may have been caused by the drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1147
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Time Course.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1148
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Exposure to suspect drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1149
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Has the subject actually received the suspect drug?  Did the AE occur in a reasonable temporal relationship to the administration of the suspect drug?",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1150
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Consistency with known drug profile.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1151
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Was the AE consistent with the previous knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same pharmacological class? Or could the AE be anticipated from its pharmacological properties?",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1152
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "De-challenge experience.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1153
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Did the AE resolve or improve on stopping or reducing the dose of the suspect drug?",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1154
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "No alternative cause.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1155
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The AE cannot be reasonably explained by another aetiology such as the underlying disease, other drugs, other host or environmental factors.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1156
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Re-challenge experience.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1157
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Did the AE reoccur if the suspected drug was reintroduced after having been stopped? AstraZeneca would not normally recommend or support a rechallenge.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1158
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Laboratory tests.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1159
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A specific laboratory investigation (if performed) has confirmed the relationship.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1160
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In difficult cases, other factors could be considered such as:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1161
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Is this a recognized feature of overdose of the drug?",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1162
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Is there a known mechanism?",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1163
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Causality of ‘related' is made if following a review of the relevant data, there is evidence for a",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1164
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "‘reasonable possibility' of a causal relationship for the individual case.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1165
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The expression ‘reasonable possibility' of a causal relationship is meant to convey, in general, that there are facts (evidence) or arguments to suggest a causal relationship.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1166
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The causality assessment is performed based on the available data including enough information to make an informed judgment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1167
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "With limited or insufficient information in the case, it is likely that the event(s) will be assessed as ‘not related'.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1168
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Causal relationship in cases where the disease under study has deteriorated due to lack of effect should be classified as no reasonable possibility.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1169
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "B 8",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1170
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1171
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Medication Error",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1172
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For the purposes of this clinical study a medication error is an unintended failure or mistake in the treatment process for an AstraZeneca study drug that either causes harm to the participant or has the potential to cause harm to the participant.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1173
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A medication error is not lack of efficacy of the drug, but rather a human or process related failure while the drug is in control of the study site staff or participant.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1174
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Medication error includes situations where an error.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1175
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "occurred",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1176
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "was identified and intercepted before the participant received the drug",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1177
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "did not occur, but circumstances were recognized that could have led to an error Examples of events to be reported in clinical studies as medication errors:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1178
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Drug name confusion",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1179
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Dispensing error e.g., medication prepared incorrectly, even if it was not actually given to the participant",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1180
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Drug not administered as indicated, for example, wrong route or wrong site of administration",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1181
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Drug not taken as indicated e.g., tablet dissolved in water when it should be taken as a solid tablet",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1182
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Drug not stored as instructed e.g., kept in the fridge when it should be at room temperature",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1183
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Wrong participant received the medication (excluding interactive voice response system",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1184
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "[IVRS] / interactive web response system [IWRS] errors)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1185
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Wrong drug administered to participant (excluding IVRS/IWRS errors)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1186
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Examples of events that",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1187
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "do not",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1188
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "require reporting as medication errors in clinical studies:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1189
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Errors related to or resulting from IVRS/IWRS - including those which lead to one of the above listed events that would otherwise have been a medication error",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1190
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Participant accidentally missed drug dose(s) e.g., forgot to take medication",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1191
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Accidental overdose (will be captured as an overdose)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1192
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Participant failed to return unused medication or empty packaging",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1193
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Errors related to background and rescue medication, or standard of care medication in open label studies, even if an AZ product",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1194
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Medication errors are not regarded as AEs but AEs may occur as a consequence of the medication error.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1195
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1196
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Appendix C",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1197
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1198
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Handling of Human Biological Samples",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1199
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "C 1",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1200
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1201
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Chain of custody of biological samples",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1202
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A full chain of custody is maintained for all samples throughout their lifecycle.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1203
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The Investigator at each centre keeps full traceability of collected biological samples from the subjects while in storage at the centre until shipment or disposal (where appropriate).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1204
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The sample receiver keeps full traceability of the samples while in storage and during use until used or disposed of or until further shipment and keeps documentation of receipt of arrival.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1205
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AstraZeneca will keep oversight of the entire life cycle through internal procedures, monitoring of study sites, auditing or process checks, and contractual requirements of external laboratory providers",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1206
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Samples retained for further use will be stored in the AZ-assigned biobanks and will be registered by the AstraZeneca Biobank Team during the entire life cycle.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1207
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "C 2",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1208
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1209
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Withdrawal of Informed Consent for donated biological samples",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1210
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If a subject withdraws consent to the use of donated biological samples, the samples will be disposed of/destroyed, and the action documented.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1211
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If samples are already analysed, AstraZeneca is not obliged to destroy the results of this research.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1212
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "As collection of the biological sample(s) is an integral part of the study, then the subject is withdrawn from further study participation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1213
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "As collection of the biological sample(s) is an optional part of the study, then the subject may continue in the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1214
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The Investigator:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1215
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Ensures subjects' withdrawal of informed consent to the use of donated samples is notified immediately to AstraZeneca",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1216
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Ensures that biological samples from that subject, if stored at the study site, are immediately identified, disposed of /destroyed, and the action documented",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1217
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Ensures the organization(s) holding the samples is/are informed about the withdrawn consent immediately and that samples are disposed of/destroyed, the action documented and the signed document returned to the study site",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1218
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Ensures that the subject and AstraZeneca are informed about the sample disposal.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1219
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AstraZeneca ensures the organizations holding the samples is/are informed about the withdrawn consent immediately and that samples are disposed of/destroyed and the action documented and returned to the study site.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1220
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "C 3",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1221
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1222
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "International Airline Transportation Association (IATA) 6.2 Guidance Document",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1223
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1224
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "International Airline Transportation Association (IATA) classifies biohazardous agents into 3 categories.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1225
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For transport purposes the classification of infectious substances according to risk groups was removed from the Dangerous Goods Regulations in the 46th edition (2005).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1226
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Infectious substances are now classified either as Category A, Category B or Exempt.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1227
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "There is no direct relationship between Risk Groups and Categories A and B.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1228
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Category A Infectious Substances",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1229
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "are infectious substances in a form that, when exposure to it occurs, is capable of causing permanent disability, life-threatening or fatal disease in otherwise healthy humans or animals.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1230
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Category A pathogens are eg, Ebola, Lassa fever virus:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1231
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1232
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "are to be packed and shipped in accordance with IATA Instruction 602.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1233
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Category B Infectious Substances",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1234
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "are infectious Substances that do not meet the criteria for inclusion in Category A.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1235
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Category B pathogens are eg, Hepatitis A, B, C, D, and E viruses, Human immunodeficiency virus types 1 and 2.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1236
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "They are assigned the following United Nations (UN) number and proper shipping name:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1237
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "UN 3373 - Biological Substance, Category B",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1238
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "are to be packed in accordance with UN3373 and IATA 650",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1239
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Exempt",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1240
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "- all other materials with minimal risk of containing pathogens",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1241
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Clinical trial samples will fall into Category B or exempt under IATA regulations",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1242
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Clinical trial samples will routinely be packed and transported at ambient temperature in IATA 650 compliant packaging",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1243
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Biological samples transported in dry ice require additional dangerous goods specification for the dry-ice content",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1244
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "IATA compliant courier and packaging materials should be used for packing and transportation and packing should be done by an IATA certified person, as applicable",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1245
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Samples routinely transported by road or rail are subject to local regulations which require that they are also packed and transported in a safe and appropriate way to contain any risk of infection or contamination by using approved couriers and packaging/containment materials at all times.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1246
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The IATA 650 biological sample containment standards are encouraged wherever possible when road or rail transport is used.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1247
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Appendix D",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1248
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1249
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Genetics",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1250
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "D 1",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1251
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1252
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Use/analysis of deoxyribonucleic acid (DNA)",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1253
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Genetic variation may impact a subject's response to therapy, susceptibility to, and severity and progression of disease.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1254
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Variable response to therapy may be due to genetic determinants that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of the drug; disease aetiology; and/or molecular subtype of the disease being treated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1255
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Therefore, where local regulations and IRB/IEC allow, a blood sample will be collected for DNA analysis from consenting subjects.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1256
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AstraZeneca intends to collect and store DNA for genetic research to explore how genetic variations may affect clinical parameters, risk and prognosis of diseases, and the response to medications.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1257
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Genetic research may lead to better understanding of diseases, better diagnosis of diseases or other improvements in health care and to the discovery of new diagnostics, treatments or medications.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1258
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In addition, collection of DNA samples from populations with well described clinical characteristics may lead to improvements in the design and interpretation of clinical trials and, possibly, to genetically guided treatment strategies.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1259
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Genetic research may consist of the analysis of the structure of the subject´s DNA, i.e., the entire genome.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1260
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The results of genetic analyses may be reported in the CSR or in a separate study summary.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1261
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The sponsor will store the DNA samples in a secure storage space with adequate measures to protect confidentiality.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1262
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The samples will be retained while research on adavosertib continues but no longer than 15 years or other period as per local requirements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1263
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "D 2",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1264
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1265
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Genetic research plan and procedures",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1266
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Selection of genetic research population",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1267
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Study selection record",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1268
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "All subjects will be asked to participate in this genetic research.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1269
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Participation is voluntary and if a subject declines to participate there will be no penalty or loss of benefit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1270
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The subject will not be excluded from any aspect of the main study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1271
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Inclusion criteria",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1272
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For inclusion in this genetic research, subjects must fulfil all of the inclusion criteria described in the main body of the Clinical Study Protocol and: Provide informed consent for the genetic sampling and analyses.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1273
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "header",
      " Exclusion criteria",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1274
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Exclusion from this genetic research may be for any of the exclusion criteria specified in the main study or any of the following:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1275
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Previous allogeneic bone marrow transplant",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1276
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Non-leukocyte depleted whole blood transfusion in 120 days of genetic sample collection",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1277
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Withdrawal of consent for genetic research:",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1278
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Subjects may withdraw from this genetic research at any time, independent of any decision concerning participation in other aspects of the main study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1279
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Voluntary withdrawal will not prejudice further treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1280
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Procedures for withdrawal are outlined in Section 7 of the main Clinical Study Protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1281
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "header",
      " Collection of samples for genetic research",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1282
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The blood sample for genetic research will be obtained from the subjects at Cycle 1 Day 1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1283
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Although DNA is stable, early sample collection is preferred to avoid introducing bias through excluding subjects who may withdraw due to an AE, such subjects would be important to include in any genetic analysis.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1284
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If for any reason the sample is not drawn at Cycle 1 Day 1, it may be taken at any visit until the last study visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1285
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Only one sample should be collected per subject for genetics during the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1286
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Samples will be collected, labelled, stored, and shipped as detailed in the Laboratory Manual.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1287
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "header",
      " Coding and storage of DNA samples",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1288
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The processes adopted for the coding and storage of samples for genetic analysis are important to maintain subject confidentiality.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1289
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Samples will be stored for a maximum of 15 years, from the date of last subject last visit, after which they will be destroyed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1290
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "DNA is a finite resource that is used up during analyses.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1291
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Samples will be stored and used until no further analyses are possible or the maximum storage time has been reached.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1292
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "An additional second code will be assigned to the blood either before or at the time of DNA extraction replacing the information on the sample tube.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1293
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Thereafter, the sample will be identifiable only by the second, unique number.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1294
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This number is used to identify the sample and corresponding data at the AstraZeneca genetics laboratories, or at the designated organisation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1295
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "No personal details identifying the individual will be available to any person (AstraZeneca employee or designated organisations working with the DNA).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1296
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The link between the subject enrolment/randomisation code and the second number will be maintained and stored in a secure environment, with restricted access at AstraZeneca or designated organisations.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1297
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The link will be used to identify the relevant DNA samples for analysis, facilitate correlation of genotypic results with clinical data, allow regulatory audit, and permit tracing of samples for destruction in the case of withdrawal of consent.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1298
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "header",
      " Ethical and regulatory requirements",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1299
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The principles for ethical and regulatory requirements for the study, including this genetics research component, are outlined in Appendix A.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1300
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "header",
      " Informed consent",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1301
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The genetic component of this study is optional and the subject may participate in other components of the main study without participating in the genetic component.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1302
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "To participate in the genetic component of the study the subject must sign and date both the consent form for the main study and the genetic component of the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1303
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Copies of both signed and dated consent forms must be given to the subject and the original filed at the study centre.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1304
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The Principal Investigator(s) is responsible for ensuring that consent is given freely and that the subject understands that they may freely withdrawal from the genetic aspect of the study at any time.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1305
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Subject data protection",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1306
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AstraZeneca will not provide individual genotype results to subjects, any insurance company, any employer, their family members, general physician unless required to do so by law.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1307
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Extra precautions are taken to preserve confidentiality and prevent genetic data being linked to the identity of the subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1308
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In exceptional circumstances, however, certain individuals might see both the genetic data and the personal identifiers of a subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1309
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For example, in the case of a medical emergency, an AstraZeneca Physician or an investigator might know a subject's identity and also have access to his or her genetic data.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1310
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In addition, Regulatory authorities may require access to the relevant files, though the subject's medical information and the genetic files would remain physically separate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1311
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Data management",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1312
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Any genotype data generated in this study will be stored at a secure system at AstraZeneca and/or designated organizations to analyse the samples.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1313
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AstraZeneca and its designated organisations may share summary results (such as genetic differences from groups of individuals with a disease) from this genetic research with other researchers, such as hospitals, academic organisations or health insurance companies.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1314
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This can be done by placing the results in scientific databases, where they can be combined with the results of similar studies to learn even more about health and disease.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1315
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The researchers can only use this information for health related research purposes.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1316
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Researchers may see summary results but they will not be able to see individual subject data or any personal identifiers.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1317
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Some or all of the clinical datasets from the main study may be merged with the genetic data in a suitable secure environment separate from the clinical database.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1318
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Statistical methods and determination of sample size",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1319
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The number of subjects that will agree to participate in the genetic research is unknown.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1320
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "It is therefore not possible to establish whether sufficient data will be collected to allow a formal statistical evaluation or whether only descriptive statistics will be generated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1321
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A Statistical Analysis Plan may be prepared where appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1322
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1323
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Appendix E",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1324
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1325
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Actions required in cases of increases in liver biochemistry and evaluation of Hy's Law",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1326
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 1",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1327
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1328
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Introduction",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1329
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This Appendix describes the process to be followed in order to identify and appropriately report Potential Hy's Law (PHL) cases and Hy's Law (HL) cases.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1330
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "It is not intended to be a comprehensive guide to the management of elevated liver biochemistries.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1331
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "During the course of the study the investigator will remain vigilant for increases in liver biochemistry.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1332
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator is responsible for determining whether a participant meets PHL criteria at any point during the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1333
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "All sources of laboratory data are appropriate for the determination of PHL and HL events; this includes samples taken at scheduled study visits and other visits including central and all local laboratory evaluations even if collected outside of the study visits; for example, PHL criteria could be met by an elevated ALT from a central laboratory and/or elevated TBL from a local laboratory.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1334
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator will also review Adverse Event data (for example, for AEs that may indicate elevations in liver biochemistry) for possible PHL events.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1335
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator participates, together with AstraZeneca clinical project representatives, in review and assessment of cases meeting PHL criteria to agree whether Hy's Law (HL) criteria are met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1336
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "HL criteria are met if there is no alternative explanation for the elevations in liver biochemistry other than drug induced liver injury  caused by the investigational medicinal product (IMP).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1337
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator is responsible for recording data pertaining to PHL/HL cases and for reporting SAEs and AEs according to the outcome of the review and assessment in line with standard safety reporting processes.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1338
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 2",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1339
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1340
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Definitions",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1341
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Potential Hy's Law (PHL)",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1342
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AST or ALT ≥ 3×ULN",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1343
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "together with",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1344
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "TBL ≥ 2×ULN at any point during the study following the start of study medication irrespective of an increase in ALP.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1345
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Hy's Law (HL)",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1346
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AST or ALT ≥ 3×ULN together with TBL ≥ 2×ULN, where no other reason, other than the IMP, can be found to explain the combination of increases, eg, elevated ALP indicating cholestasis, viral hepatitis, another drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1347
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For PHL and HL the elevation in transaminases must precede or be coincident with (ie, on the same day) the elevation in TBL, but there is no specified timeframe within which the elevations in transaminases and TBL must occur.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1348
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 3",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1349
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1350
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Identification of Potential Hy's Law cases",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1351
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "In order to identify cases of PHL it is important to perform a comprehensive review of laboratory data for any participant who meets any of the following identification criteria in isolation or in combination:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1352
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "ALT ≥ 3 × ULN",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1353
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "AST ≥ 3 × ULN",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1354
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "TBL ≥ 2 × ULN",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1355
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Local laboratories being used:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1356
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator will without delay review each new laboratory report and if the identification criteria are met will:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1357
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Determine whether the participant meets PHL criteria (see Section E 2 Definitions within this Appendix for definition) by reviewing laboratory reports from all previous visits",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1358
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Promptly enter the laboratory data into the laboratory eCRF",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1359
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 4",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1360
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1361
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Follow-up",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1362
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 4.1",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1363
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1364
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Potential Hy's Law criteria not met",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1365
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If the participant does not meet PHL criteria the investigator will:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1366
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1367
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Perform follow-up on subsequent laboratory results according to the guidance provided in the Clinical Study Protocol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1368
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 4.2",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1369
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1370
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Potential Hy's Law criteria met",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1371
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If the participant does meet PHL criteria the investigator will:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1372
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Determine whether PHL criteria were met at any study visit prior to starting study treatment (See Section E 6)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1373
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Notify the AstraZeneca representative who will then inform the Study Team",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1374
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Within 1 day of PHL criteria being met, the investigator will report the case as an SAE of Potential Hy's Law; serious criteria ‘Important medical event' and causality assessment ‘yes/related' according to Clinical Study Protocol (CSP) process for SAE reporting.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1375
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "For participants that met PHL criteria prior to starting IMP, the investigator is not required to submit a PHL SAE unless there is a significant change",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1376
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "#",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1377
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "in the participant's condition",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1378
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The Study Physician contacts the investigator, to provide guidance, discuss and agree an approach for the study participants' follow-up (including any further laboratory testing) and the continuous review of data",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1379
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Subsequent to this contact the investigator will:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1380
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Monitor the participant until liver biochemistry parameters and appropriate clinical symptoms and signs return to normal or baseline levels, or as long as medically indicated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1381
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Completes follow-up SAE Form as required.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1382
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Investigate the aetiology of the event and perform diagnostic investigations as discussed with the Study Physician.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1383
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Complete the three Liver eCRF Modules as information becomes available",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1384
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "#",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1385
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A ‘significant' change",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1386
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "in the participant's condition refers to a clinically relevant change in any of the individual liver biochemistry parameters (ALT, AST or TBL) in isolation or in combination, or a clinically relevant change in associated symptoms.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1387
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The determination of whether there has been a significant change will be at the discretion of the investigator, this may be in consultation with the Study Physician if there is any uncertainty.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1388
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 5",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1389
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1390
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Review and assessment of Potential Hy's Law cases",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1391
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The instructions in this section should be followed for all cases where PHL criteria are met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1392
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "As soon as possible after the biochemistry abnormality was initially detected, the Study Physician contacts the investigator in order to review available data and agree on whether there is an alternative explanation for meeting PHL criteria other than drug induced liver injury caused by the study drug, to ensure timely analysis and reporting to health authorities within 15 calendar days from date PHL criteria was met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1393
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The AstraZeneca Global Clinical Lead or equivalent and Global Safety Physician will also be involved in this review together with other subject matter experts as appropriate.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1394
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "According to the outcome of the review and assessment, the investigator will follow the instructions below.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1395
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Where there is an agreed alternative explanation",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1396
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "for the ALT or AST and TBL elevations, a determination of whether the alternative explanation is an AE will be made and subsequently whether the AE meets the criteria for a SAE:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1397
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If the alternative explanation is",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1398
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "not",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1399
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "an AE, record the alternative explanation on the appropriate eCRF",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1400
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If the alternative explanation is an AE/SAE: update the previously submitted Potential Hy's Law SAE and AE eCRFs accordingly with the new information (reassessing event term; causality and seriousness criteria) following the AstraZeneca standard processes.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1401
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If it is agreed that there is",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1402
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "no",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1403
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "explanation that would explain the ALT or AST and TBL elevations other than the study drug:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1404
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Send updated SAE (report term ‘Hy's Law') according to AstraZeneca standard processes.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1405
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The ‘Medically Important' serious criterion should be used if no other serious criteria apply",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1406
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "As there is no alternative explanation for the HL case, a causality assessment of ‘related' should be assigned.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1407
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If, there is an unavoidable delay, of over 15 calendar days in obtaining the information necessary to assess whether or not the case meets the criteria for HL, then it is assumed that there is no alternative explanation until such time as an informed decision can be made:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1408
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Provides any further update to the previously submitted SAE of Potential Hy's Law, (report term now ‘Hy's Law case') ensuring causality assessment is related to IMP and seriousness criteria is medically important, according to CSP process for SAE reporting.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1409
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Continue follow-up and review according to agreed plan.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1410
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Once the necessary supplementary information is obtained, repeat the review and assessment to determine whether HL criteria are still met.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1411
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Update the previously submitted PHL SAE report following CSP process for SAE reporting, according to the outcome of the review and amending the reported term if an alternative explanation for the liver biochemistry elevations is determined.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1412
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 6",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1413
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1414
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Actions required when Potential Hy's Law criteria are met before and after starting study treatment",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1415
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This section is applicable to participants who meet PHL criteria on study treatment, having previously met PHL criteria at a study visit prior to starting study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1416
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "At the first on-study treatment occurrence of PHL criteria being met the investigator will determine if there has been a significant change in the participants' condition",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1417
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "#",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1418
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "compared with the last visit where PHL criteria were met",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1419
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "#",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1420
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If there is no significant change no action is required",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1421
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If there is a significant change, notify the AstraZeneca representative, who will inform the Study Team, then follow the subsequent process described in Section",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1422
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 4.2",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1423
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 7",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1424
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1425
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Actions required for repeat episodes of potential Hy's Law",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1426
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This section is applicable when a participant meets PHL criteria on study treatment and has already met PHL criteria at a previous on study treatment visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1427
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The requirement to conduct follow-up, review and assessment of a repeat occurrence(s) of PHL is based on the nature of the alternative cause identified for the previous occurrence.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1428
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The investigator should determine the cause for the previous occurrence of PHL criteria being met and answer the following question:",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1429
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Was the alternative cause for the previous occurrence of PHL criteria being met found to be the disease under study eg, chronic or progressing malignant disease, severe infection or liver disease  or did the participant meet PHL criteria prior to starting study treatment and at their first on-study treatment visit as described in Section E 6 of this Appendix?",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1430
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1431
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "No",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1432
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      ": follow the process described in Section E 4.2 for reporting PHL as an SAE",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1433
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1434
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Yes",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1435
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      ": Determine if there has been a significant change in the participant's condition",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1436
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "#",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1437
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "compared with when PHL criteria were previously met",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1438
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If there is no significant change no action is required",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1439
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If there is a significant change follow the process described in Section E 4.2 for reporting PHL as an SAE",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1440
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "# A ‘significant' change in the participant's condition refers to a clinically relevant change in any of the individual liver biochemistry parameters (ALT, AST or TBL) in isolation or in combination, or a clinically relevant change in associated symptoms.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1441
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The determination of whether there has been a significant change will be at the discretion of the investigator, this may be in consultation with the Study Physician if there is any uncertainty.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1442
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "E 8",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1443
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 26, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1444
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "References",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1445
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Aithal et al, 2011",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1446
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Aithal et al 2011, Clinical Pharmacology and Therapeutics 89(6):806-815.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1447
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "FDA Guidance for Industry, July 2009",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1448
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "FDA Guidance for Industry (issued July 2009) ‘Drug-induced liver injury: Premarketing clinical evaluation'.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1449
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Available from; https://www.fda.gov/regulatory-information/search-fdaguidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1450
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Appendix F",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1451
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1452
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Heart Failure Stages - New York Heart Association (NYHA) Classification",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1453
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The Stages of Heart Failure -NYHA Classification",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1454
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Class I (Mild)",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1455
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "No Limitation of physical activity.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1456
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnoea (shortness of breath).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1457
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Class II (Mild)",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1458
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Slight limitation of physical activity.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1459
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnoea.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1460
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Class III (Moderate)",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1461
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Marked limitation of physical activity.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1462
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Comfortable at rest, but less than ordinary physical activity results in fatigue, palpitation, or dyspnoea.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1463
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Class IV (Severe)",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1464
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Unable to carry out any physical activity without discomfort.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1465
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Symptoms of cardiac insufficiency at rest.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1466
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "If any physical activity is undertaken, physical discomfort is increased.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1467
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Reference",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1468
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The Criteria Committee of the New York Heart Association.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1469
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Nomenclature and criteria for diagnosis of diseases of the heart and great vessels.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1470
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "9th ed. Boston (MA): Little, Brown & Co; 1994:253-256.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1471
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Appendix G",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1472
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1473
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Guidelines for Evaluation of Objective Tumour Response Using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1474
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Introduction",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1475
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "This appendix details the implementation of RECIST v1.1 (Eisenhauer et al 2009)for the study with regards to investigator assessment of tumour burden including protocol-specific requirements for this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1476
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Definition of Measurable, Non-measurable, Target and Non-target Lesions",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1477
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Subjects with at least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT, MRI or plain X-ray should be included in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1478
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Measurable lesions",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1479
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have a short axis ≥ 15 mm) with CT or MRI and which is suitable for accurate repeated measurements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1480
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Non-measurable lesions",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1481
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "All other lesions, including small lesions (longest diameter < 10 mm or pathological lymph nodes with ≥ 10 mm to < 15 mm short axis at baseline.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1482
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Nodes with < 10 mm short axis are considered non-pathological and should not be recorded as non-target lesions (NTLs)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1483
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Truly non-measurable lesions include the following: bone lesions, leptomeningeal disease, ascites, pleural / pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical examination that are not measurable by CT or MRI",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1484
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Previously irradiated lesions as localised post-radiation changes, which affect lesion sizes, may occur.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1485
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Therefore, lesions that have been previously irradiated will not be considered measurable and should be selected as NTLs at baseline and followed up as part of the NTL assessment",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1486
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Skin lesions assessed by clinical examination",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1487
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Special cases",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1488
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, can be considered measurable if the soft tissue component meets the definition of measurability.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1489
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Blastic lesions are considered non-measurable.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1490
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Cystic metastases can be considered measurable lesions if they meet the criteria for measurability from a radiological point of view, but if non-cystic lesions are present in the same subject, these non-cystic lesions should be selected as the target lesions (TLs).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1491
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Target lesions",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1492
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "A maximum of 5 measurable lesions (with a maximum of 2 lesions per organ), representative of all lesions involved suitable for accurate repeated measurement, should be identified as TLs at baseline.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1493
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "Non-target lesions",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1494
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at baseline.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1495
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "header",
      " Methods of Measurement",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1496
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The same method of assessment and the same technique should be used to characterise each identified and reported lesion at baseline and during follow-up.",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1497
    ],
    [
      "1",
      "Supporting Documentation and Operational Considerations",
      "text",
      "The methods to be used for RECIST assessment are summarised in Table 15 and those excluded for tumour assessments in this study are discussed below, with the rationale provided.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS",
      "11",
      "1",
      1498
    ],
    [
      "",
      "Unmapped",
      "text",
      "Table 15",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1499
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1500
    ],
    [
      "",
      "Unmapped",
      "text",
      "Summary of Methods of Assessment",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1501
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Target Lesions</td>\n      <td>Non target lesions</td>\n      <td>New Lesions</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>CT (preferred) MRI</td>\n      <td>CT (preferred) MRI Plain X-ray (includes chest X-ray) Clinical examination</td>\n      <td>CT (preferred) MRI Plain X-ray (includes chest X-ray) Clinical examination Ultrasound Bone scan FDG-PET</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "19",
        "TableName": "Summary of Methods of Assessment",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1502
    ],
    [
      "",
      "Unmapped",
      "text",
      "CT and MRI are generally considered to be the best currently available and reproducible methods to measure TLs selected for response assessment and to assess NTLs and identification of new lesions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1503
    ],
    [
      "",
      "Unmapped",
      "text",
      "In this study it is recommended that CT examinations will be used to assess tumour burden at baseline and follow-up visits.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1504
    ],
    [
      "",
      "Unmapped",
      "text",
      "CT examination with intravenous contrast media administration is the preferred method.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1505
    ],
    [
      "",
      "Unmapped",
      "text",
      "MRI should be used where CT is not feasible or it is medically contra-indicated.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1506
    ],
    [
      "",
      "Unmapped",
      "text",
      "For assessment of brain lesions MRI is the preferred method.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1507
    ],
    [
      "",
      "Unmapped",
      "header",
      " Clinical examination",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1508
    ],
    [
      "",
      "Unmapped",
      "text",
      "Clinical examination will not be used for assessment of TLs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1509
    ],
    [
      "",
      "Unmapped",
      "text",
      "Clinically detected lesions can be selected as TLs if they are then assessed by CT or MRI scans.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1510
    ],
    [
      "",
      "Unmapped",
      "text",
      "Clinical examination can be used to assess NTLs in subjects that also have other lesions assessable by CT, MRI or plain Xray and to identify the presence of new lesions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1511
    ],
    [
      "",
      "Unmapped",
      "header",
      " X-rays Plain X-ray",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1512
    ],
    [
      "",
      "Unmapped",
      "text",
      "Plain X-rays may be used as a method of assessment for bone NTLs and to identify the presence of new bone lesions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1513
    ],
    [
      "",
      "Unmapped",
      "header",
      " Chest X-ray",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1514
    ],
    [
      "",
      "Unmapped",
      "text",
      "Chest X-rays will not be used for assessment of TLs as they will be assessed by CT or MRI examination.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1515
    ],
    [
      "",
      "Unmapped",
      "text",
      "Chest X-rays can, however, be used to assess NTLs and to identify the presence of new lesions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1516
    ],
    [
      "",
      "Unmapped",
      "header",
      " Ultrasound",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1517
    ],
    [
      "",
      "Unmapped",
      "text",
      "Ultrasound examination will not be used for assessment of TLs and NTLs as it is not a reproducible method, does not provide an accurate assessment of tumour size and it is subjective and operator dependent.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1518
    ],
    [
      "",
      "Unmapped",
      "text",
      "Ultrasound examination can, however, be used to identify the presence of new lesions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1519
    ],
    [
      "",
      "Unmapped",
      "text",
      "If new clinical symptoms occur and an ultrasound is performed then new lesions should be confirmed by CT or MRI examination.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1520
    ],
    [
      "",
      "Unmapped",
      "header",
      " Endoscopy and laparoscopy",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1521
    ],
    [
      "",
      "Unmapped",
      "text",
      "Endoscopy and laparoscopy will not be used for tumour assessments as they are not validated in the context of tumour measurements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1522
    ],
    [
      "",
      "Unmapped",
      "text",
      "Tumour markers",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1523
    ],
    [
      "",
      "Unmapped",
      "text",
      "Tumour markers will not be used for tumour response assessments per RECIST v1.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1524
    ],
    [
      "",
      "Unmapped",
      "header",
      " Cytology and histology",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1525
    ],
    [
      "",
      "Unmapped",
      "text",
      "Histology will not be used as part of the tumour response assessment per RECIST v1.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1526
    ],
    [
      "",
      "Unmapped",
      "text",
      "Cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment is required when the measurable tumour has met criteria for response or SD.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1527
    ],
    [
      "",
      "Unmapped",
      "text",
      "In such circumstances, the cytology is necessary to differentiate between response / SD (an effusion may be a side effect of the treatment) and PD (if the neoplastic origin of the fluid is confirmed).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1528
    ],
    [
      "",
      "Unmapped",
      "text",
      "Where cytology findings are not available, any effusion that significantly worsens (from trace to large) or the appearance of a clinically significant effusion (requiring change in drug therapy) during the study treatment will be considered to be progression of NTLs or disease progression due to new lesions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1529
    ],
    [
      "",
      "Unmapped",
      "header",
      " Isotopic bone scan",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1530
    ],
    [
      "",
      "Unmapped",
      "text",
      "Bone lesions identified on an isotopic bone scan at baseline and confirmed by CT, MRI or Xray at baseline should be recorded as NTLs and followed by the same method as per baseline assessment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1531
    ],
    [
      "",
      "Unmapped",
      "text",
      "Isotopic bone scans may be used as a method of assessment to identify the presence of new bone lesions at follow-up visits.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1532
    ],
    [
      "",
      "Unmapped",
      "text",
      "New lesions will be recorded where a positive hot-spot that was not present on the baseline bone scan assessment is identified on a bone scan performed at any time during the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1533
    ],
    [
      "",
      "Unmapped",
      "text",
      "The Investigator should consider the positive hot-spot to be a significant new site of malignant disease and represent true disease progression in order to record the new lesion.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1534
    ],
    [
      "",
      "Unmapped",
      "text",
      "Confirmation by CT, MRI and x-ray is recommended where bone scan findings are equivocal.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1535
    ],
    [
      "",
      "Unmapped",
      "header",
      " Fluorodeoxyglucose positron emission tomography (FDG-PET) scan",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1536
    ],
    [
      "",
      "Unmapped",
      "text",
      "FDG-PET scans may be used as a method for identifying new lesions, according with the following algorithm: New lesions will be recorded where there is positive fluorodeoxyglucose (FDG) uptake (defined as when an uptake greater than twice that of the surrounding tissue is observed) not present on baseline FDG-PET scan or in a location corresponding to a new lesion on CT/MRI at the same follow-up visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1537
    ],
    [
      "",
      "Unmapped",
      "text",
      "If there is no baseline FDG-PET scan available, and no evidence of new lesions on CT/MRI scans then follow-up CT/MRI assessments should be continued, scheduled as per protocol or clinical indicated, in order to confirm new lesions.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1538
    ],
    [
      "",
      "Unmapped",
      "header",
      " Tumour response evaluation Schedule of evaluation",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1539
    ],
    [
      "",
      "Unmapped",
      "text",
      "Baseline tumour assessments should encompass all areas of known predilection for metastases in the disease under evaluation and should additionally investigate areas that may be involved based on signs and symptoms of individual subjects and should be performed no more than 28 days before the start of study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1540
    ],
    [
      "",
      "Unmapped",
      "text",
      "Follow-up assessments should be performed every 9 weeks (± 7 days) relative to the date of first dose until discontinuation of study treatment or withdrawal of consent.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1541
    ],
    [
      "",
      "Unmapped",
      "text",
      "Any other sites at which new disease is suspected should also be adequately imaged at follow-up.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1542
    ],
    [
      "",
      "Unmapped",
      "header",
      " Target lesions Documentation of target lesions",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1543
    ],
    [
      "",
      "Unmapped",
      "text",
      "The site and location of each TL should be documented as well as the longest diameter for non-nodal lesions (or short axis for lymph nodes).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1544
    ],
    [
      "",
      "Unmapped",
      "text",
      "All measurements should be recorded in millimetres.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1545
    ],
    [
      "",
      "Unmapped",
      "text",
      "At baseline, the sum of the diameters for all TLs will be calculated and reported as the baseline sum of diameters.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1546
    ],
    [
      "",
      "Unmapped",
      "text",
      "At follow-up visits the sum of diameters for all TLs will be calculated and reported as the follow-up sum of diameters.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1547
    ],
    [
      "",
      "Unmapped",
      "text",
      "Special cases:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1548
    ],
    [
      "",
      "Unmapped",
      "text",
      "For TLs measurable in 2 or 3 dimensions, always report the longest diameter.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1549
    ],
    [
      "",
      "Unmapped",
      "text",
      "For pathological lymph nodes measurable in 2 or 3 dimensions, always report the short axis.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1550
    ],
    [
      "",
      "Unmapped",
      "text",
      "If the CT/MRI slice thickness used is > 5 mm, the minimum size of measurable disease at baseline should be twice the slice thickness of the baseline scan.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1551
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a lesion has completely disappeared, the longest diameter should be recorded as 0 mm.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1552
    ],
    [
      "",
      "Unmapped",
      "text",
      "If two or more TLs merge then the sum of the diameters of the combined lesion should be recorded for one of the lesions and 0 mm recorded for the other lesion(s)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1553
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a TL is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1554
    ],
    [
      "",
      "Unmapped",
      "text",
      "If an accurate measure can be given, this should be recorded, even if it is below 5 mm.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1555
    ],
    [
      "",
      "Unmapped",
      "header",
      " Evaluation of target lesions",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1556
    ],
    [
      "",
      "Unmapped",
      "text",
      "Table 16 provides the definitions of the criteria used to determine objective tumour visit response for TLs.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 15  Summary of Methods of Assessment",
      "",
      "2",
      1557
    ],
    [
      "",
      "Unmapped",
      "text",
      "Table 16",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1558
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1559
    ],
    [
      "",
      "Unmapped",
      "text",
      "Overall Visit Response for Target Lesions",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1560
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Complete Response (CR)</td>\n      <td>Disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to < 10 mm.</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Partial Response (PR)</td>\n      <td>At least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters.</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Stable Disease (SD)</td>\n      <td>Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Progressive Disease (PD)</td>\n      <td>At least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Not Evaluable (NE)</td>\n      <td>Only relevant if any of the TLs were not assessed or not evaluable or had a lesion intervention at this visit. Note: If the sum of diameters meets the progressive disease criteria, progressive disease overrides not evaluable as a TL response</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "20",
        "TableName": "Overall Visit Response for Target Lesions",
        "Header": []
      },
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1561
    ],
    [
      "",
      "Unmapped",
      "header",
      " Non-Target lesions Evaluation of non-target lesions",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1562
    ],
    [
      "",
      "Unmapped",
      "text",
      "All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at baseline.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1563
    ],
    [
      "",
      "Unmapped",
      "text",
      "Measurements are not required for these lesions but their status should be followed at subsequent visits.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1564
    ],
    [
      "",
      "Unmapped",
      "text",
      "At each visit, an overall assessment of the NTL response should be recorded by the investigator.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1565
    ],
    [
      "",
      "Unmapped",
      "text",
      "Table 17 provides the definitions of the criteria used to determine and record overall response for NTLs at the investigational site at each visit.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 16  Overall Visit Response for Target Lesions",
      "",
      "2",
      1566
    ],
    [
      "",
      "Unmapped",
      "text",
      "Table 17",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1567
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1568
    ],
    [
      "",
      "Unmapped",
      "text",
      "Overall Visit Response for Non-Target Lesions",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1569
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Complete Response (CR)</td>\n      <td>Disappearance of all NTLs since baseline. All lymph nodes must be non-pathological in size (< 10 mm short axis).</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Non-CR/Non-PD</td>\n      <td>Persistence of one or more NTLs.</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Progressive Disease (PD)</td>\n      <td>Unequivocal progression of existing NTLs. Unequivocal progression may be due to an important progression in one lesion only or in several lesions. In all cases the progression MUST clinically significant for the physician to consider changing or stopping therapy</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Not Evaluable (NE)</td>\n      <td>Only relevant when one or some of the NTLs were not assessed and in the investigator’s opinion they are not able to provide an evaluable overall NTL assessment at this visit. Note: For subjects without TLs at baseline, this is relevant if any of the NTLs were not assessed at this visit and the progression criteria have not been met.</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "21",
        "TableName": "Overall Visit Response for Non-Target Lesions",
        "Header": []
      },
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1570
    ],
    [
      "",
      "Unmapped",
      "text",
      "To achieve ‘unequivocal progression' on the basis of NTLs, there must be an overall level of substantial worsening in non-target disease such that, even in presence of SD or PR in TLs, the overall tumour burden has increased sufficiently to merit discontinuation of therapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1571
    ],
    [
      "",
      "Unmapped",
      "text",
      "A modest ‘increase' in the size of one or more NTLs is usually not sufficient to qualify for unequivocal progression status.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1572
    ],
    [
      "",
      "Unmapped",
      "header",
      " New Lesions",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1573
    ],
    [
      "",
      "Unmapped",
      "text",
      "Details of any new lesions will also be recorded with the date of assessment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1574
    ],
    [
      "",
      "Unmapped",
      "text",
      "The presence of one or more new lesions is assessed as progression.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1575
    ],
    [
      "",
      "Unmapped",
      "text",
      "A lesion identified at a follow up assessment in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1576
    ],
    [
      "",
      "Unmapped",
      "text",
      "The finding of a new lesion should be unequivocal: i.e., not attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumour.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1577
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a new lesion is equivocal, for example because of its small size, the treatment and tumour assessments should be continued until the new lesion has been confirmed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1578
    ],
    [
      "",
      "Unmapped",
      "text",
      "If repeat scans confirm there is a new lesion, then the progression date should be declared using the date of the initial scan.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1579
    ],
    [
      "",
      "Unmapped",
      "header",
      " Symptomatic deterioration",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1580
    ],
    [
      "",
      "Unmapped",
      "text",
      "Symptomatic deterioration is not a descriptor of an objective response: it is a reason for stopping study therapy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1581
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects with ‘symptomatic deterioration' requiring discontinuation of study treatment without objective evidence of disease progression at that time will undergo no further tumour assessments in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1582
    ],
    [
      "",
      "Unmapped",
      "text",
      "Tumour response data for such subjects will be censored at the date of their last RECIST assessment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1583
    ],
    [
      "",
      "Unmapped",
      "text",
      "Evaluation of Overall Visit Response and Best Overall Response",
      { "IsBold": true, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1584
    ],
    [
      "",
      "Unmapped",
      "text",
      "The overall visit response will be derived using the algorithm shown in Table 18",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 17  Overall Visit Response for Non-Target Lesions",
      "",
      "2",
      1585
    ],
    [
      "",
      "Unmapped",
      "text",
      "Table 18",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1586
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1587
    ],
    [
      "",
      "Unmapped",
      "text",
      "Overall Visit Response",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1588
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Target lesions</td>\n      <td>Non-Target lesions</td>\n      <td>New Lesions</td>\n      <td>Overall response</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>CR</td>\n      <td>CR</td>\n      <td>No</td>\n      <td>CR</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>CR</td>\n      <td>NA</td>\n      <td>No</td>\n      <td>CR</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NA</td>\n      <td>CR</td>\n      <td>No</td>\n      <td>CR</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>PR</td>\n      <td>Non PD or NE</td>\n      <td>No</td>\n      <td>PR</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>SD</td>\n      <td>Non PD or NE</td>\n      <td>No</td>\n      <td>SD</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>NA</td>\n      <td>Non CR/Non PD</td>\n      <td>No</td>\n      <td>SD (Non CR/non PD)</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>NE</td>\n      <td>Non-PD or NE</td>\n      <td>No</td>\n      <td>NE</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>NA</td>\n      <td>NE</td>\n      <td>No</td>\n      <td>NE</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>PD</td>\n      <td>Any</td>\n      <td>Yes or No</td>\n      <td>PD</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>Any</td>\n      <td>PD</td>\n      <td>Yes or No</td>\n      <td>PD</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>Any</td>\n      <td>Any</td>\n      <td>Yes</td>\n      <td>PD</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "22",
        "TableName": "Overall Visit Response",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1589
    ],
    [
      "",
      "Unmapped",
      "header",
      " Specifications for Radiological Imaging",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1590
    ],
    [
      "",
      "Unmapped",
      "text",
      "These notes are recommendations for use in clinical studies.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1591
    ],
    [
      "",
      "Unmapped",
      "text",
      "The use of standardised protocols for CT and MRI allows comparability both within and between different studies, irrespective of where the examination has been undertaken.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1592
    ],
    [
      "",
      "Unmapped",
      "header",
      " CT Scan",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1593
    ],
    [
      "",
      "Unmapped",
      "text",
      "CT scans of the chest, abdomen, and pelvis should be contiguous throughout all the anatomical regions of interest.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1594
    ],
    [
      "",
      "Unmapped",
      "text",
      "The most critical CT image acquisition parameters for optimal tumour evaluation using RECIST v1.1 are anatomic coverage, contrast administration, slice thickness, and reconstruction interval.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1595
    ],
    [
      "",
      "Unmapped",
      "header",
      " Anatomic coverage",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1596
    ],
    [
      "",
      "Unmapped",
      "text",
      "Optimal anatomic coverage for most solid tumours is the chest, abdomen and pelvis.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1597
    ],
    [
      "",
      "Unmapped",
      "text",
      "Coverage should encompass all areas of known predilection for metastases in the disease under evaluation and should additionally investigate areas that may be involved based on signs and symptoms of individual subjects.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1598
    ],
    [
      "",
      "Unmapped",
      "text",
      "Because a lesion later identified in a body part not scanned at baseline would be considered as a new lesion representing disease progression, careful consideration should be given to the extent of imaging coverage at baseline and at subsequent follow-up time points.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1599
    ],
    [
      "",
      "Unmapped",
      "text",
      "This will enable better consistency not only of tumour measurements but also identification of new disease.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1600
    ],
    [
      "",
      "Unmapped",
      "text",
      "Intravenous contrast administration",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1601
    ],
    [
      "",
      "Unmapped",
      "text",
      "Optimal visualisation and measurement of metastases in solid tumours requires consistent administration (dose and rate) of intravenous contrast as well as timing of scanning.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1602
    ],
    [
      "",
      "Unmapped",
      "text",
      "Typically, most abdominal imaging is performed during the portal venous phase and (optimally) about the same time frame after injection on each examination.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1603
    ],
    [
      "",
      "Unmapped",
      "text",
      "An adequate volume of a suitable contrast agent should be given so that the metastases are demonstrated to best effect and a consistent method is used on subsequent examinations for any given subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1604
    ],
    [
      "",
      "Unmapped",
      "text",
      "It is very important that the same technique be used at baseline and on follow- up examinations for a given subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1605
    ],
    [
      "",
      "Unmapped",
      "text",
      "For subjects who develop contraindications to contrast after baseline contrast CT is done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) should be performed should also be based on the tumour type, anatomic location of the disease and should be optimised to allow for comparison to the prior studies if possible.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1606
    ],
    [
      "",
      "Unmapped",
      "text",
      "Each case should be discussed with the radiologist to determine if substitution of these other approaches is possible and, if not, the subject should be considered NE from that point forward.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1607
    ],
    [
      "",
      "Unmapped",
      "text",
      "Care must be taken in measurement of TLs on a different modality and interpretation of non-target disease or new lesions, since the same lesion may appear to have a different size using a new modality.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1608
    ],
    [
      "",
      "Unmapped",
      "text",
      "Oral contrast is recommended to help visualise and differentiate structures in the abdomen.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1609
    ],
    [
      "",
      "Unmapped",
      "text",
      "If iodine contrast media is medically contraindicated at baseline or at any time during the course of the study then the recommended methods are: CT thoracic examination without contrast and abdominal and pelvic MRI with contrast.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1610
    ],
    [
      "",
      "Unmapped",
      "text",
      "If MRI cannot be performed then CT without intravenous contrast is an option for the thorax, abdomen and pelvic examinations.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1611
    ],
    [
      "",
      "Unmapped",
      "text",
      "For assessment of brain lesions MRI is the preferred method.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1612
    ],
    [
      "",
      "Unmapped",
      "text",
      "Slice thickness and reconstruction material",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1613
    ],
    [
      "",
      "Unmapped",
      "text",
      "It is recommended that CT scans be performed at 5 mm contiguous slice thickness and this guideline presumes a minimum 5 mm thickness in recommendations for the measurable lesion definition.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1614
    ],
    [
      "",
      "Unmapped",
      "text",
      "Exceptionally, particular institutions may perform medically acceptable scans at slice thicknesses greater than 5 mm.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1615
    ],
    [
      "",
      "Unmapped",
      "text",
      "If this occurs, the minimum size of measurable lesions at baseline should be twice the slice thickness of the baseline scans.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1616
    ],
    [
      "",
      "Unmapped",
      "text",
      "All window settings should be included in the assessment, particularly in the thorax where lung and soft tissue windows should be considered.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1617
    ],
    [
      "",
      "Unmapped",
      "text",
      "When measuring lesions, the TLs should be measured on the same window setting for repeated examinations throughout the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1618
    ],
    [
      "",
      "Unmapped",
      "text",
      "All images from each examination should be included in the assessment and not “selected” images of the apparent lesion.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1619
    ],
    [
      "",
      "Unmapped",
      "header",
      " MRI Scan",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1620
    ],
    [
      "",
      "Unmapped",
      "text",
      "MRI has excellent contrast, spatial and temporal resolution; however, there are many image acquisition variables involved in MRI, which greatly impact image quality, lesion conspicuity and measurement.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1621
    ],
    [
      "",
      "Unmapped",
      "text",
      "Furthermore, the availability of MRI is variable globally.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1622
    ],
    [
      "",
      "Unmapped",
      "text",
      "The modality used at follow-up should be the same as was used at baseline and the lesions should be measured/assessed on the same pulse sequence.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1623
    ],
    [
      "",
      "Unmapped",
      "text",
      "Generally, axial imaging of the abdomen and pelvis with T1 and T2 weighted imaging along with gadolinium-enhanced imaging should be performed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1624
    ],
    [
      "",
      "Unmapped",
      "text",
      "The field of view, matrix, number of excitations, phase encode steps, use of fat suppression and fast sequences should be optimised for the specific body part being imaged as well as the scanner utilised.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1625
    ],
    [
      "",
      "Unmapped",
      "text",
      "It is beyond the scope of this appendix to prescribe specific MRI pulse sequence parameters for all scanners, body parts and diseases.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1626
    ],
    [
      "",
      "Unmapped",
      "text",
      "Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1627
    ],
    [
      "",
      "Unmapped",
      "text",
      "Body scans should be performed with breath-hold scanning techniques if possible.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1628
    ],
    [
      "",
      "Unmapped",
      "text",
      "For these reasons, CT is the imaging modality of choice.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1629
    ],
    [
      "",
      "Unmapped",
      "header",
      " FDG-PET scans",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1630
    ],
    [
      "",
      "Unmapped",
      "text",
      "FDG-PET has gained acceptance as a valuable tool for detecting, staging and restaging several malignancies.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1631
    ],
    [
      "",
      "Unmapped",
      "text",
      "If FDG-PET scans are included in a protocol, an FDG uptake period of 60 min prior to imaging has been decided as the most appropriate for imaging of subjects with malignancy.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1632
    ],
    [
      "",
      "Unmapped",
      "text",
      "Whole-body acquisition is important since this allows for sampling of all areas of interest and can assess if new lesions have appeared thus determining the possibility of interval progression of disease.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1633
    ],
    [
      "",
      "Unmapped",
      "text",
      "Images from the base of the skull to the level of the mid-thigh should be obtained 60 min post injection.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1634
    ],
    [
      "",
      "Unmapped",
      "text",
      "Positron emission tomography (PET) camera specifications are variable and manufacturer specific, so every attempt should be made to use the same scanner, or the same model scanner, for serial scans on the same subject.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1635
    ],
    [
      "",
      "Unmapped",
      "text",
      "Wholebody acquisitions can be performed in either 2- or 3-dimensional mode with attenuation correction, but the method chosen should be consistent across all subjects and serial scans in the clinical trial.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1636
    ],
    [
      "",
      "Unmapped",
      "header",
      " PET/CT scans",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1637
    ],
    [
      "",
      "Unmapped",
      "text",
      "At present, low dose or attenuation correction CT portions of a combined PET-CT are of limited use in anatomically based efficacy assessments and it is therefore suggested that they should not be substituted for dedicated diagnostic contrast enhanced CT scans for tumour measurements by RECIST v1.1.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1638
    ],
    [
      "",
      "Unmapped",
      "text",
      "In exceptional situations, if a site can document that the CT performed as part of a PET-CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast) then the CT portion of the PET-CT can be used for RECIST measurements.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1639
    ],
    [
      "",
      "Unmapped",
      "text",
      "However, this is not recommended because the PET portion of the CT introduces additional data that may bias an investigator if it is not routinely or serially performed.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1640
    ],
    [
      "",
      "Unmapped",
      "header",
      " REFERENCES Eisenhauer et al 2009",
      { "IsBold": false, "font_size": 22, "font_style": "Heading6" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1641
    ],
    [
      "",
      "Unmapped",
      "text",
      "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1642
    ],
    [
      "",
      "Unmapped",
      "text",
      "S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1643
    ],
    [
      "",
      "Unmapped",
      "text",
      "New response evaluation criteria in solid tumours: Revised RECIST guideline (version",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1644
    ],
    [
      "",
      "Unmapped",
      "text",
      "1.1).  European Journal of Cancer.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1645
    ],
    [
      "",
      "Unmapped",
      "text",
      "45 (2009) 228-247.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1646
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1647
    ],
    [
      "",
      "Unmapped",
      "text",
      "H",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1648
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1649
    ],
    [
      "",
      "Unmapped",
      "text",
      "Acceptable Birth Control Methods",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1650
    ],
    [
      "",
      "Unmapped",
      "text",
      "WoCBP and their sexually active partners must agree to the use of TWO highly effective forms of contraception in combination (as listed below).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1651
    ],
    [
      "",
      "Unmapped",
      "text",
      "Barrier methods of contraception may be considered acceptable when combined with one of the highly effective contraception methods described below.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1652
    ],
    [
      "",
      "Unmapped",
      "text",
      "This should be started from 2 weeks prior to the study drug exposure and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1653
    ],
    [
      "",
      "Unmapped",
      "text",
      "Male subjects must use a condom for the duration of study drug exposure and for 3 months after the last dose of the study treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1654
    ],
    [
      "",
      "Unmapped",
      "text",
      "Female partners of male subjects should also use a highly effective form of contraception if they are of childbearing potential (as listed below).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1655
    ],
    [
      "",
      "Unmapped",
      "text",
      "Male subjects should not donate sperm for the duration of study drug exposure and for until 3 months after the last dose of the study treatment.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1656
    ],
    [
      "",
      "Unmapped",
      "text",
      "Highly effective methods of contraception include:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1657
    ],
    [
      "",
      "Unmapped",
      "text",
      "Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral,",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1658
    ],
    [
      "",
      "Unmapped",
      "text",
      "Placement of an intrauterine device (IUD) or intrauterine system (IUS),",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1659
    ],
    [
      "",
      "Unmapped",
      "text",
      "Bilateral tubal occlusion,",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1660
    ],
    [
      "",
      "Unmapped",
      "text",
      "Male partner sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate),",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1661
    ],
    [
      "",
      "Unmapped",
      "text",
      "Acceptable method of contraception:",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1662
    ],
    [
      "",
      "Unmapped",
      "text",
      "Barrier methods of contraception: condom with spermicide",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1663
    ],
    [
      "",
      "Unmapped",
      "text",
      "I",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1664
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1665
    ],
    [
      "",
      "Unmapped",
      "text",
      "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1666
    ],
    [
      "",
      "Unmapped",
      "text",
      "These scales and criteria are used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the subject's daily living abilities, and determine appropriate treatment and prognosis.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1667
    ],
    [
      "",
      "Unmapped",
      "text",
      "They are included here for health care professionals to access.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1668
    ],
    [
      "",
      "Unmapped",
      "text",
      "ECOG PERFORMANCE STATUS*",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1669
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Grade</td>\n      <td>ECOG</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>0</td>\n      <td>Fully active, able to carry on all pre-disease performance without restriction</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>1</td>\n      <td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>2</td>\n      <td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>3</td>\n      <td>Capable of only limited self-care, confined to bed or chair more than 50% of waking hours</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>4</td>\n      <td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>5</td>\n      <td>Dead</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "23",
        "TableName": "ECOG PERFORMANCE STATUS*",
        "Header": []
      },
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1670
    ],
    [
      "",
      "Unmapped",
      "text",
      "J",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1671
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1672
    ],
    [
      "",
      "Unmapped",
      "text",
      "Disallowed Medications and Medications to be Administered with Caution",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1673
    ],
    [
      "",
      "Unmapped",
      "text",
      "A formal clinical drug interaction study, evaluating the effect of adavosertib on PK of substrates for CYP3A, CYP2C19, CYP1A2, has been conducted in advanced solid tumour patients.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1674
    ],
    [
      "",
      "Unmapped",
      "text",
      "This study's results suggest that adavosertib is a weak inhibitor of these enzymes and is unlikely to result in clinically significant drug interaction.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1675
    ],
    [
      "",
      "Unmapped",
      "text",
      "In vitro",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1676
    ],
    [
      "",
      "Unmapped",
      "text",
      "data has shown that adavosertib is metabolised predominantly by CYP3A4, with a flavin-containing monooxygenase (FMO) 3 and/or FMO5 component.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1677
    ],
    [
      "",
      "Unmapped",
      "text",
      "As a result, there is potential for the exposure of adavosertib to be affected by drugs which inhibit or induce CYP3A4 metabolism.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1678
    ],
    [
      "",
      "Unmapped",
      "text",
      "An exploratory assessment of the effect of aprepitant on adavosertib exposure in oncology patients suggests that there is a drug interaction between adavosertib and aprepitant, as exposure to adavosertib increased by ~40% when aprepitant was co-administered with adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1679
    ],
    [
      "",
      "Unmapped",
      "text",
      "The observed increase in adavosertib exposure is likely the result of CYP3A4 inhibition by aprepitant.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1680
    ],
    [
      "",
      "Unmapped",
      "text",
      "This increase in exposure is statistically significant.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1681
    ],
    [
      "",
      "Unmapped",
      "text",
      "At the selected MTDs, this increase may also be of clinical importance.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1682
    ],
    [
      "",
      "Unmapped",
      "text",
      "Therefore, concomitant treatment with aprepitant and fosaprepitant is not allowable per protocol until further evaluation.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1683
    ],
    [
      "",
      "Unmapped",
      "text",
      "Potent or moderate inhibitors or inducers of CYP3A4 should be avoided until additional data on drug-drug interactions becomes available.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1684
    ],
    [
      "",
      "Unmapped",
      "text",
      "As grapefruit and Seville oranges are known to contain moderate CYP3A4 inhibitors, these fruits or their products (including marmalade, juice, etc.) should be avoided while taking adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1685
    ],
    [
      "",
      "Unmapped",
      "text",
      "Adavosertib has been shown to be a weak CYP1A2 inducer",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1686
    ],
    [
      "",
      "Unmapped",
      "text",
      "in vitro",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1687
    ],
    [
      "",
      "Unmapped",
      "text",
      "(39% increase in activity of positive control).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1688
    ],
    [
      "",
      "Unmapped",
      "text",
      "Given the nature of the adavosertib dosing schedule, however, the risk of induction in the clinic is considered low.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1689
    ],
    [
      "",
      "Unmapped",
      "text",
      "No specific precautions are recommended at this time, except to be initially vigilant when using CYP1A2 substrates with a narrow therapeutic range.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1690
    ],
    [
      "",
      "Unmapped",
      "text",
      "Transporter studies (",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1691
    ],
    [
      "",
      "Unmapped",
      "text",
      "in vitro",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1692
    ],
    [
      "",
      "Unmapped",
      "text",
      ") have shown that adavosertib is both a substrate and inhibitor (inhibitory concentration 50% [IC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1693
    ],
    [
      "",
      "Unmapped",
      "text",
      "50",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1694
    ],
    [
      "",
      "Unmapped",
      "text",
      "] 20 µM) of P-gp.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1695
    ],
    [
      "",
      "Unmapped",
      "text",
      "Maximum impact of these finding is likely to occur for drugs administered orally at the same time as adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1696
    ],
    [
      "",
      "Unmapped",
      "text",
      "Caution should therefore be exercised when agents that are inhibitors or substrates of P-gp are administered concomitantly with adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1697
    ],
    [
      "",
      "Unmapped",
      "text",
      "In vitro",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1698
    ],
    [
      "",
      "Unmapped",
      "text",
      "transporter studies have shown adavosertib to be an inhibitor of BCRP (IC",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1699
    ],
    [
      "",
      "Unmapped",
      "text",
      "50",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1700
    ],
    [
      "",
      "Unmapped",
      "text",
      "5.1 µM).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1701
    ],
    [
      "",
      "Unmapped",
      "text",
      "This finding is particularly relevant for drugs administered orally where exposure is normally limited by BCRP-mediated efflux, in particular some statins such as atorvastatin and",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1702
    ],
    [
      "",
      "Unmapped",
      "text",
      "rosuvastatin.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1703
    ],
    [
      "",
      "Unmapped",
      "text",
      "Other drugs where the disposition is mediated via BCRP should be administered with caution, dose modification considered or substituted by an alternative drug.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1704
    ],
    [
      "",
      "Unmapped",
      "text",
      "Metformin should be avoided in this study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1705
    ],
    [
      "",
      "Unmapped",
      "text",
      "Adavosertib has been shown to be an inhibitor of MATE1 and MATE2K transporters.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1706
    ],
    [
      "",
      "Unmapped",
      "text",
      "A drug interaction with substrates of either transporter cannot be ruled out, the most important substrate known to date being metformin.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1707
    ],
    [
      "",
      "Unmapped",
      "text",
      "Caution should be used when administering drugs that are substrates of these transporters (eg, cimetidine, acyclovir, fexofenadine) as the clinical relevance of adavosertib inhibition of the MATE pathway is not known in these compounds.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1708
    ],
    [
      "",
      "Unmapped",
      "text",
      "Herbal preparations/medications are not allowed throughout the study.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1709
    ],
    [
      "",
      "Unmapped",
      "text",
      "These herbal medications include, but are not limited to, those containing: St. John's wort, kava, ephedra (ma huang), gingko biloba, DHEA, yohimbe, saw palmetto, and ginseng.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1710
    ],
    [
      "",
      "Unmapped",
      "text",
      "Subjects should stop using these herbal medications 7 days prior to first dose of adavosertib.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1711
    ],
    [
      "",
      "Unmapped",
      "text",
      "In addition, any other drugs should be avoided at the Investigator's discretion if, in their opinion, co-administration with adavosertib may increase the risk of a clinically significant drug interaction.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1712
    ],
    [
      "",
      "Unmapped",
      "text",
      "A list of the main CYP3A4 inhibitors (strong and moderate) and inducers, P-gp substrates and inhibitors, and BCRP substrates are shown below.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1713
    ],
    [
      "",
      "Unmapped",
      "text",
      "This is not an exhaustive list, and further details can be found at Expert Opin.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1714
    ],
    [
      "",
      "Unmapped",
      "text",
      "Drug Metab. Toxicol.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1715
    ],
    [
      "",
      "Unmapped",
      "text",
      "(2013) 9(6):737-751.",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1716
    ],
    [
      "",
      "Unmapped",
      "text",
      "CYP3A4 Inhibitors",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1717
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Strong</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Boceprevir Clarithromycin Cobicistat (GS-9350) Conivaptan Danoprevir Elvitegravir Fosamprenavir Grapefruit juice Idelalisib Indinavir Itraconazole Ketoconazole</td>\n      <td>LCL161 Lopinavir Mibefradil Nefazodone Nelfinavir Posaconazole Ritonavir Saquinavir Telaprevir Telithromycin Tipranavir Troleandomycin Voriconazole</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Moderate</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>ACT-178882 Amprenavir Aprepitant Atazanavir Casopitant Ciprofloxacin Crizotinib Darunavir Dronedarone Diltiazem Erythromycin</td>\n      <td>FK1706 Fluconazole Fosamprenavir Imatinib Ledipasvir Lomitapide Netupitant Schisandra sphenanthera Seville orange juice Tofisopam Verapamil</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "24",
        "TableName": "",
        "Header": [0, 2]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1718
    ],
    [
      "",
      "Unmapped",
      "text",
      "CYP3A4 Inducers (Strong and Moderate)",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1719
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Avasimibe Bosentan Carbamazepine Efavirenz Enzalutamide Etravirine Genistein Lersivirine Lopinavir Mitotane Modafinil</td>\n      <td>Nafcillin Phenobarbital Phenytoin Rifabutin Rifampin Ritonavir Semagacestat St John's Wort Thioridazine Tipranavir</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "25",
        "TableName": "CYP3A4 Inducers (Strong and Moderate)",
        "Header": []
      },
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1720
    ],
    [
      "",
      "Unmapped",
      "text",
      "P-gp Substrates",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1721
    ],
    [
      "",
      "Unmapped",
      "text",
      "If a subject requires digoxin during the study, or is already receiving treatment with digoxin, monitoring digoxin levels is recommended according to local practice (as the levels of digoxin may increase).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1722
    ],
    [
      "",
      "Unmapped",
      "text",
      "Monitoring digoxin levels is also recommended when the subject has completed dosing with the study treatment (as the levels of digoxin may then decrease).",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1723
    ],
    [
      "",
      "Unmapped",
      "text",
      "P-gp Inhibitors (Strong)",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1724
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Cyclosporine Elacridar Erythromycin Itraconazole Ketoconazole</td>\n      <td>LY335979 Quinidine Ritonavir Valspodar Verapamil</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "26",
        "TableName": "P-gp Inhibitors (Strong)",
        "Header": []
      },
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1725
    ],
    [
      "",
      "Unmapped",
      "text",
      "BCRP Substrates",
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1726
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Atorvastatin Daunorubicin Doxorubicin</td>\n      <td>Rosuvastatin Sulfasalazine Topotecan</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "27",
        "TableName": "",
        "Header": []
      },
      { "IsBold": false, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1727
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Table 18  Overall Visit Response",
      "",
      "2",
      1728
    ],
    [
      "",
      "Unmapped",
      "text",
      "Appendix K",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1729
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1730
    ],
    [
      "",
      "Unmapped",
      "text",
      "Abbreviations",
      { "IsBold": true, "font_size": 28, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1731
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Abbreviation or special term</td>\n      <td>Explanation</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5-HT</td>\n      <td>5-hydroxytryptamine</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>AE</td>\n      <td>Adverse event</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>ALP</td>\n      <td>Alkaline phosphatase</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>ALT</td>\n      <td>Alanine aminotransferase</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>ANC</td>\n      <td>Absolute neutrophil count</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>AST</td>\n      <td>Aspartate aminotransferase</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>AUC</td>\n      <td>Area under the plasma concentration-time curve</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>AUC 0-10/24</td>\n      <td>Area under the plasma concentration-time curve from zero to 10/24 hours</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>AUC 0-t</td>\n      <td>Area under the plasma concentration-time curve from zero to the time of the last measurable concentration</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>BCRP</td>\n      <td>Breast cancer resistance protein</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>CBC</td>\n      <td>Complete blood counts</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>CDC2</td>\n      <td>Cell division cycle 2,</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>CDK1</td>\n      <td>Cyclin-dependent kinases 1</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>CDK2</td>\n      <td>Cyclin-dependent kinases 2</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>C max</td>\n      <td>Maximum plasma drug concentration observed</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>CR</td>\n      <td>Complete response</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>CrCl</td>\n      <td>Creatinine clearance</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>CRF</td>\n      <td>Case report form</td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>CSP</td>\n      <td>Clinical Study Protocol</td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>CSR</td>\n      <td>Clinical Study Report</td>\n    </tr>\n    <tr>\n      <th>21</th>\n      <td>CT</td>\n      <td>Computed tomography</td>\n    </tr>\n    <tr>\n      <th>22</th>\n      <td>CTCAE</td>\n      <td>Common Terminology Criteria for Adverse Events</td>\n    </tr>\n    <tr>\n      <th>23</th>\n      <td>C trough</td>\n      <td>Trough plasma concentration</td>\n    </tr>\n    <tr>\n      <th>24</th>\n      <td>CYP</td>\n      <td>Cytochrome P450</td>\n    </tr>\n    <tr>\n      <th>25</th>\n      <td>DCR</td>\n      <td>Disease control rate</td>\n    </tr>\n    <tr>\n      <th>26</th>\n      <td>DHEA</td>\n      <td>Dehydroepiandrosterone</td>\n    </tr>\n    <tr>\n      <th>27</th>\n      <td>DLT</td>\n      <td>Dose-limiting toxicity</td>\n    </tr>\n    <tr>\n      <th>28</th>\n      <td>DNA</td>\n      <td>Deoxyribonucleic acid</td>\n    </tr>\n    <tr>\n      <th>29</th>\n      <td>DoR</td>\n      <td>Duration of response</td>\n    </tr>\n    <tr>\n      <th>30</th>\n      <td>ECG</td>\n      <td>Electrocardiogram</td>\n    </tr>\n    <tr>\n      <th>31</th>\n      <td>ECOG</td>\n      <td>Eastern Cooperative Oncology Group</td>\n    </tr>\n    <tr>\n      <th>32</th>\n      <td>eCRF</td>\n      <td>Electronic case report form</td>\n    </tr>\n    <tr>\n      <th>33</th>\n      <td>EDC</td>\n      <td>Electronic Data Capture</td>\n    </tr>\n    <tr>\n      <th>34</th>\n      <td>EOT</td>\n      <td>End of treatment</td>\n    </tr>\n    <tr>\n      <th>35</th>\n      <td>FDG</td>\n      <td>Fluorodeoxyglucose</td>\n    </tr>\n    <tr>\n      <th>36</th>\n      <td>FDG-PET</td>\n      <td>Fluorodeoxyglucose positron emission tomography</td>\n    </tr>\n    <tr>\n      <th>37</th>\n      <td>FMO</td>\n      <td>Flavin-containing monooxygenase</td>\n    </tr>\n    <tr>\n      <th>38</th>\n      <td>GCP</td>\n      <td>Good Clinical Practice</td>\n    </tr>\n    <tr>\n      <th>39</th>\n      <td>G-CSF</td>\n      <td>Granulocyte-colony stimulating factor</td>\n    </tr>\n    <tr>\n      <th>40</th>\n      <td>GMP</td>\n      <td>Good Manufacturing Practice</td>\n    </tr>\n    <tr>\n      <th>41</th>\n      <td>HL</td>\n      <td>Hy’s Law</td>\n    </tr>\n    <tr>\n      <th>42</th>\n      <td>IATA</td>\n      <td>International Airline Transportation Association</td>\n    </tr>\n    <tr>\n      <th>43</th>\n      <td>IB</td>\n      <td>Investigator’s Brochure</td>\n    </tr>\n    <tr>\n      <th>44</th>\n      <td>IC 50</td>\n      <td>Inhibitory concentration 50%</td>\n    </tr>\n    <tr>\n      <th>45</th>\n      <td>ICF</td>\n      <td>Informed consent form</td>\n    </tr>\n    <tr>\n      <th>46</th>\n      <td>ICH</td>\n      <td>International Council for Harmonisation</td>\n    </tr>\n    <tr>\n      <th>47</th>\n      <td>IEC</td>\n      <td>Independent ethics committee</td>\n    </tr>\n    <tr>\n      <th>48</th>\n      <td>IMP</td>\n      <td>Investigational medicinal product</td>\n    </tr>\n    <tr>\n      <th>49</th>\n      <td>IRB</td>\n      <td>Institutional review board</td>\n    </tr>\n    <tr>\n      <th>50</th>\n      <td>IV</td>\n      <td>Intravenous (ly)</td>\n    </tr>\n    <tr>\n      <th>51</th>\n      <td>IVRS</td>\n      <td>Interactive voice response system</td>\n    </tr>\n    <tr>\n      <th>52</th>\n      <td>IWRS</td>\n      <td>Interactive web response system</td>\n    </tr>\n    <tr>\n      <th>53</th>\n      <td>λ z</td>\n      <td>Elimination rate constant</td>\n    </tr>\n    <tr>\n      <th>54</th>\n      <td>MATE1</td>\n      <td>Multidrug and Toxin Extruder 1</td>\n    </tr>\n    <tr>\n      <th>55</th>\n      <td>MATE2K</td>\n      <td>Multidrug and Toxin Extruder 2K</td>\n    </tr>\n    <tr>\n      <th>56</th>\n      <td>MRI</td>\n      <td>Magnetic resonance imaging</td>\n    </tr>\n    <tr>\n      <th>57</th>\n      <td>MTD</td>\n      <td>Maximum-tolerated dose</td>\n    </tr>\n    <tr>\n      <th>58</th>\n      <td>NE</td>\n      <td>Not evaluable</td>\n    </tr>\n    <tr>\n      <th>59</th>\n      <td>NTL</td>\n      <td>Non-target lesion</td>\n    </tr>\n    <tr>\n      <th>60</th>\n      <td>NYHA</td>\n      <td>New York Heart Association</td>\n    </tr>\n    <tr>\n      <th>61</th>\n      <td>ORR</td>\n      <td>Objective response rate</td>\n    </tr>\n    <tr>\n      <th>62</th>\n      <td>PD</td>\n      <td>Progressive disease</td>\n    </tr>\n    <tr>\n      <th>63</th>\n      <td>PET</td>\n      <td>Positron emission tomography</td>\n    </tr>\n    <tr>\n      <th>64</th>\n      <td>PFS</td>\n      <td>Progression free survival</td>\n    </tr>\n    <tr>\n      <th>65</th>\n      <td>P-gp</td>\n      <td>P-glycoprotein</td>\n    </tr>\n    <tr>\n      <th>66</th>\n      <td>PHL</td>\n      <td>Potential Hy’s Law</td>\n    </tr>\n    <tr>\n      <th>67</th>\n      <td>PK</td>\n      <td>Pharmacokinetics</td>\n    </tr>\n    <tr>\n      <th>68</th>\n      <td>PO</td>\n      <td>By mouth</td>\n    </tr>\n    <tr>\n      <th>69</th>\n      <td>PR</td>\n      <td>Partial response</td>\n    </tr>\n    <tr>\n      <th>70</th>\n      <td>PS</td>\n      <td>Performance Status</td>\n    </tr>\n    <tr>\n      <th>71</th>\n      <td>QD</td>\n      <td>Once daily</td>\n    </tr>\n    <tr>\n      <th>72</th>\n      <td>QTc</td>\n      <td>Corrected QT interval</td>\n    </tr>\n    <tr>\n      <th>73</th>\n      <td>QTcF</td>\n      <td>Corrected QT interval using the Fridericia formula</td>\n    </tr>\n    <tr>\n      <th>74</th>\n      <td>RECIST</td>\n      <td>Response Evaluation Criteria in Solid Tumours</td>\n    </tr>\n    <tr>\n      <th>75</th>\n      <td>SAE</td>\n      <td>Serious adverse event</td>\n    </tr>\n    <tr>\n      <th>76</th>\n      <td>SD</td>\n      <td>Stable disease</td>\n    </tr>\n    <tr>\n      <th>77</th>\n      <td>SoA</td>\n      <td>Schedule of Activities</td>\n    </tr>\n    <tr>\n      <th>78</th>\n      <td>SRC</td>\n      <td>Safety Review Committee</td>\n    </tr>\n    <tr>\n      <th>79</th>\n      <td>t ½</td>\n      <td>Terminal half life</td>\n    </tr>\n    <tr>\n      <th>80</th>\n      <td>TBL</td>\n      <td>Total bilirubin</td>\n    </tr>\n    <tr>\n      <th>81</th>\n      <td>TL</td>\n      <td>Target lesion</td>\n    </tr>\n    <tr>\n      <th>82</th>\n      <td>t max</td>\n      <td>Time of maximum plasma drug concentration observed</td>\n    </tr>\n    <tr>\n      <th>83</th>\n      <td>ULN</td>\n      <td>Upper limit of normal</td>\n    </tr>\n    <tr>\n      <th>84</th>\n      <td>WEE1</td>\n      <td>A nuclear kinase belonging to the Ser/Thr family of protein kinases in the fission yeast Schizosaccharomyces pombe (S. pombe) .</td>\n    </tr>\n    <tr>\n      <th>85</th>\n      <td>WNL</td>\n      <td>Within normal limits</td>\n    </tr>\n    <tr>\n      <th>86</th>\n      <td>WoCBP</td>\n      <td>Women of childbearing potential</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "28",
        "TableName": "",
        "Header": [0]
      },
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1732
    ],
    [
      "",
      "Unmapped",
      "table",
      "",
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1733
    ],
    [
      "",
      "Unmapped",
      "table",
      "",
      { "IsBold": true, "font_size": 20, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1734
    ],
    [
      "",
      "Unmapped",
      "text",
      "SIGNATURE PAGE",
      { "IsBold": true, "font_size": 30, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1735
    ],
    [
      "",
      "Unmapped",
      "text",
      "This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1736
    ],
    [
      "",
      "Unmapped",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Document Name: d601hc00008-csp-v1</td>\n      <td>Document Name: d601hc00008-csp-v1</td>\n      <td>Document Name: d601hc00008-csp-v1</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Document Title:</td>\n      <td>D601HC00008 Clinical Study Protocol version 1</td>\n      <td>D601HC00008 Clinical Study Protocol version 1</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Document ID:</td>\n      <td>Doc ID-004179564</td>\n      <td>Doc ID-004179564</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Version Label:</td>\n      <td>1.0 CURRENT LATEST APPROVED</td>\n      <td>1.0 CURRENT LATEST APPROVED</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Server Date (dd-MMM-yyyy HH:mm ‘UTC’Z)</td>\n      <td>Signed by</td>\n      <td>Meaning of Signature</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>09-Mar-2020 13:03 UTC</td>\n      <td>Lone Ottesen</td>\n      <td>Content Approval</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>09-Mar-2020 12:06 UTC</td>\n      <td>Lyn Weller</td>\n      <td>Content Approval</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>09-Mar-2020 09:54 UTC</td>\n      <td>Pingping Ni</td>\n      <td>Management Approval</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>09-Mar-2020 06:51 UTC</td>\n      <td>Sakura Iizumi</td>\n      <td>Content Approval</td>\n    </tr>\n  </tbody>\n</table>",
        "TableIndex": "31",
        "TableName": "This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature",
        "Header": [1, 2, 3]
      },
      { "IsBold": true, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1737
    ],
    [
      "",
      "Unmapped",
      "text",
      "Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.",
      { "IsBold": false, "font_size": 22, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1738
    ],
    [
      "",
      "Unmapped",
      "text",
      "VERSION HISTORY",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1739
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1740
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1741
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1742
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1743
    ],
    [
      "",
      "Unmapped",
      "text",
      "2",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1744
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1745
    ],
    [
      "",
      "Unmapped",
      "text",
      "TABLE OF CONTENTS",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1746
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1747
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1748
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1749
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1750
    ],
    [
      "",
      "Unmapped",
      "text",
      "3",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1751
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1752
    ],
    [
      "",
      "Unmapped",
      "text",
      "1 PROTOCOL SUMMARY",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1753
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1754
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1755
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1756
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1757
    ],
    [
      "",
      "Unmapped",
      "text",
      "7",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1758
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1759
    ],
    [
      "",
      "Unmapped",
      "text",
      "1.1 Schedule of Activities (SoA)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1760
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1761
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1762
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1763
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1764
    ],
    [
      "",
      "Unmapped",
      "text",
      "7",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1765
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1766
    ],
    [
      "",
      "Unmapped",
      "text",
      "1.2 Synopsis",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1767
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1768
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1769
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1770
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1771
    ],
    [
      "",
      "Unmapped",
      "text",
      "12",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1772
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1773
    ],
    [
      "",
      "Unmapped",
      "text",
      "1.3 Schema",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1774
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1775
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1776
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1777
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1778
    ],
    [
      "",
      "Unmapped",
      "text",
      "14",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1779
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1780
    ],
    [
      "",
      "Unmapped",
      "text",
      "2 INTRODUCTION",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1781
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1782
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1783
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1784
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1785
    ],
    [
      "",
      "Unmapped",
      "text",
      "15",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1786
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1787
    ],
    [
      "",
      "Unmapped",
      "text",
      "2.1 Study rationale",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1788
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1789
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1790
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1791
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1792
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1793
    ],
    [
      "",
      "Unmapped",
      "text",
      "15",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1794
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1795
    ],
    [
      "",
      "Unmapped",
      "text",
      "2.2 Background",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1796
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1797
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1798
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1799
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1800
    ],
    [
      "",
      "Unmapped",
      "text",
      "16",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1801
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1802
    ],
    [
      "",
      "Unmapped",
      "text",
      "2.2.1 Experience in humans",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1803
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1804
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1805
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1806
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1807
    ],
    [
      "",
      "Unmapped",
      "text",
      "16",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1808
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1809
    ],
    [
      "",
      "Unmapped",
      "text",
      "2.3 Benefit/risk assessment",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1810
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1811
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1812
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1813
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1814
    ],
    [
      "",
      "Unmapped",
      "text",
      "16",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1815
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1816
    ],
    [
      "",
      "Unmapped",
      "text",
      "3 OBJECTIVES AND ENDPOINTS",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1817
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1818
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1819
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1820
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1821
    ],
    [
      "",
      "Unmapped",
      "text",
      "17",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1822
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1823
    ],
    [
      "",
      "Unmapped",
      "text",
      "4 STUDY DESIGN",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1824
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1825
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1826
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1827
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1828
    ],
    [
      "",
      "Unmapped",
      "text",
      "17",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1829
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1830
    ],
    [
      "",
      "Unmapped",
      "text",
      "4.1 Overall design",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1831
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1832
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1833
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1834
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1835
    ],
    [
      "",
      "Unmapped",
      "text",
      "17",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1836
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1837
    ],
    [
      "",
      "Unmapped",
      "text",
      "4.2 Scientific rationale for study design",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1838
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1839
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1840
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1841
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1842
    ],
    [
      "",
      "Unmapped",
      "text",
      "18",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1843
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1844
    ],
    [
      "",
      "Unmapped",
      "text",
      "4.3 Justification for dose",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1845
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1846
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1847
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1848
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1849
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1850
    ],
    [
      "",
      "Unmapped",
      "text",
      "18",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1851
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1852
    ],
    [
      "",
      "Unmapped",
      "text",
      "4.4 End of study definition",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1853
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1854
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1855
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1856
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1857
    ],
    [
      "",
      "Unmapped",
      "text",
      "19",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1858
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1859
    ],
    [
      "",
      "Unmapped",
      "text",
      "5 STUDY POPULATION",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1860
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1861
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1862
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1863
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1864
    ],
    [
      "",
      "Unmapped",
      "text",
      "19",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1865
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1866
    ],
    [
      "",
      "Unmapped",
      "text",
      "5.1 Inclusion criteria",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1867
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1868
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1869
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1870
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1871
    ],
    [
      "",
      "Unmapped",
      "text",
      "19",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1872
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1873
    ],
    [
      "",
      "Unmapped",
      "text",
      "5.2 Exclusion criteria",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1874
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1875
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1876
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1877
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1878
    ],
    [
      "",
      "Unmapped",
      "text",
      "20",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1879
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1880
    ],
    [
      "",
      "Unmapped",
      "text",
      "5.3 Lifestyle restrictions",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1881
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1882
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1883
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1884
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1885
    ],
    [
      "",
      "Unmapped",
      "text",
      "23",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1886
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1887
    ],
    [
      "",
      "Unmapped",
      "text",
      "5.3.1 Meals and Dietary Restrictions",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1888
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1889
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1890
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1891
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1892
    ],
    [
      "",
      "Unmapped",
      "text",
      "23",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1893
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1894
    ],
    [
      "",
      "Unmapped",
      "text",
      "5.3.2 Contraception",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1895
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1896
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1897
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1898
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1899
    ],
    [
      "",
      "Unmapped",
      "text",
      "23",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1900
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1901
    ],
    [
      "",
      "Unmapped",
      "text",
      "5.4 Screen failures",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1902
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1903
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1904
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1905
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1906
    ],
    [
      "",
      "Unmapped",
      "text",
      "23",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1907
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1908
    ],
    [
      "",
      "Unmapped",
      "text",
      "6 STUDY TREATMENTS",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1909
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1910
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1911
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1912
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1913
    ],
    [
      "",
      "Unmapped",
      "text",
      "24",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1914
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1915
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.1 Treatments administered",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1916
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1917
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1918
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1919
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1920
    ],
    [
      "",
      "Unmapped",
      "text",
      "24",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1921
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1922
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.1.1 Investigational products",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1923
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1924
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1925
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1926
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1927
    ],
    [
      "",
      "Unmapped",
      "text",
      "24",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1928
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1929
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.2 Preparation/handling/storage/accountability",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1930
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1931
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1932
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1933
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1934
    ],
    [
      "",
      "Unmapped",
      "text",
      "24",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1935
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1936
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.3 Measures to minimise bias: randomisation and blinding",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1937
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1938
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1939
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1940
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1941
    ],
    [
      "",
      "Unmapped",
      "text",
      "25",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1942
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1943
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.4 Treatment compliance",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1944
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1945
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1946
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1947
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1948
    ],
    [
      "",
      "Unmapped",
      "text",
      "25",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1949
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1950
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.5 Concomitant therapy",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1951
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1952
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1953
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1954
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1955
    ],
    [
      "",
      "Unmapped",
      "text",
      "26",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1956
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1957
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.5.1 Prohibited concomitant medications",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1958
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1959
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1960
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1961
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1962
    ],
    [
      "",
      "Unmapped",
      "text",
      "26",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1963
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1964
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.5.2 Restricted concomitant medications",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1965
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1966
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1967
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1968
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1969
    ],
    [
      "",
      "Unmapped",
      "text",
      "26",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1970
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1971
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.5.3 Permitted concomitant medications",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1972
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1973
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1974
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1975
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1976
    ],
    [
      "",
      "Unmapped",
      "text",
      "27",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1977
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1978
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.5.4 Other concomitant treatment",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1979
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1980
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1981
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1982
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1983
    ],
    [
      "",
      "Unmapped",
      "text",
      "28",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1984
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1985
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.6 Dose modification",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1986
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1987
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1988
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1989
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1990
    ],
    [
      "",
      "Unmapped",
      "text",
      "28",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1991
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1992
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.6.1 Dose escalation guideline",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1993
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1994
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1995
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1996
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1997
    ],
    [
      "",
      "Unmapped",
      "text",
      "28",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1998
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      1999
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.6.2 Dose-limiting Toxicity (DLT)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2000
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2001
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2002
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2003
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2004
    ],
    [
      "",
      "Unmapped",
      "text",
      "28",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2005
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2006
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.6.3 Safety Review Committee (SRC)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2007
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2008
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2009
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2010
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2011
    ],
    [
      "",
      "Unmapped",
      "text",
      "29",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2012
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2013
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.6.4 Dose modifications due to toxicities",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2014
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2015
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2016
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2017
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2018
    ],
    [
      "",
      "Unmapped",
      "text",
      "30",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2019
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2020
    ],
    [
      "",
      "Unmapped",
      "text",
      "6.7 Treatment after the end of the study",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2021
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2022
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2023
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2024
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2025
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2026
    ],
    [
      "",
      "Unmapped",
      "text",
      "31",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2027
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2028
    ],
    [
      "",
      "Unmapped",
      "text",
      "7 DISCONTINUATION OF TREATMENT AND SUBJECT WITHDRAWAL",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2029
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2030
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2031
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2032
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2033
    ],
    [
      "",
      "Unmapped",
      "text",
      "31",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2034
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2035
    ],
    [
      "",
      "Unmapped",
      "text",
      "7.1 Discontinuation of study treatment",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2036
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2037
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2038
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2039
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2040
    ],
    [
      "",
      "Unmapped",
      "text",
      "31",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2041
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2042
    ],
    [
      "",
      "Unmapped",
      "text",
      "7.1.1 Temporary discontinuation",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2043
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2044
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2045
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2046
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2047
    ],
    [
      "",
      "Unmapped",
      "text",
      "32",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2048
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2049
    ],
    [
      "",
      "Unmapped",
      "text",
      "7.1.1.1 Interruptions for intercurrent, non-toxicity related events",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2050
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2051
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2052
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2053
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2054
    ],
    [
      "",
      "Unmapped",
      "text",
      "32",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2055
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2056
    ],
    [
      "",
      "Unmapped",
      "text",
      "7.1.2 Procedures for discontinuation of study treatment",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2057
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2058
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2059
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2060
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2061
    ],
    [
      "",
      "Unmapped",
      "text",
      "32",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2062
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2063
    ],
    [
      "",
      "Unmapped",
      "text",
      "7.2 Lost to follow-up",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2064
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2065
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2066
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2067
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2068
    ],
    [
      "",
      "Unmapped",
      "text",
      "32",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2069
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2070
    ],
    [
      "",
      "Unmapped",
      "text",
      "7.3 Withdrawal from the study",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2071
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2072
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2073
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2074
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2075
    ],
    [
      "",
      "Unmapped",
      "text",
      "33",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2076
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2077
    ],
    [
      "",
      "Unmapped",
      "text",
      "8 STUDY ASSESSMENTS AND PROCEDURES",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2078
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2079
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2080
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2081
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2082
    ],
    [
      "",
      "Unmapped",
      "text",
      "33",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2083
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2084
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.1 Efficacy assessments",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2085
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2086
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2087
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2088
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2089
    ],
    [
      "",
      "Unmapped",
      "text",
      "36",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2090
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2091
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.1.1 Tumour assessments",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2092
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2093
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2094
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2095
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2096
    ],
    [
      "",
      "Unmapped",
      "text",
      "36",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2097
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2098
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.1.2 Tumour markers",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2099
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2100
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2101
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2102
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2103
    ],
    [
      "",
      "Unmapped",
      "text",
      "36",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2104
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2105
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.2 Safety assessments",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2106
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2107
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2108
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2109
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2110
    ],
    [
      "",
      "Unmapped",
      "text",
      "36",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2111
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2112
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.2.1 Clinical safety laboratory assessments",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2113
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2114
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2115
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2116
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2117
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2118
    ],
    [
      "",
      "Unmapped",
      "text",
      "36",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2119
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2120
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.2.2 Physical examinations",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2121
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2122
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2123
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2124
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2125
    ],
    [
      "",
      "Unmapped",
      "text",
      "38",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2126
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2127
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.2.3 Vital signs, weight and height",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2128
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2129
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2130
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2131
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2132
    ],
    [
      "",
      "Unmapped",
      "text",
      "38",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2133
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2134
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.2.4 Performance Status (PS)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2135
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2136
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2137
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2138
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2139
    ],
    [
      "",
      "Unmapped",
      "text",
      "38",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2140
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2141
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.2.5 Electrocardiograms (ECGs)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2142
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2143
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2144
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2145
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2146
    ],
    [
      "",
      "Unmapped",
      "text",
      "38",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2147
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2148
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3 Collection of adverse events (AEs)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2149
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2150
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2151
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2152
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2153
    ],
    [
      "",
      "Unmapped",
      "text",
      "39",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2154
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2155
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.1 Adverse events of special interest (AESIs)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2156
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2157
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2158
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2159
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2160
    ],
    [
      "",
      "Unmapped",
      "text",
      "39",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2161
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2162
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.2 Method of detecting adverse events (AEs) and serious adverse events (SAEs)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2163
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2164
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2165
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2166
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2167
    ],
    [
      "",
      "Unmapped",
      "text",
      "39",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2168
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2169
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.3 Time period and frequency for collecting adverse event (AE) and serious",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2170
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2171
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2172
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2173
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2174
    ],
    [
      "",
      "Unmapped",
      "text",
      "adverse event (SAE) information",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2175
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2176
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2177
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2178
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2179
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2180
    ],
    [
      "",
      "Unmapped",
      "text",
      "40",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2181
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2182
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.4 Follow-up of adverse events (AEs) and serious adverse events (SAEs)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2183
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2184
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2185
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2186
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2187
    ],
    [
      "",
      "Unmapped",
      "text",
      "40",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2188
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2189
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.5 Adverse event (AE) data collection",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2190
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2191
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2192
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2193
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2194
    ],
    [
      "",
      "Unmapped",
      "text",
      "40",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2195
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2196
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.6 Causality collection",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2197
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2198
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2199
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2200
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2201
    ],
    [
      "",
      "Unmapped",
      "text",
      "41",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2202
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2203
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.7 Adverse events (AEs) based on signs and symptoms",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2204
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2205
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2206
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2207
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2208
    ],
    [
      "",
      "Unmapped",
      "text",
      "41",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2209
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2210
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.8 Adverse events (AEs) based on examinations and tests",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2211
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2212
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2213
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2214
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2215
    ],
    [
      "",
      "Unmapped",
      "text",
      "41",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2216
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2217
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.9 Hy's Law",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2218
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2219
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2220
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2221
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2222
    ],
    [
      "",
      "Unmapped",
      "text",
      "42",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2223
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2224
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.3.10 Disease progression",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2225
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2226
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2227
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2228
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2229
    ],
    [
      "",
      "Unmapped",
      "text",
      "42",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2230
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2231
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4 Safety reporting and medical management",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2232
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2233
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2234
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2235
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2236
    ],
    [
      "",
      "Unmapped",
      "text",
      "42",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2237
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2238
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.1 Reporting of serious adverse events (SAEs)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2239
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2240
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2241
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2242
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2243
    ],
    [
      "",
      "Unmapped",
      "text",
      "42",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2244
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2245
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.2 Pregnancy",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2246
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2247
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2248
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2249
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2250
    ],
    [
      "",
      "Unmapped",
      "text",
      "43",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2251
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2252
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.2.1 Maternal exposure",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2253
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2254
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2255
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2256
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2257
    ],
    [
      "",
      "Unmapped",
      "text",
      "43",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2258
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2259
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.2.2 Paternal exposure",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2260
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2261
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2262
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2263
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2264
    ],
    [
      "",
      "Unmapped",
      "text",
      "44",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2265
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2266
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.3 Overdose",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2267
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2268
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2269
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2270
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2271
    ],
    [
      "",
      "Unmapped",
      "text",
      "44",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2272
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2273
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.4 Medication error",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2274
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2275
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2276
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2277
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2278
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2279
    ],
    [
      "",
      "Unmapped",
      "text",
      "45",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2280
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2281
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.5 Management of toxicities",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2282
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2283
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2284
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2285
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2286
    ],
    [
      "",
      "Unmapped",
      "text",
      "45",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2287
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2288
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.5.1 Management of haematologic toxicity",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2289
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2290
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2291
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2292
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2293
    ],
    [
      "",
      "Unmapped",
      "text",
      "46",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2294
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2295
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.4.5.2 Management of Non-haematologic toxicity",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2296
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2297
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2298
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2299
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2300
    ],
    [
      "",
      "Unmapped",
      "text",
      "48",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2301
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2302
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.5 Pharmacokinetics (PK)",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2303
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2304
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2305
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2306
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2307
    ],
    [
      "",
      "Unmapped",
      "text",
      "50",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2308
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2309
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.5.1 Collection of pharmacokinetic samples",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2310
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2311
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2312
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2313
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2314
    ],
    [
      "",
      "Unmapped",
      "text",
      "50",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2315
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2316
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.5.2 Determination of drug concentration",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2317
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2318
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2319
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2320
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2321
    ],
    [
      "",
      "Unmapped",
      "text",
      "52",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2322
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2323
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.5.3 Storage and destruction of pharmacokinetic samples",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2324
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2325
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2326
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2327
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2328
    ],
    [
      "",
      "Unmapped",
      "text",
      "52",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2329
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2330
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.5.4 Calculation or derivation of pharmacokinetic variables",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2331
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2332
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2333
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2334
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2335
    ],
    [
      "",
      "Unmapped",
      "text",
      "52",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2336
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2337
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.6 Pharmacodynamics",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2338
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2339
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2340
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2341
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2342
    ],
    [
      "",
      "Unmapped",
      "text",
      "53",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2343
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2344
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.7 Genetics",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2345
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2346
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2347
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2348
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2349
    ],
    [
      "",
      "Unmapped",
      "text",
      "53",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2350
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2351
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.7.1 Optional exploratory genetic sample",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2352
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2353
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2354
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2355
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2356
    ],
    [
      "",
      "Unmapped",
      "text",
      "53",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2357
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2358
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.7.2 Storage and destruction of genetic samples",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2359
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2360
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2361
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2362
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2363
    ],
    [
      "",
      "Unmapped",
      "text",
      "53",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2364
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2365
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.8 Biomarkers",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2366
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2367
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2368
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2369
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2370
    ],
    [
      "",
      "Unmapped",
      "text",
      "53",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2371
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2372
    ],
    [
      "",
      "Unmapped",
      "text",
      "8.9 Medical Resource Utilization and Health Economics",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2373
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2374
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2375
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2376
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2377
    ],
    [
      "",
      "Unmapped",
      "text",
      "53",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2378
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2379
    ],
    [
      "",
      "Unmapped",
      "text",
      "9 STATISTICAL CONSIDERATIONS",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2380
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2381
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2382
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2383
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2384
    ],
    [
      "",
      "Unmapped",
      "text",
      "54",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2385
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2386
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.1 Statistical hypotheses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2387
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2388
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2389
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2390
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2391
    ],
    [
      "",
      "Unmapped",
      "text",
      "54",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2392
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2393
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.2 Sample size determination",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2394
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2395
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2396
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2397
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2398
    ],
    [
      "",
      "Unmapped",
      "text",
      "54",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2399
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2400
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.3 Populations for analyses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2401
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2402
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2403
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2404
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2405
    ],
    [
      "",
      "Unmapped",
      "text",
      "54",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2406
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2407
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.4 Statistical analyses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2408
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2409
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2410
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2411
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2412
    ],
    [
      "",
      "Unmapped",
      "text",
      "54",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2413
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2414
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.4.1 Demographic data",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2415
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2416
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2417
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2418
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2419
    ],
    [
      "",
      "Unmapped",
      "text",
      "55",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2420
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2421
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.4.2 Exposure",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2422
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2423
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2424
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2425
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2426
    ],
    [
      "",
      "Unmapped",
      "text",
      "55",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2427
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2428
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.4.3 Safety analyses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2429
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2430
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2431
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2432
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2433
    ],
    [
      "",
      "Unmapped",
      "text",
      "55",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2434
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2435
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.4.4 Pharmacokinetics (PK) analyses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2436
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2437
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2438
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2439
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2440
    ],
    [
      "",
      "Unmapped",
      "text",
      "56",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2441
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2442
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.4.5 Efficacy analyses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2443
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2444
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2445
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2446
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2447
    ],
    [
      "",
      "Unmapped",
      "text",
      "56",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2448
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2449
    ],
    [
      "",
      "Unmapped",
      "text",
      "9.5 Interim analyses",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2450
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2451
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2452
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2453
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2454
    ],
    [
      "",
      "Unmapped",
      "text",
      "57",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2455
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2456
    ],
    [
      "",
      "Unmapped",
      "text",
      "10 REFERENCES",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2457
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2458
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2459
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2460
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2461
    ],
    [
      "",
      "Unmapped",
      "text",
      "58",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2462
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2463
    ],
    [
      "",
      "Unmapped",
      "text",
      "11 SUPPORTING DOCUMENTATION AND OPERATIONALCONSIDERATIONS",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2464
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2465
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2466
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2467
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2468
    ],
    [
      "",
      "Unmapped",
      "text",
      "60",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2469
    ],
    [
      "",
      "Unmapped",
      "text",
      "",
      { "IsBold": false, "font_size": -1, "font_style": "" },
      "Supporting Documentation and Operational Considerations",
      "Appendix K  Abbreviations",
      "",
      "2",
      2470
    ]
  ],
  "metadata": {
    "protocol_title": "A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumour Activity of Adavosertib (AZD1775) in Japanese Patients with Advanced Solid Tumours",
    "protocol_title_short": "",
    "amendment_number": "Y",
    "trial_phase": "I",
    "sponsor": "3-D Pharmaceuticals",
    "sponsor_address": "",
    "drug": "",
    "approval_date": "20200309",
    "version_number": "",
    "version_date": "",
    "blinded": "OPEN-LABEL",
    "compound_number": "",
    "control": "",
    "investigator": "",
    "study_id": "",
    "number_of_subjects": "[3, inf]",
    "participant_age": "[0h, 60y)",
    "participant_sex": "MALE",
    "exclusion_criteria": "Physical, psychological, familial, sociological, or geographical, or any other conditions that do not permit compliance with protocol/study assessments.",
    "inclusion_criteria": "Measurable or non-measurable disease according to RECIST v1.1 or Appendix G.",
    "indication": "ABCC6 deficiency",
    "objectives_section": "RECIST v1.1 by investigator assessment",
    "study_population": "patient, subject, ad.. ( ), treated with diagnosis of entity: basic, word .. Diseases and Symptom.. and Diseases and Sym.. showing symptoms of ..",
    "entities_in_assessments": "",
    "soa_epochs": "",
    "assessment_footnote": "",
    "upload_date": "20210218093024",
    "protocol_number": "Protocol-A2",
    "study_status": "",
    "accuracy": ""
  }
}
